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ABSTRACT
Puumala hantavirus (PUUV) causes a mild type of hemorrhagic fever with renal
syndrome called nephropathia epidemica (NE). After an incubation period of 1-8
weeks, NE presents with sudden high fever, headache, nausea, abdominal pain,
backache, visual disturbances, and impaired renal function. The severity of NE
varies from asymptomatic to rare fatal cases, and its pathogenesis is not completely
understood. An important feature in hantaviral infections is capillary leakage due to
increased capillary permeability. The mechanisms behind this phenomenon are
unclear, although immunological responses have been suggested to be important.
In the present study, the association of immunological factors, i.e. interleukin
(IL)-6, C-reactive protein (CRP), pentraxin-3 (PTX3), indoleamine 2,3-dioxygenase
(IDO), and cell-free DNA (cf-DNA), with the severity of NE was analyzed.
Furthermore, their possible role in the pathogenesis was assessed.
Pentraxins are a family of acute-phase proteins. CRP is a short pentraxin mainly
produced in the liver in response to inflammatory signals. IL-6, in turn, is a
multifunctional cytokine involved in immune responses and inflammation.
Increased cytokine levels have previously been found in the plasma, urine, and
tissues  of  patients  with  hantavirus  infection.  In  Study  I,  plasma  IL-6  and  CRP  as
well as their association with disease severity reflecting variables were studied in
118 hospital-treated patients with acute NE. High plasma IL-6 levels were found to
associate with clinically severe acute NE. High IL-6 levels were also found as an
independent risk factor for impaired renal function. High plasma CRP, in turn, did
not have an association with a more severe course of the disease. On the contrary,
high CRP levels turned out to be a possible protective factor for renal function.
PTX3 is  a  long  pentraxin  produced  at  the  site  of  inflammation.  In  Study  II,  61
hospitalized PUUV-infected patients were studied to assess the associations of
plasma PTX3 with variables reflecting the severity of acute NE. PTX3 levels were
shown to be elevated during the acute phase of the disease. High PTX3 associated
with  a  more  severe  course  of  NE  and,  most  of  all,  with  significant
thrombocytopenia. It also associated with the activation of the complement system.
Thus, PTX3 could possibly be involved in the pathogenesis of thrombocytopenia in
NE through the activated complement cascade.
IDO is the rate-limiting enzyme in tryptophan catabolism to kynurenine leading
to depletion of tryptophan as well as T cell suppression. In Study III, 102
hospitalized patients were studied to establish the association of serum IDO enzyme
with  the  variables  reflecting  the  severity  of  acute  NE.  Serum  tryptophan  and
kynurenine levels were determined by reverse-phase high-performance liquid
chromatography, and tryptophan/kynurenine ratio reflecting IDO activity was
calculated.  IDO levels  were  found to  be  elevated  during  acute  NE.  High  IDO was
revealed to associate with clinically severe NE and it presented as an independent
risk factor for significant renal insufficiency. Furthermore, serum IDO levels were
shown to peak before serum creatinine levels. It is conceivable that IDO is involved
in the pathogenesis of renal insufficiency in PUUV infection. The possible
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mechanisms are promotion of tubular epithelial cell apoptosis or
immunosuppression through T cell suppression.
Elevated  levels  of  cf-DNA  have  been  previously  reported  in  different  clinical
disorders. The current view is that, in these conditions, cf-DNA originates from
apoptotic or necrotic cells and therefore reflects the amount of cellular damage. In
Study IV, total cf-DNA was studied in the plasma of 61 patients and urine of 20
patients with acute NE. Also, a qualitative high-sensitivity lab-on-a-chip DNA assay
was carried out in 20 patients to elucidate the appearance of cf-DNA in plasma and
urine. The plasma levels of cf-DNA were found to be elevated during acute PUUV
infection and correlate with the apoptotic band (150-200 base pairs) intensity. The
total plasma cf-DNA concentration also correlated with leukocytosis,
thrombocytopenia, and the length of hospitalization. The urinary excretion of cf-
DNA, in turn, was not elevated during the acute infection and it did not correlate
with any of the disease severity reflecting variables.
In conclusion, high plasma IL-6, PTX3, cf-DNA, and serum IDO levels reflect
the clinical severity of NE, while high CRP concentration seems to protect against
renal failure and does not predict a severe course of NE. Neither does urinary
excretion of cf-DNA reflect the degree of inflammation in the kidney. Furthermore,
PTX3 might be involved in the pathogenesis of thrombocytopenia and IDO, in turn,
could act in the pathogenesis of renal insufficiency.
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TIIVISTELMÄ
Hantaviruksiin kuuluva Puumala-virus aiheuttaa lievän munuaisoireisen
verenvuotokuumeen, jota kutsutaan myyräkuumeeksi. Tauti alkaa äkillisesti 1-8
viikon itämisajan jälkeen korkealla kuumeella ja päänsäryllä, joita seuraa
pahoinvointi, vatsa- ja selkäkivut, näköhäiriöt sekä munuaisten vajaatoiminta.
Puumala-virusinfektion vaikeusaste vaihtelee oireettomasta harvinaisiin kuolemaan
johtaviin tapauksiin. Myyräkuumeen taudin kehittymistä ei täysin tunneta.
Hantavirusinfektioissa tärkeä piirre on kapillaarien läpäisevyyden lisääntymisestä
johtuva kapillaarivuoto. Tämän ilmiön taustalla olevat mekanismit ovat epäselviä,
mutta immunologisilla reaktioilla on arveltu olevan tärkeä osuus.
Tässä väitöskirjatyössä tutkittiin immunologisten tekijöiden, interleukiini (IL)-
6:n, C-reaktiivisen proteiinin (CRP), pentraksiini-3:n (PTX3), indoleamiini 2,3-
dioksygenaasin (IDO) ja soluvapaan DNA:n (cf-DNA), yhteyttä myyräkuumeen
vaikeusasteeseen. Myös näiden tekijöiden mahdollista osuutta taudin kehittymisessä
arvioitiin.
Pentraksiinit ovat ryhmä akuutin faasin proteiineja. CRP on lyhyt pentraksiini,
jota tuotetaan pääasiassa maksassa vasteena tulehduksellisille signaaleille. IL-6
puolestaan on sytokiini, jolla on useita tehtäviä ja joka on osallisena
immuunivasteen säätelyssä ja tulehdusreaktioissa. Lisääntyneitä
sytokiinipitoisuuksia on aiemmin todettu hantavirusinfektiopotilaiden plasmassa,
virtsassa ja kudoksissa. Osatyössä I tutkittiin plasman IL-6- ja CRP-pitoisuuksia
sekä niiden yhteyttä taudin vaikeusastetta kuvastaviin muuttujiin 118
sairaalahoidetulla myyräkuumepotilaalla. Korkean IL-6-pitoisuuden todettiin
liittyvän vaikeaan akuuttiin myyräkuumeeseen. Se osoittautui myös itsenäiseksi
riskitekijäksi munuaisten vajaatoiminnalle. Korkea plasman CRP puolestaan ei
liittynyt vaikeampaan tautiin. Päinvastoin, korkea CRP osoittautui mahdolliseksi
munuaisten toimintaa suojaavaksi tekijäksi.
PTX3 on pitkä pentraksiini, jota tuotetaan tulehduspaikalla. Osatyössä II tutkittiin
61 sairaalahoidettua myyräkuumepotilasta plasman PTX3-pitoisuuden ja taudin
vaikeusastetta kuvastavien muuttujien yhteyden selvittämiseksi. PTX3-pitoisuuden
todettiin olevan koholla akuutissa myyräkuumeessa. Korkea PTX3-pitoisuus oli
yhteydessä vaikeaan myyräkuumeeseen ja erityisesti matalaan verihiutaletasoon.
Korkea PTX3 oli yhteydessä myös komplementtijärjestelmän aktivaatioon. Näin
ollen PTX3 voisi olla osallisena matalan trombosyyttitason kehittymisessä
myyräkuumeessa aktivoituneen komplementtijärjestelmän kautta.
IDO on katabolianopeutta rajoittava entsyymi tryptofaanin pilkkoutumisessa
kynureniiniksi, mikä johtaa tryptofaanin puutteeseen ja T-solujen estoon. Osatyössä
III tutkittiin seerumin IDO-entsyymin ja myyräkuumeen vaikeusastetta kuvastavien
muuttujien yhteyttä 102 sairaalahoidetulla potilaalla. Seerumin tryptofaanin ja
kynureniinin pitoisuudet määritettiin ja laskettiin IDO-aktiivisuutta heijastava
tryptofaani/kynureniini-suhde. IDO-pitoisuuden todettiin olevan koholla akuutissa
myyräkuumeessa. Korkea IDO-pitoisuus oli yhteydessä vaikeaan myyräkuumeeseen
ja osoittautui merkittävän munuaisten vajaatoiminnan itsenäiseksi riskitekijäksi.
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Lisäksi seerumin IDO-pitoisuus oli korkeimmillaan ennen kreatiniinipitoisuuden
huippua. IDO saattaa olla mukana munuaisten vajaatoiminnan kehittymisessä
myyräkuumepotilailla. Mahdollisia mekanismeja ovat tubulaaristen epiteelisolujen
apoptoosi tai T-solujen eston aiheuttama immuunilama.
Kohonneita soluvapaan DNA:n pitoisuuksia on aiemmin raportoitu erilaisissa
sairauksissa. Nykykäsityksen mukaan soluvapaa DNA on näissä tiloissa peräisin
apoptoottisista tai nekroottisista soluista ja siten kuvastaa solutuhon määrää.
Osatyössä IV plasman soluvapaan DNA:n pitoisuus määritettiin 61
myyräkuumepotilaalta ja virtsan soluvapaan DNA:n eritys 20 potilaalta. Lisäksi
tehtiin kvalitatiivinen DNA-määritys 20 potilaalle sekä plasmasta että virtsasta
soluvapaan DNA:n ulkomuodon selvittämiseksi. Plasman soluvapaan DNA:n
pitoisuudet todettiin koholla oleviksi akuutissa myyräkuumeessa ja ne korreloivat
apoptoottisen juosteen (150-200 emäsparia) voimakkuuden kanssa. Plasman
soluvapaan DNA:n kokonaismäärä korreloi myös positiivisesti valkosolutason ja
sairaalahoidon keston sekä negatiivisesti verihiutaletason kanssa. Virtsan
soluvapaan DNA:n eritys puolestaan ei ollut akuutissa myyräkuumeessa koholla,
eikä se korreloinut minkään taudin vaikeusastetta kuvastavan muuttujan kanssa.
Yhteenvetona todetaan, että korkea IL-6, PTX3, IDO ja plasman soluvapaa DNA
liittyvät vaikeaan myyräkuumeeseen. Korkea CRP puolestaan näyttäisi suojaavan
munuaistoimintaa eikä kuvasta vaikeaa tautia. Virtsan soluvapaan DNA:n eritys ei
kuvasta tulehduksen määrää munuaisissa. PTX3 voi olla mukana matalan
verihiutaletason kehittymisessä ja IDO puolestaan munuaisten vajaatoiminnan
kehittymisessä myyräkuumeessa.
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1. INTRODUCTION
Puumala hantavirus (PUUV) causes a mild hemorrhagic fever with renal syndrome
(HFRS), called nephropathia epidemica (NE) (Vapalahti et al. 2003). The natural
carrier rodent of PUUV is the bank vole (Myodes glareolus) (Brummer-
Korvenkontio et al. 1980). Other hantaviruses causing HFRS include Hantaan
(HTNV), Dobrava (DOBV), Saaremaa (SAAV), Amur, and Seoul (SEOV) viruses
(Vapalahti et al. 2003, Heyman and Vaheri 2008). In the Americas, Sin Nombre
(SNV), Andes (ANDV), Black Creek Canal, and several other viruses cause
hantavirus cardiopulmonary syndrome (HCPS) (Kanerva et al. 1998a). NE occurs in
Finland, elsewhere in Scandinavia, in Western Russia, the Balkans, and many parts
of Central-Western Europe (Vapalahti et al. 2003). In Finland, 1,000-3,000
serological PUUV infection diagnoses are made annually (THL 2012).
The clinical picture of NE varies from a subclinical disease to rare fatal cases
(Makary et al. 2010). Usual symptoms include sudden high fever, headache,
abdominal pain, nausea, backache, and visual disturbances, while serious
hemorrhagic manifestations are uncommon (Lähdevirta 1971, Settergren et al. 1989,
Mustonen et al. 1994a, Braun et al. 2010). Renal involvement causes proteinuria,
hematuria, and oliguria, which is followed by polyuria (Lähdevirta 1971, Settergren
et al. 1989, Mustonen et al. 1994a, Braun et al. 2010). Minority of patients need
transient hemodialysis treatment during the oliguric phase. The characteristic
histopathologic renal finding is acute tubulointerstitial nephritis and common
laboratory findings include leukocytosis, thrombocytopenia, anemia, and elevation
of  plasma  C-reactive  protein  (CRP)  and  creatinine  levels  (Settergren  et  al.  1989,
Mustonen et al. 1994a, Mustonen et al. 1994b). The pathogenesis of NE is not
completely understood. An important feature in hantaviral infections is universally
increased capillary permeability, but the mechanisms behind this phenomenon are
unclear (Cosgriff 1991). It has been suggested that immunological factors are
essential in the pathogenesis of NE (Cosgriff 1991, Kanerva et al. 1998a).
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Pentraxins are a family of acute-phase proteins, which are characterized by a
cyclic multimeric structure (Bottazzi et al. 2009). CRP is the prototype short
pentraxin mainly produced in the liver in response to inflammatory signals
(Mantovani et al. 2008, Bottazzi et al. 2009). Interleukin (IL)-6 is the main inducer
of CRP production (Ganter et al. 1989). The major functions of CRP are
complement activation, enhancement of phagocytosis, and induction of cytokine
synthesis (Volanakis 2001, Ablij and Meinders 2002). CRP is widely used in
clinical practice in the context of assessing the severity of various infectious
diseases. Studies concerning the ability of CRP to predict the severity of the disease
in viral infections have produced controversial results.
Pentraxin 3 (PTX3) is the prototype protein of the long pentraxin group
members. It is produced by a variety of peripheral tissues and cells, mainly
mononuclear phagocytes and dendritic cells, in response to pro-inflammatory
signals, such as IL-1?, tumor necrosis factor (TNF)-? and Toll-like receptor (TLR)
activation (Mantovani et al. 2006, Mantovani et al. 2008, Bottazzi et al. 2009).
PTX3 can interact with a number of selected bacteria, fungi and viruses, promoting
phagocytosis and clearance of the microbe (Deban et al. 2009). It has the capacity to
bind complement component C1q and to participate in the activation of the classical
complement pathway (Bottazzi et al. 1997). PTX3 also interacts with factor H, an
alternative pathway regulator (Deban et al. 2008). Furthermore, it plays a role in
tuning inflammation, in matrix deposition and female fertility (Mantovani et al.
2006, Deban et al. 2009). Previously, in the context of viral infections, PTX3
concentrations have been detected to be higher in patients suffering from dengue
shock syndrome than in patients with dengue fever or dengue hemorrhagic fever
(Mairuhu et al. 2005).
IL-6 is a multifunctional cytokine involved in immune responses and
inflammation. Increased cytokine levels have previously been found in the plasma,
urine, and tissues of patients with hantaviral infection (Linderholm et al. 1996,
Temonen et al. 1996, Mäkelä et al. 2004). In addition, high IL-6 level has been
found to be associated with the severity of NE (Linderholm et al. 1996, Takala et al.
2000, Mäkelä et al. 2004, Sadeghi et al. 2011). In other viral infections, the results
concerning IL-6 in the prediction of disease severity have been controversial.
Indoleamine 2,3-dioxygenase (IDO) is an enzyme catalyzing the first and rate-
limiting step in the pathway of tryptophan catabolism to kynurenine and its
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derivatives (Mellor and Munn 2004, Mellor 2005). IDO is expressed widely in
various immune cells, including macrophages and dendritic cells (Mellor and Munn
2004, Mellor 2005). It is also expressed in other types of cells, such as tumor cells,
fibroblasts, and renal tubular epithelial cells (TEC) (Mellor and Munn 2004, Mellor
2005, Mohib et al. 2007). Interferon (IFN)-? is the strongest known inducer of IDO
(Mellor and Munn 2004). Increased IDO activity results in the depletion of
tryptophan leading to inhibition of T cell responses and proliferation, and thus to
immunosuppression and immunotolerance (Hwu et al. 2000, Mellor et al. 2002,
Mellor and Munn 2004, Mellor 2005). By reducing tryptophan, IDO activity also
inhibits the multiplication of various bacteria and intracellular parasites, and the
replication of viruses (Mellor and Munn 2004). Previously, increased IDO activity
has been detected in some viral infections, such as dengue virus infection and
chronic hepatitis C virus (HCV) infection (Larrea et al. 2007, Becerra et al. 2009).
Furthermore, in the case of human immunodeficiency virus (HIV) infection,
enhanced tryptophan degradation by IDO was associated with disease progression
and complications (Schroecksnadel et al. 2007).
Circulating cell-free DNA (cf-DNA) has recently been studied in various acute
and chronic disorders. Elevated levels of cf-DNA have been reported in different
conditions, such as in cancer, autoimmune diseases, stroke, myocardial infarction,
trauma and sepsis (Lo et al. 2000, Jahr et al. 2001, Rainer et al. 2003, Antonatos et
al. 2006, Zhong et al. 2007b, Saukkonen et al. 2008, Mosca et al. 2009, Huttunen et
al. 2011b). It has also been suggested that cf-DNA could be used as a predictor of
outcome in these conditions (Butt and Swaminathan 2008). Although the
concentrations are low, detectable levels of cf-DNA are present also in the plasma
of healthy individuals (Zhong et al. 2007a). The current view is that, in different
diseases, cf-DNA originates from apoptotic or necrotic cells and therefore reflects
the amount of cellular damage (Jahr et al. 2001). Studies on plasma cf-DNA in viral
infections are sparse and urine levels of cf-DNA have not previously been studied in
viral infections.
In the present study, CRP, PTX3, IL-6, IDO, and cf-DNA were studied in acute
PUUV infection. The association of these immunological variables with the severity
of the disease was examined as well as their possible role in the pathogenesis of NE.
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2. REVIEW OF THE LITTERATURE
2.1 Puumala virus and other hantaviruses
2.1.1 Virology
PUUV was found in the lungs of bank voles (Myodes glareolus) collected in the
Puumala region, in Finland, in 1977 (Brummer-Korvenkontio et al. 1980). PUUV
belongs to the Hantavirus genus and the Bunyaviridae family (Schmaljohn and
Dalrymple 1983, Schmaljohn et al. 1985). Hantaviruses are enveloped RNA viruses
possessing a three-segmented negative stranded RNA genome (Schmaljohn and
Dalrymple 1983, Schmaljohn et al. 1985). The large (L) segment encodes the viral
RNA-dependent RNA-polymerase, which is thought to be responsible for the
transcription and replication of the viral genome (Plyusnin 2002). The medium (M)
segment encodes the surface envelope glycoproteins Gn and Gc, which are believed
to recognize hantavirus receptors on target cells (Plyusnin 2002). Finally, the small
(S) segment encodes the nucleocapsid (N) protein, which encapsidates the genome
RNA into three viral chromosomes (Plyusnin 2002).
Hantaviruses are maintained in persistently infected rodent hosts and each
hantavirus associates predominantly with one specific rodent species (Kanerva et al.
1998a, Plyusnin 2002). The rodent carriers are asymptomatic and excrete the virus
in their urine, saliva and feces, thus offering a route of transmission to humans (Lee
et al. 1981, Hardestam et al. 2008). The carrier rodent of PUUV, the bank vole, is
found throughout Europe, with the exception of the Mediterranean region and the
northern parts of Finland, Sweden and Norway (Vapalahti et al. 2003). Hantaviruses
cause two clinical syndromes in humans, HFRS and HCPS (Kanerva et al. 1998a,
Jonsson et al. 2010). The HFRS causing viruses are distributed in Asia and Europe,
whereas  the  HCPS  causing  viruses  are  prevalent  in  the  Americas  (Kanerva  et  al.
1998a, Jonsson et al. 2010). Furthermore, several hantaviruses have not been
associated with any human disease. Table 1 shows the hantaviruses associated with
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human infections, their rodent hosts, hantaviral clinical syndromes, and geographic
distribution.
Table 1. Human pathogenetic hantaviruses, clinical disease, rodent hosts and
geographic distribution.
Virus Rodent host Distribution
HFRS causing viruses
Hantaan Apodemus agrarius China, Russia, Korea
Dobrava Apodemus flavicollis Balkans
Seoul Rattus norvegicus Worldwide
Saaremaa Apodemus agrarius Europe
Amur Apodemus peninsulae Russian Far East
Puumala Myodes glareolus Europe
HCPS causing viruses
Sin Nombre Peromyscus maniculatus North America
New York Peromyscus leucopus North America
Monongahela Peromyscus maniculatus
numiterrae
North America
Bayou Oryzomys palustris North America
Black Creek Canal Sigmodon hispidus North America
Laguna Negra Calomys laucha Paraguay, Bolivia, Argentina
Andes Oligoryzomys
longicaudatus
Argentina, Chile
Orán Oligoryzomys
longicaudatus
Argentina
Choclo Oligoryzomys fulvescens Panama
Lechiguanas Oligoryzomys flavescens Argentina
Araraquara Bolomys lasiurus Brazil
Juquitiba Oligoryzomys nigripes Brazil
Bermejo Oligoryzomys chocoensis Argentina
Maciel Bolomys obscurus Argentina
Muleshoe Sigmodon hispidus North America
Castelo Dos Sonhos Unknown Brazil
Araucaria Unknown Brazil
Hu39694 Unknown Argentina
HFRS=hemorrhagic fever with renal syndrome
HCPS= hantavirus cardiopulmonary syndrome
The table is adapted from two articles (Khaiboullina et al. 2005, Jonsson et al. 2010).
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2.1.2 Epidemiology
Only around 2,000 HCPS cases have been reported world wide so far, with
approximately 300 people being affected annually (Muranyi et al. 2005, Jonsson et
al. 2010). At the same time, HFRS affects approximately 150,000-200,000 people
every year (Muranyi et al. 2005, Jonsson et al. 2010). More than half of the cases
occur in China, where HTNV and SEOV viruses cause HFRS (Jonsson et al. 2010).
In Europe, PUUV causes most HFRS cases (Heyman and Vaheri 2008). A minority
of HFRS cases in Europe are caused by DOBV in the Balkans and SAAV (Heyman
and Vaheri 2008).
Finnish PUUV infections account for approximately 70 % of all European HFRS
cases (Heyman and Vaheri 2008). During recent years, the annual number of
serological diagnoses of PUUV infection has been approximately 1,000-3,000 in
Finland (THL 2012). The annual incidence has an increasing trend, with an average
annual incidence of 31/100,000 (Makary et al. 2010). The average PUUV
seroprevalence in Finnish population is 5 %, implying that many infections remain
undiagnosed or present as subclinical (Brummer-Korvenkontio et al. 1999). Earlier,
it had been observed that outbreaks occurred usually every 3-4 years. However, a
recent study detected that since 1998, two consecutive years with high epidemic
peaks were followed by one year with a low epidemic peak (Makary et al. 2010). In
addition, the incidence varies widely by season. The epidemic usually starts in late
summer, with an increasing incidence in late autumn or early winter (Makary et al.
2010). During spring, the incidence is at its lowest. The age groups 34-49 years as
well as 50-64 years have the highest incidence and the majority of the patients
(62 %) are males (Makary et al. 2010). Other countries besides Finland, where more
than one thousand PUUV cases in total have been recorded, include Sweden,
Norway, Belgium, France, and Germany (Heyman and Vaheri 2008). However,
some countries, such as Estonia, have not reported their PUUV cases until recently.
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2.2 Hantaviral clinical manifestations
2.2.1 Hemorrhagic fever with renal syndrome
The clinical picture of HFRS varies from asymptomatic to fatal. In PUUV, SAAV
and SEOV infections, the mortality rate is low, while in HFRS cases caused by
HTNV or DOBV, it varies from 3 to 16 % (Kanerva et al. 1998a, Avsic-Zupanc et
al. 1999, Peters et al. 1999, Vapalahti et al. 2003). The disease can be divided into
five phases: febrile, hypotensive, oliguric, polyuric, and convalescence (Kanerva et
al. 1998a, Peters et al. 1999, Jonsson et al. 2010).
The disease starts with a sudden onset of high fever, followed by headache, back
and abdominal pains and nausea (Kanerva et al. 1998a, Peters et al. 1999).
Additional findings during the febrile phase include photophobia, myopia, dizziness,
flushing of the face, periorbital edema, and conjunctival infection (Kanerva et al.
1998a, Peters et al. 1999). The febrile phase lasts for 3-5 days, and at the end of this
phase, hypotension may develop rapidly leading, in severe cases, to shock and
cardiovascular collapse (Kanerva et al. 1998a, Peters et al. 1999).
After the febrile and hypotensive phases, the oliguric phase begins, lasting for 1-
16 days (Jonsson et al. 2010). Hemodialysis treatment is needed for approximately
20 % of patients with SEOV infection and for 40 % of patients with HTNV
infection, whereas among NE patients the need for hemodialysis is only up to 6 %
(Mustonen et al. 1994a, Jonsson et al. 2010). Petecchiae are common and also
severe internal bleedings can be seen, especially in HTNV infection (Kanerva et al.
1998a, Jonsson et al. 2010). Furthermore, disseminated intravascular coagulopathy
(DIC) is found in 20 % of HTNV patients (Kanerva et al. 1998a, Peters et al. 1999).
Typical laboratory findings include thrombocytopenia, leukocytosis with a left shift,
increased hematocrit due to vascular leakage, elevated serum creatinine level,
elevated liver enzymes, hypoproteinemia, as well as proteinuria and hematuria
(Kanerva et al. 1998a, Vapalahti et al. 2003, Jonsson et al. 2010).
The oliguric phase accounts for approximately 50 % of all HFRS-related deaths
(Jonsson et al. 2010). In most cases, mortality caused by HFRS is due to
complications from renal insufficiency, shock, or hemorrhages (Jonsson et al. 2010).
After the polyuric phase has started, recovery is the rule (Kanerva et al. 1998a).
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2.2.2 Nephropathia epidemica
2.2.2.1 Clinical characteristics
In acute NE, the incubation period varies from 1 to 8 weeks (Settergren et al. 1989).
The disease starts with sudden high fever and headache, followed by nausea,
vomiting, abdominal pains, and backache (Lähdevirta 1971, Settergren et al. 1989,
Mustonen et al. 1994a, Braun et al. 2010). Myalgia and visual disturbances are also
common. The ocular symptoms have multifactorial origin, they are partly due to a
myopic shift, but also extraocular mechanisms may be involved (Hautala et al.
2011a). Distinguishing the typical five phases of HFRS (febrile, hypotensive,
oliguric, polyuric, and convalescent) may be difficult and they are not always
present due to the relative mildness of the disease.
Serious hemorrhagic complications are rare in NE. However, mild bleeding
manifestations occur, such as conjunctival or retinal bleeding, petechiae,
macroscopic hematuria, melena, hematemesis, epistaxis and bleeding from puncture
sites (Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a). Some
hemorrhagic manifestation has been reported in 10-37 % of patients and epistaxis in
11-28 % of patients (Lähdevirta 1971, Settergren et al. 1989). In a Finnish study
with 10 patients, mild gastrointestinal bleeding was demonstrated by gastroscopy in
all of the patients studied (Nuutinen et al. 1992). Furthermore, there are case reports
of  hypophyseal  hemorrhages,  as  well  as,  in  rare  fatal  cases,  hemorrhages  of  other
organs (Valtonen et al. 1995, Hautala et al. 2002).
Central nervous system (CNS)-related symptoms are usual in NE. Typical
manifestations include headache, insomnia, as well as somnolence, dizziness,
restlessness, anxiety, and amnesia (Lähdevirta 1971, Settergren et al. 1989,
Mustonen et al. 1994a, Braun et al. 2010). In a recent study, 58 patients with PUUV
infection were studied and 87 % suffered symptoms suggestive of CNS involvement
(Hautala et al. 2010). In this study, also cerebrospinal fluid was studied and, in half
of the samples, it proved positive for PUUV immunoglobulin (Ig)M, elevated
protein level, or leukocyte count. Magnetic resonance imaging (MRI) revealed
pituitary hemorrhage in 2/58 patients (Hautala et al. 2010). Young male patients
have  been  shown to  be  at  elevated  risk  for  serious  CNS complications  during  NE
(Hautala et al. 2011b).
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There are case reports of hypopituitarism during acute NE linked to pituitary
hemorrhages or other pituitary abnormalities in MRI (Hautala et al. 2002, Hautala et
al. 2010, Hautala et al. 2011b). In a recent study, hormonal deficiencies were
examined in 54 patients (Mäkelä et al. 2010). It was revealed that 56 % of patients
had abnormalities of the gonadal and/or thyroid axis during the acute infection. The
acute hormonal alterations of central origin were associated with the severity of
renal impairment and the degree of inflammation. The endothelial damage and
increased vascular permeability during the acute infection, as well as the tight
interaction between the immune and endocrine systems could be involved in the
pathogenesis of the hormonal defects (Mäkelä et al. 2010).
2.2.2.2 Renal involvement
Renal involvement is manifested by transient proteinuria, microscopic hematuria,
and renal function impairment, which is demonstrated as oliguria and a rise in serum
creatinine level (Lähdevirta 1971). Oliguria is then followed by polyuria and a
spontaneous recovery (Lähdevirta 1971). Transient hemodialysis treatment is
needed by up to 6 % of hospital-treated patients (Settergren et al. 1989, Mustonen et
al. 1994a, Braun et al. 2010).
The characteristic histopathologic renal finding is acute tubulointerstitial
nephritis. Interstitial edema, inflammatory cell infiltrations, as well as tubular
epithelial and luminal alterations are seen (Mustonen et al. 1994b). The infiltrating
cells include plasma cells, monocytes, macrophages, and lymphocytes, as well as
polymorphonuclear cells, mainly eosinophils and neutrophils (Mustonen et al.
1994b, Temonen et al. 1996). CD8+ T cells predominate the lymphocytic infiltrate
(Temonen et al. 1996). Also interstitial hemorrhages are seen in 20-60 % of biopsies
(Collan  et  al.  1991,  Mustonen  et  al.  1994b).  In  immunofluorescence  (IF)  analysis,
deposits of IgG, IgM, complement component C3 and fibrinogen have been found
along the tubular basement membrane in about half of the cases (Collan et al. 1991).
Also weak glomerular mesangial alterations are present in 25 % of the cases
(Mustonen et al. 1994b). Furthermore, IF has revealed glomerular deposits of IgG,
IgM, IgA and complement components C3 and C1q (Collan et al. 1991, Mustonen
et al. 1994b). However, in a Finnish study with 86 patients, the glomerular IF
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finding was normal in 43 % of the biopsies (Mustonen et al. 1994b). Tubular,
interstitial and glomerular histologic lesions have been associated with the clinical
severity of renal failure (Mustonen et al. 1994b). However, the glomerular
alterations have not related to the amount of urine protein excretion (Mustonen et al.
1994b).
2.2.2.3 Cardiological findings
In a Croatian study of 79 patients with HFRS, electrocardiography (ECG)
alterations were present in 38 % of the patients and three patients were diagnosed to
have myocarditis (Puljiz et al. 2005). All ECG changes were transient in this study.
There are also some case reports of myocarditis in patients with PUUV infection
(Lähdevirta 1971, Mustonen et al. 1994a, Valtonen et al. 1995). In a Finnish study
with 70 PUUV-infected patients, ECG changes were observed in 57 % of patients
(Mäkelä et al. 2009). Moreover, in this study, echocardiography (ECHO) showed
impaired left ventricular contraction in six patients and mild pericardial effusion in
one patient. All ECG and ECHO findings returned to normal. Acute renal failure
with fluid retention, abnormal plasma electrolyte levels, fever, and cytokine release
could be the possible pathogenetic mechanisms for the myocardial involvement
(Mäkelä et al. 2009). However, no differences were found in the clinical or
laboratory findings between patients with and without ECG or ECHO changes.
Thus, the pathogenesis of the cardiac involvement in NE is unclear.
2.2.2.4 Laboratory findings
Thrombocytopenia is seen in 57-75 % of patients with acute PUUV infection
(Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010).
In a Finnish study with 126 patients, the mean minimum platelet count reduced
clearly and was 117 x109/l, while the lowest platelet count was 10 x109/l (Mustonen
et al. 1994a). In a Swedish study with 74 patients, the median platelet count was 96
x109/l (Settergren et al. 1989). The mechanisms behind this phenomenon remain to
be clarified. DIC promoted by vascular injury has been suggested as a possible
cause of thrombocytopenia in NE (Cosgriff 1991). DIC has been reported in 5-26 %
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of PUUV-infected patients (Settergren et al. 1989, Laine et al. 2010). In a Finnish
study  with  19  patients  with  NE,  thrombocytopenia  was  detected  to  associate  with
decreased natural anticoagulants, shortened thrombin time and enhanced
fibrinolysis, but not with the degree of renal insufficiency (Laine et al. 2010). It is
suggested that the interaction of platelets with endothelium, their activation and P-
selectin expression could provide mechanisms of thrombocytopenia during
hantavirus infection. Furthermore, enhanced platelet adhesion and activation could
result in platelet consumption and thrombocytopenia (Laine et al. 2011).
Anemia is present in 33-50 % of patients with NE (Lähdevirta 1971, Mustonen et
al. 1994a). It is probably due to the infection itself, as well as renal insufficiency and
blood dilution during the oliguric phase, although hemorrhagic manifestations can
also play a role. Hemoconcentration caused by increased capillary permeability on
the other hand, can cause increased hemoglobin levels, which has been detected in
12-52 % of patients with NE (Lähdevirta 1971, Settergren et al. 1989). Leukocytosis
has been reported in 36-57 % of patients and elevated CRP level in almost all of the
patients (Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al.
2010). However, CRP level has ranged from 0 mg/l to 295 mg/l (Settergren et al.
1989, Mustonen et al. 1994a).
In most hospital-treated patients (85-96 %) with acute PUUV infection, serum
creatinine level is elevated (Lähdevirta 1971, Settergren et al. 1989, Braun et al.
2010). In a Finnish study with 126 patients, the mean creatinine value was 439
?mol/l while in a Swedish study with 74 patients, the median creatinine value was
386 ?mol/l and 35 % of patients had creatinine >500 ?mol/l (Settergren et al. 1989,
Mustonen et al. 1994a). In urinalysis, proteinuria is the most common finding,
detected in 82-100 % of patients, and it is in the nephrotic range in 25-34 % of
patients (Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Mäkelä et
al. 2004, Braun et al. 2010). Microscopic hematuria is present in 58-85 % of patients
(Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010).
Other often recorded laboratory findings in NE include elevated liver enzymes,
transient electrolyte abnormalities, such as hypocalcemia, hyponatremia,
hyperphosphatemia, hypokalemia and hyperkalemia, as well as hypoproteinemia
due to hypoalbuminemia (Lähdevirta 1971, Settergren et al. 1989, Mustonen et al.
1994a).
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2.2.2.5 Radiological findings
Abnormal findings on chest radiographs have been reported in 16-35 % of patients
with NE (Lähdevirta 1971, Mustonen et al. 1994a, Kanerva et al. 1996, Paakkala et
al. 2004b). Pleural effusion, atelectasis, and interstitial infiltration are the most
common X-ray findings (Kanerva et al. 1996, Paakkala et al. 2004b). Radiological
pulmonary manifestations have been associated with the degree of renal
insufficiency and fluid volume overload, as well as with high blood pressure,
leukocytosis and thrombocytopenia (Kanerva et al. 1996, Paakkala et al. 2004b). In
a Swedish study, 19 patients were studied with pulmonary computed tomography
(CT) and infiltrates or pleural effusions were seen in 10 (53 %) patients (Linderholm
et al. 1992). A recent Finnish study with 13 patients showed that, when examined
with high-resolution pulmonary CT, almost every patient (12/13) showed lung
parenchymal abnormalities (Paakkala et al. 2011).
Renal ultrasound (US) findings in PUUV-infected patients have been analyzed in
three studies (Paakkala et al. 2002, Paakkala et al. 2004a, Paakkala et al. 2004b).
When renal US was performed on 23 patients, the findings were abnormal in every
case (Paakkala et al. 2002). The resistive index was abnormal in 12/23 patients and
fluid collections were found in 13/23 patients. Furthermore, the severity of the
findings  was  associated  with  fluid  volume  overload  and  the  degree  of  renal
insufficiency (Paakkala et al. 2002, Paakkala et al. 2004b). The kidneys were also
examined by renal MRI as well as magnetic resonance renography (MRR) in 20
Finnish NE patients (Paakkala et al. 2005, Paakkala et al. 2006). Renal MRI changes
occurred in every patient and the severity of the findings in MRI was mildly
associated with severe renal insufficiency and fluid volume overload, as well as with
high blood pressure, inflammation, and thrombocytopenia (Paakkala et al. 2005).
Measurable functional MRR findings, in turn, were recorded in 14/20 patients and
the severity of these findings had mild association with the degree of renal
insufficiency and fluid volume overload (Paakkala et al. 2006).
2.2.2.6 Diagnosis
The  diagnosis  of  acute  PUUV  infection  is  based  on  the  clinical  picture  and  is
serologically confirmed. It is based on an IgM-capture enzyme immunoassay test
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and baculovirus-expressed PUUV full-length N protein (Vapalahti et al. 1996,
Vaheri et al. 2008). A rapid immunogromatographic PUUV IgM test is also
available (Hujakka et al. 2001). Antibodies are present usually in the first serum
sample taken, but in 2-4 % of PUUV infections, seroconversion may take up to five
days after the onset of the disease (Kallio-Kokko et al. 1998).
2.2.2.7 Treatment and prevention
The  treatment  of  NE  consists  of  supportive  care  with  careful  monitoring  and
management of fluid and electrolyte balance, diuresis, and respiration, as well as
pain relief. In addition to hemodialysis therapy, ventilation support may be needed.
There is no specific therapy available for NE. The antiviral drug ribavirin has
been studied in the treatment of HFRS in China, in a prospective, double-blind and
placebo-controlled trial (Huggins et al. 1991). This study showed a sevenfold
decrease in mortality risk with intravenous ribavirin therapy. Furthermore, oliguria
and hemorrhages were less common in the ribavirin group (Huggins et al. 1991).
Another study in HFRS patients were carried out in Korea and it suggested that
ribavirin therapy may decrease renal complications (Rusnak et al. 2009). However,
there are no studies regarding PUUV-infected patients and ribavirin therapy.
In the context of prevention, avoiding the exposure to rodents and their excreta is
of importance. The most important risk factors for contracting PUUV infection are
smoking and living in buildings with holes allowing rodents to enter (Vapalahti et
al. 2010). Vaccines have been developed against viruses causing HFRS in Asia, but
there are no vaccines available against DOBV or PUUV (Schmaljohn 2009).
However, there are recent promising results from a phase 1 study concerning HTNV
and PUUV DNA vaccines tested as single or in combination in three groups of nine
volunteers (Boudreau et al. 2012).
2.2.2.8 Prognosis
The natural course of NE is usually favorable and the outcome is spontaneous
recovery. However, in rare cases, the disease can be fatal. The reported mortality in
Finland is 0.08 % (Makary et al. 2010).
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There are several studies concerning the long-term outcome of PUUV infection.
In two earlier Finnish studies, 20 and nine patients were studied 1-7 years and 4-5
years after acute NE, respectively (Lähdevirta 1971, Lähdevirta et al. 1978). In the
first study, it was detected that five patients had slightly reduced creatinine
clearance and the renal concentration capacity was decreased in eight patients
(Lähdevirta 1971). In the second study, creatinine clearance was normal in all of the
patients, but five patients had slightly depressed tubular function (Lähdevirta et al.
1978). In two more recent Finnish studies with 46 and 37 patients with previous NE
and 38 healthy seronegative controls, it was revealed that 5-6 years after NE, the
patients had higher glomerular filtration rate, greater urinary protein excretion and
higher systolic blood pressure compared to the controls (Mäkelä et al. 2000,
Miettinen et al. 2009). Thirty-six patients who participated in the first study were
also examined 10 years after acute NE (Miettinen et al. 2006). It was revealed that
the glomerular hyperfiltration and proteinuria detected at five years after the acute
disease had disappeared. The prevalence of hypertension was also no longer
statistically significantly higher than in the controls. However, the possibility
remained  that  NE may dispose  some patients  to  the  development  of  hypertension.
Otherwise, the long term prognosis of NE is favorable (Miettinen et al. 2006).
Finally,  another  study  revealed  that  the  clinical  severity  of  acute  PUUV  infection
does not predict the long term outcome with reference to renal function, blood
pressure or 24-hour urinary protein excretion (Miettinen et al. 2010).
Furthermore, the prognosis of the hormonal deficiencies detected during acute
NE has been studied (Mäkelä et al. 2010). Thirty patients out of 54 had hormonal
alterations during the acute phase. After a median follow-up of five years, nine
patients (17 %) were diagnosed with a chronic hormonal deficit. Hypopituitarism,
primary hypothyroidism and chronic testicular failure were each diagnosed in five
patients. The occurrence of these long-term hormonal defects was not associated
with the severity of the acute infection (Mäkelä et al. 2010).
2.2.3 Hantavirus cardiopulmonary syndrome
In contrast to HFRS, HCPS is typically characterized by cardiopulmonary
dysfunction instead of hemorrhages and renal failure (Kanerva et al. 1998a, Peters et
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al. 1999, Jonsson et al. 2010, Simpson et al. 2010). The severity of this dysfunction
can range from mild hypoxemia with stable hemodynamics to rapidly progressive
respiratory failure with cardiogenic shock (Peters et al. 1999). The disease can be
divided into four clinical phases: prodrome, pulmonary edema and shock, diuresis,
and convalescence (Simpson et al. 2010). After an incubation period of 1-6 weeks,
the disease starts with fever, chills, myalgia, headache, and gastrointestinal
symptoms (Kanerva et al. 1998a, Peters et al. 1999, Jonsson et al. 2010, Simpson et
al. 2010). Then, after 3-6 days, progressive cough, tachypnea, tachycardia, and
hypotension develop, leading to respiratory decompensation, pulmonary edema and
shock (Kanerva et al. 1998a, Simpson et al. 2010). Mortality most commonly occurs
within the first 24 hours of this phase (Simpson et al. 2010). Again, after 3-6 days,
surviving patients enter the diuretic phase with rapid resolution of respiratory and
hemodynamic abnormalities (Simpson et al. 2010).
Typical laboratory findings in HCPS are thrombocytopenia, leukocytosis with a
left shift, and circulating immunoblastoid lymphocytes (Peters et al. 1999, Simpson
et al. 2010). Although thrombocytopenia is present in 79 % of patients, hemorrhages
are rare (Simpson et al. 2010). Hemoconcentration due to capillary leakage, elevated
liver enzymes and lactate dehydrogenase, hypoalbuminemia, as well as proteinuria
are also common findings (Simpson et al. 2010). Although 20-48 % of patients
present with elevated creatinine levels, severe renal failure is uncommon (Peters et
al. 1999, Simpson et al. 2010).
Chest  radiographic  abnormalities  are  present  in  most  patients  on  admission  and
the typical finding is interstitial pulmonary edema (Kanerva et al. 1998a, Peters et
al. 1999, Simpson et al. 2010). Two thirds of the patients subsequently develop
alveolar edema, which is typically bibasilar and perihilar (Kanerva et al. 1998a,
Peters et al. 1999). Furthermore, pleural effusion develops in all patients as the
disease progresses (Simpson et al. 2010). The heart size remains normal, but ECHO
reveals moderately to severely depressed left ventricular systolic function (Peters et
al. 1999). Death, if it occurs, is caused by progressive myocardial insufficiency
(Simpson et al. 2010).
The mortality of HCPS is high, 35-60 % (Jonsson et al. 2010, Simpson et al.
2010). The surviving patients take typically a few months to convalesce, but it can
take as long as two years to fully recover (Simpson et al. 2010).
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Recently, growing evidence has showed that there are similarities in the clinical
picture of HFRS and HCPS and the symptoms overlap to some extent (Rasmuson et
al. 2011a, Clement et al. 2012).
2.3 Pathogenesis and immunology in hantaviral
infections
2.3.1 Increased capillary permeability
Pathological changes in both HFRS and HCPS are characterized by an increased
capillary permeability in the affected organs and endothelial cells are considered the
primary targets of hantavirus infection (Cosgriff 1991, Zaki et al. 1995, Kanerva et
al. 1998a). Increased capillary permeability and vascular leakage explain many
signs and symptoms in HFRS and HCPS, such as hypotension and shock, abdominal
pains and retroperitoneal edema, as well as pleural effusion and pulmonary edema
(Cosgriff 1991, Kanerva et al. 1998a). The exact pathogenetic mechanisms behind
this central phenomenon in hantavirus infections are currently not completely
understood.
2.3.2 Apoptosis
Apoptosis is a genetically controlled cell death process playing an important role in
physiological conditions, such as multicellular organism development and tissue
regeneration, as well as in some pathological conditions including inflammation and
infection (Strasser et al. 2000). Hantaviruses have been considered noncytopathic.
Endothelial cells, the primary targets in naturally acquired hantavirus infections, are
infected in vitro with no cytopathic effects (Yanagihara and Silverman 1990).
Human cell lines infected with PUUV have also shown no cytopathic effects
(Temonen et al. 1993). However, under certain conditions Tula hantavirus induces
apoptosis in cultured Vero E6 (green monkey kidney) cells, a commonly used cell
line in hantavirus infections (Li et al. 2004, Li et al. 2005). Furthermore, two studies
have shown that hantavirus infection is able to cause apoptosis in Vero E6 or human
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embryonic kidney cells (Kang et al. 1999, Markotic et al. 2003). In addition,
apoptosis has been detected in lymphocytes during HFRS (Akhmatova et al.
2003)(cited in (Li et al. 2005)). Finally, a Swedish study with 18 PUUV-infected
patients showed that serum level of the epithelial cell apoptosis marker, caspase-
cleaved cytokeratin-18, is increased during the acute infection indicating apoptosis
of epithelial cells (Klingström et al. 2006). The tissue damage is suggested to be due
to immunopathogenic mechanisms.
2.3.3 Integrins and vascular endothelial growth factor
The cellular entry of pathogenic hantaviruses is mediated by ?3-integrins
(Gavrilovskaya et al. 1998, Gavrilovskaya et al. 1999). Integrins are heterodimeric
surface receptors on endothelial cells and platelets mediating cell-to-cell adhesion,
cell migration, extracellular matrix protein recognition, and platelet aggregation.
Integrins are composed of ? and ? subunits (Albelda and Buck 1990). ?3-integrins
have an important role in regulating vascular integrity, endothelial cell permeability,
and platelet functions (Mackow and Gavrilovskaya 2009). Pathogenic hantaviruses
may inhibit these functions, thus interfering with the endothelial permeability.
Supporting this assumption, it has been demonstrated that pathogenic hantaviruses
inhibit ?3-integrin directed endothelial cell migration, whereas non-pathogenic
hantaviruses do not (Gavrilovskaya et al. 2002). Further, the surface density of
platelet ?3-integrin has been demonstrated to correlate with disease severity in
HTNV infection (Liu et al. 2008).
Vascular endothelial growth factor (VEGF) is expressed on angiogenic
endothelium and is able to induce vascular permeability (Dvorak 2006). ?3-integrins
regulate vascular permeability through effects on VEGF (Gavrilovskaya et al.
2008). ?3-integrin and VEGF receptor-2 (VEGFR2) form a functional complex and
interact with each other (Wang et al. 2012). It has been demonstrated that
pathogenic hantaviruses enhance the permeability of endothelial cells in response to
VEGF, while non-pathogenic hantaviruses have no effect on endothelial cells
(Gavrilovskaya et al. 2008, Wang et al. 2012). This occurs concurrently with
inhibition of ?3-integrin functions (Gavrilovskaya et al. 2008). Further, hantavirus-
directed permeability has been inhibited by antibodies against VEGF2
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(Gavrilovskaya et al. 2008, Gorbunova et al. 2011). This finding may offer a
therapeutic possibility in hantavirus infections.
2.3.4 T lymphocytes
The cytotoxic CD8+ T lymphocytes specific for hantavirus are assumed to play an
important role in the pathogenesis of hantaviral infections (Terajima et al. 2007). On
the other hand, T cells have an essential role in the clearance of the virus infection
(Terajima and Ennis 2011).
At the onset of HFRS and HCPS, increased amounts of circulating CD8+ T cells
are observed (Huang et al. 1994, Ennis et al. 1997, Kilpatrick et al. 2004). A recent
Swedish study showed that, in NE, a primary effector CD8+ T cell response
develops rapidly after virus infection peaking within two weeks after the beginning
of symptoms (Lindgren et al. 2011). In HTNV infection, also a decreased CD4+
helper cell/CD8+ ratio has been demonstrated (Huang et al. 1994). In addition,
CD8+ T lymphocytes predominate the cell infiltrate in the kidneys during the acute
phase of NE as well as in the lungs in lethal HCPS cases (Zaki et al. 1995, Temonen
et al. 1996). Bronchoalvelolar lavage fluid from patients with NE has also been
shown  to  contain  higher  amount  of  CD8+  T  cells  and  natural  killer  (NK)  cells
compared to healthy controls (Linderholm et al. 1993). Endobronchial mucosal
biopsies from patients with NE have revealed increased numbers of both CD8+ and
CD4+ T cells (Rasmuson et al. 2011b). These findings indicate a local immune
response in the lungs. A recent study detected that urine type 2 cytokine-specific
transcription  factor  (GATA-3)  necessary  for  the  generation  of  type  2  T  cells  is  an
independent risk factor for severe PUUV-induced acute kidney injury either
reflecting enhanced type 2 T cell responses or kidney injury (Libraty et al. 2012).
Furthermore, a rapid expansion and long-term persistence of elevated NK cells in
PUUV infection has also been reported recently (Björkström et al. 2011).
The virus-specific CD8+ memory T cell population has been demonstrated to
develop during the convalescent phase of NE (Tuuminen et al. 2007). Furthermore,
the memory T cells have been shown to persist thereafter for several years as well
after PUUV as ANDV infection (Van Epps et al. 2002, Manigold et al. 2010). These
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persisting memory T cells may play a role in the long-lasting immunity after a
hantavirus infection.
It has been suggested that virus-specific cytotoxic T cells play an important role
in the development of endothelial cell dysfunction and capillary leakage in HFRS
and HCPS (Terajima et al. 2007). Supporting this idea, it has been shown that
hantavirus-specific cytotoxic T cells recognize and increase the permeability of
human endothelial cells infected with SNV (Hayasaka et al. 2007). Furthermore, the
frequency of circulating virus-specific CD8+ T cells has been demonstrated to
associate  with  the  severity  of  HCPS  (Kilpatrick  et  al.  2004).  CD4+  regulatory  T-
cells (Tregs), in turn, have been shown to be reduced in HFRS compared to healthy
controls and correlate negatively with the severity of the disease (Zhu et al. 2009).
Inefficient control of effector T cells by Tregs may contribute to the pathogenesis of
hantavirus infection. A Chinese study reported that the frequency of HTNV-specific
T cells was lower in patients with severe disease (Wang et al. 2009a). However, in
this study, the frequency of CD4+ and CD8+ T cells was combined.
2.3.5 Cytokines
Cytokines are mediators of information between cells. They are produced by a
number of different cell types, such as monocytes, macrophages, and lymphocytes,
in  response  to  inflammatory  signals  and  participate  in  the  regulation  of  the
inflammatory response. Cytokines can be functionally divided into pro-
inflammatory (such as IL-1, IL-6, TNF-?, IL-2, IL-12) and anti-inflammatory (such
as transforming growth factor (TGF)-?, IL-1Ra, IL-10) cytokines. In addition to
acute phase protein induction, cytokines, especially TNF-?, IL-1, and IL-6, are
mediators responsible for fever and septic shock (Akira et al. 1990, Tracey and
Cerami 1994). The cytokine production occuring during hantaviral infection may be
one of the major causes of the symptoms in HFRS and HCPS and they are thought
to play an important role in the vascular leakage observed in these diseases. TNF-?
is known to be able to increase vascular permeability (Tracey and Cerami 1994).
Increased cytokine levels have been found in plasma, urine and tissues of patients
with hantaviral infection. In HFRS caused by HTNV, elevated levels of IFN-? and
IFN-? were found in sera of 110 patients of the Korean war (Krakauer et al. 1994).
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Further, IL-1? was detectable, whereas in healthy controls it was not (Krakauer et
al. 1995). A Swedish study with 15 patients with NE showed IL-6 and TNF-?
concentrations to be elevated in all and IL-10 concentrations in most patients in the
acute phase (Linderholm et al. 1996). Maximum levels of TNF-? and IL-6 also
correlated positively with the maximum level of serum creatinine and TNF-? also
inversely with mean blood pressure. A Finnish study conducted with 19 PUUV-
infected patients showed soluble IL-2 receptor (sIL-2R), IL-6, and IL-8
concentrations to be elevated. There was also an inverse correlation between the
mean arterial pressure and sIL-2R as well as between minimum platelet count and
sIL-2R  and  IL-6  (Takala  et  al.  2000).  However,  no  correlation  between  serum
creatinine and cytokine levels was found in this study.
A Finnish study with 70 PUUV-infected patients found plasma levels and urinary
excretion of IL-6 to be increased. However, there was no correlation between
plasma and urinary levels indicating possible local production of IL-6 in the kidneys
(Mäkelä et al. 2004). Urinary excretion of IL-6 correlated with urinary albumin, IgG
and protein excretions, but not with serum creatinine levels. In another Finnish
study, TNF-?, TGF-?, and platelet-derived growth factor expression was detected to
be increased in the kidneys of PUUV-infected patients in the peritubular area of the
distal  nephron  (Temonen  et  al.  1996).  In  a  study  carried  out  in  the  United  States,
cytokine-producing cells were detected in the lungs, kidneys, liver, and spleen of
patients with fatal HCPS (Mori et al. 1999). The number of cytokine-producing cells
in the lungs was higher than in the kidneys and in the liver suggesting that local
cytokine production may play an important role in the pathogenesis of HCPS.
Some recent studies have provided more information concerning cytokines in
hantaviral infections. A Swedish study compared cytokine levels between 19 male
and 20 female patients with NE (Klingström et al. 2008). Interestingly, the females
showed higher plasma levels of IL-9, fibroblast growth factor 2, and granulocyte-
macrophage colony-stimulating factor and lower levels of IL-8 and IFN-?-induced
protein 10 in the acute phase of the disease as compared to the males. Thus, PUUV
infection may induce sex-dependent differences in the innate immune responses in
humans, which may contribute to the higher incidence of NE among males.
A Slovenian study was carried out with 61 patients with PUUV infection and 52
patients with DOBV infection (Saksida et al. 2011). Increased levels of IL-10, IFN-
?,  and  TNF-? were  found  in  almost  all  of  the  serum  samples.  The  concentrations
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were higher in patients infected with DOBV than PUUV. Furthermore, the levels of
IL-10 and TNF-? were higher in patients with a more severe clinical course of
DOBV infection. However, PUUV-infected patients presented no differences in
cytokine concentrations according to disease severity, but showed higher IL-12
levels than DOBV-infected patients. The authors suggested that the imbalance in the
production of pro-inflammatory and regulatory cytokines may be associated with
the disease severity of hantaviral infection (Saksida et al. 2011).
This hypothesis is supported by the results of a study with 21 HCPS patients and
21 controls carried out in Brazil (Borges et al. 2008). In this study, the levels of pro-
inflammatory IL-6 and TNF-? as well IFN-? were found to be elevated but the level
of  an  anti-inflammatory  cytokine,  TGF-?,  was  reduced.  The  levels  of  the  pro-
inflammatory cytokines correlated with disease severity and, in fatal cases, very
high IL-6 levels were seen. Finally, a German study with 64 patients with acute NE
support the idea of imbalance in cytokine production (Sadeghi et al. 2011).
Significantly elevated levels of IL-2, IL-6, IL-8, TGF-?1, and TNF-? were detected.
Furthermore, disease severity characterized by elevated creatinine and low platelet
counts correlated with high pro-inflammatory IL-6 and TNF-? levels but low anti-
inflammatory TGF-?1 levels. Also the cytokine levels in the early and late phases of
the disease were compared. The levels of the pro-inflammatory cytokines decreased,
whereas TGF-?1 levels increased. The authors conclude that possibly delayed
induction of the protective immune mechanism to downregulate the early pro-
inflammatory immune response contributes to the pathogenesis of human hantaviral
infection.
2.3.6 Host genetic factors
The clinical course of hantaviral infections is influenced by host-related factors.
Several studies have been carried out in relation to host genetics in NE. Human
leukocyte antigens (HLA) are major cell surface antigens, whose role is to present
pathogen-derived antigens to T cells and to initiate adaptive immune responses
(Klein and Sato 2000). In a Finnish study with 74 patients, HLA alleles B8,
C4A*Q0, and DRB1*0301 associated with the most severe form of the disease
(Mustonen et al. 1996). Furthermore, all patients suffering from shock and most
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patients requiring dialysis treatment were positive for HLA B8 allele. On the
contrary, HLA B27 was shown to be less frequent in patients with NE than in the
general population and it was associated with a mild form of the disease (Mustonen
et al. 1998). In 39 Finnish pediatric patients, no significant differences in the clinical
picture with and without HLA B8-DRB1*03 haplotype were found (Mustonen et al.
2004). However, this haplotype was detected in a significantly higher proportion of
patients than in the general population.
Polymorphism at position -308 of the TNF-? gene promoter region was studied
in 59 Finnish patients and 40 controls (Kanerva et al. 1998b). TNF2, a high-
producing genotype of TNF-?, was found to be more frequent in hospitalized NE
patients as compared to controls. Yet another Finnish study showed that the clinical
course of NE is more severe in TNF2 carriers than non-carriers (Mäkelä et al. 2001).
However, a study on TNF-? gene promoter polymorphism at position -238 in 36
Belgian patients showed that the low producer genotype was associated with a more
severe clinical course of NE (Maes et al. 2006). The discrepancy between these
results may be explained by the findings of 116 patients with NE in a Finnish study,
where the TNF?(-308) showed unlikely to be of marked significance to the outcome
of  NE  (Mäkelä  et  al.  2002).  The  association  of  TNF2  allele  with  severe  NE  is
probably due to strong linkage with HLA-B8-DR3 haplotype. Thus, TNF2 is not an
independent risk factor for severe NE, but a passive component in the extended
haplotype. Moreover, a Finnish study with 87 NE patients and 400 blood donors as
controls indicated that NE patients were more often IL-1receptor antagonist-2 allele
and IL-1?-2 allele negative than the seronegative controls (Mäkelä et al. 2001).
Host genetic factors in association with chest radiography findings have been
studied in 114 Finnish patients with NE (Paakkala et al. 2008). Both the presence
and severity of abnormal NE-related radiography findings associated with the B8,
DR3, and TNF2 alleles. Pleural effusion, a sign of increased capillary permeability,
showed the strongest association with these genetic factors. The association of HLA
haplotype with CNS-related symptoms has been studied in 58 Finnish patients with
NE (Hautala et al. 2010). A significant negative correlation between cerebrospinal
fluid inflammation and DR15(2)-DQ6 haplotype was found, indicating that host
genetics may have a role in CNS involvement. HLA-B, HLA-DRB1, TNF-?(-308)
and IL-6(-174) alleles were studied in 43 patients six years after NE (Miettinen et al.
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2010). The genetic factors determined did not predict the long term outcome of the
patients.
Studies concerning other hantaviruses than PUUV and host genetic factors are
not abundant. In Chinese patients with HFRS caused by HTNV, HLA-DRB1*09
and HLA-B*46-DRB1*09 haplotypes were significantly more frequent than in
controls in a study with 77 patients and 83 healthy controls (Wang et al. 2009b). A
Brazilian study with 26 HCPS patients and 96 individuals with hantavirus
seroconversion found TNF2 allele more frequent among the patients than in
individuals with positive serology without a history of HCPS (Borges et al. 2010). A
Slovenian study examined HLA haplotypes in 88 PUUV-infected and 72 DOBV-
infected patients (Korva et al. 2011). PUUV-infected patients, especially with a
severe form of the disease, showed to have more frequently HLA-DRB1*13
haplotype  than  DOBV-infected  patients.  HLA-B*07,  in  turn,  showed  to  have  a
possible protective role in PUUV infection. Furthermore, DOBV-infected patients
had a significantly higher frequency of HLA-B*35 than PUUV-infected patients.
Thus, different hantaviruses may be presented differently through the same HLA
molecules.
2.3.7 Complement system
The complement system has three major pathways: the classical, alternative, and the
lectin-dependent pathway. These pathways are activated differently, but they all
converge at the point of cleavage of complement component C3 (Walport 2001).
The end-product of the complement cascade is the cytolytic membrane-attack
complex, which is formed by sequential assembly of the complement components
C5b, C6, C7, and C9 to a target cell membrane (Walport 2001). If the complexes are
formed without a target membrane in a fluid phase, C5b-9 binds to S-protein or
clusterin, and a non-lytic soluble SC5b-9 terminal complex is formed (Podack and
Muller-Eberhard 1979).
The activation of the complement system in acute PUUV infection has been
analyzed in two Finnish studies. In the first study, 25 patients with acute NE were
examined (Paakkala et al. 2000). Complement activation was observed in 23 (92 %)
patients.  In  10  patients,  the  complement  system  was  activated  mainly  through  the
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alternative route, in six, mainly through the classical route and, in five, through both
the alternative and the classical route. Furthermore, the classical pathway activation
was associated with a severe clinical course of NE (Paakkala et al. 2000). A recent
study with 61 patients with acute NE analyzed the levels of SC5b-9, C3, and C4
(Sane et al. 2011). It was found that the alternative pathway of the complement
system was activated during the acute phase of the infection, as evidenced by
increased levels of SC5b-9 and decreased levels of C3. Apparently, the level of
complement activation correlated with the severity of the disease. It is further
suggested that the complement activation may contribute to the pathogenesis of
acute NE by contributing to the development of vascular leakage (Sane et al. 2011).
2.3.8 Humoral immunity
Both HFRS and HCPS induce high levels of virus-specific IgM directed against the
N protein as well as Gn and Gc glycoproteins (Groen et al. 1992, Lundkvist et al.
1993, Bostik et al. 2000). The N protein, however, has been demonstrated to be the
major antigenic protein in PUUV infection (Lundkvist et al. 1993). Hantavirus-
specific IgM antibodies are positive early after the onset of the disease, remain
detectable during the convalescent phase, and usually become undetectable 2-5
months after the infection (Lundkvist et al. 1993, Elgh et al. 1998).
Hantavirus-specific IgG antibodies also appear during the acute phase, but an
increase in IgG levels is seen during the early convalescent phase (Groen et al.
1992, Lundkvist et al. 1993). The acute phase IgG response is mainly directed
towards the N protein, while IgG antibodies directed against the glycoproteins
appear later in the early convalescent phase (Lundkvist et al. 1993).
The levels of total IgA as well as virus-specific IgA1 antibodies have been shown
to  be  elevated  during  acute  HFRS as  well  as  during  HCPS (Bostik  et  al.  2000,  de
Carvalho Nicacio et al. 2000, Padula et al. 2000). Furthermore, PUUV-specific IgA
has still been detectable over 10 years after the infection (de Carvalho Nicacio et al.
2000). Moreover, total IgE as well as virus-specific IgE have been reported to be
elevated during acute PUUV infection (Alexeyev et al. 1994).
The neutralizing antibodies develop early after hantavirus infection and they are
usually  present  at  the  onset  of  the  disease  (Hörling  et  al.  1992).  They   control  the
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infection and in HCPS it has been shown that high neutralizing antibody titres in the
acute phase associate with a milder clinical course of the disease (Bharadwaj et al.
2000). It is believed that hantaviruses leave a life-long immunity. In support of this
assumption, PUUV IgG antibodies against N protein and Gn and Gc proteins as well
as virus-neutralizing antibodies have been detected several decades after the
infection (Settergren et al. 1991, Hörling et al. 1992, Lundkvist et al. 1993). The
humoral cross-reactivity between different hantaviruses is high, particularly between
viruses carried by the same rodent genus (Lundkvist et al. 1997, Maes et al. 2004). It
is not known, whether a previous hantavirus infection protects from an infection by
another hantavirus.
2.3.9 Mechanisms of hantavirus pathogenesis
The pathogenesis of hantavirus infections remains presently unclear. However, the
capillary leakage syndrome is a central phenomenon and many signs and symptoms
of  as  well  HFRS  as  HCPS  can  be  explained  by  this  phenomenon.  Host  genetics
influence both the susceptibility to hantavirus infections and the severity of the
disease. Immunological factors rather than direct cytopathy probably play an
important role in the pathogenesis and the development of increased vascular
permeability. Although signs of apoptosis have been detected during PUUV
infection, they have been attributed to immune responses. The most important
immunological factors considering the pathogenesis of hantavirus infection are
probably cytokines and T cells. An imbalance in the production of pro-inflammatory
and  anti-inflammatory  cytokines,  which  could  downregulate  the  early  pro-
inflammatory immune response, may be important. The virus-specific cytotoxic T
cells are assumed to play an important role in the development of endothelial cell
dysfunction and capillary leakage. However, also inefficient control of effector T
cells by Tregs may contribute to the pathogenesis. The exact mechanisms behind the
increased vascular permeability are unclear. However, the role of VEGF interacting
with  ?3-integrin may be important. Furthermore, the complement system may also
be involved in the development of capillary leakage. The virus-specific neutralizing
antibodies  play  a  role  in  the  control  of  infection  and  the  evolvement  of  the  long-
lasting immunity.
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2.4 Pentraxins
Pentraxins are a family of acute-phase pattern recognition receptor (PRR) proteins,
which are characterized by a cyclic multimeric structure (Garlanda et al. 2005,
Bottazzi et al. 2009). PRRs recognize microbial structures called pathogen-
associated molecular patterns and activate the innate immune response (Garlanda et
al. 2005). Members of the pentraxin family include the short pentraxins, i.e. CRP
and serum amyloid P, as well as the long pentraxins, e.g. PTX3 and neuronal
pentraxin (Garlanda et al. 2005).
2.4.1 C-reactive protein
CRP was originally described and named for its ability to bind in a calcium-
dependent way the C-polysaccharide of Streptococcus pneumoniae (Tillett and
Francis 1930, Abernethy and Avery 1941). CRP is the prototype of an acute phase
response protein produced in the liver in various inflammatory and infectious
conditions mainly in response to IL-6 (Volanakis 2001, Garlanda et al. 2005). The
main functions of CRP are the activation of the classical complement pathway,
enhancement of phagocytosis, and induction of cytokine production (Volanakis
2001, Ablij and Meinders 2002). CRP plays an important role in the innate immune
response against different micro-organisms. It is rapidly increased up to 1,000-fold
after the onset of a stimulus (Ablij and Meinders 2002). Numerous other conditions
besides infections and inflammation, such as trauma, surgery, burns, necrosis,
myocardial infarction, malignancies, childbirth, strenuous exercise, and stress, can
stimulate the production of CRP (Volanakis 2001, Ablij and Meinders 2002). CRP
may  also  have  a  role  in  the  development  of  atherosclerosis  and  cardiovascular
diseases (Ablij and Meinders 2002).
CRP is widely used in clinical practice in the evaluation of disease severity in
different infections as well as inflammatory disorders. It is commonly used in
assessing the severity and prognosis of various bacterial infections. However, in
pneumonia as well as in sepsis, the results have been controversial concerning the
predictive value of CRP in these conditions (Suprin et al. 2000, Pettilä et al. 2002,
Muller et al. 2007, Chalmers et al. 2008, Silvestre et al. 2009). Furthermore, the
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ability  of  CRP  to  discriminate  or  predict  the  outcome  of  sepsis  has  been  disputed
(Mitaka 2005, Silvestre et al. 2009, Tsalik et al. 2011).
CRP is also used in the context of distinguishing viral from bacterial infections,
although its discriminative value has been debated (Salonen and Vaheri 1981,
Gendrel et al. 1999, Heiskanen-Kosma and Korppi 2000). Although CRP
concentrations tend to be higher in invasive bacterial infections than in viral
infections, the concentrations overlap and concentrations of 100 mg/l or higher have
been reported in different viral infections, including NE (Salonen and Vaheri 1981,
Settergren et al. 1989, Mustonen et al. 1994a).
Studies concerning CRP and the prognosis of the viral infection are not very
abundant. In children, CRP concentrations do not relate to the severity of influenza
or adenovirus infection (Appenzeller et al. 2002, Edelbauer et al. 2006). In influenza
A H1N1pdm09 virus infection, CRP has been shown to be an independent
prognostic factor for intensive care unit admission and mechanical ventilation
(Zimmerman et al. 2010). Furthermore, persistence of elevated CRP levels after
treatment has related to poor prognosis in influenza A H1N1 (Wen et al. 2011). In
severe acute respiratory syndrome (SARS), elevated CRP level at admission has
been shown to be a predictive factor for death (Wang et al. 2004). In HIV, CRP is
significantly related to all-cause mortality as well as disease progression (Neaton et
al. 2010). This association is seen also in children (Drain et al. 2007). In acute
hepatitis A virus infection, elevated CRP is an independent risk factor for the
development of acute kidney injury (Choi et al. 2011). In dengue virus infection,
elevated CRP levels associated with the severity of dengue hemorrhagic fever (Levy
et al. 2010). In children with dengue virus infection, CRP concentrations were
higher in dengue hemorrhagic fever patients than in patients with dengue fever
(Juffrie et al. 2001). However, in Vietnamese children with dengue hemorrhagic
fever, no association of CRP with disease severity could be detected (Bethell et al.
1998).  In  Crimean-Congo  hemorrhagic  fever,  CRP  proved  to  be  a  risk  factor  for
severe  clinical  course  of  the  disease  and  fatality  (Yilmaz  et  al.  2010,  Ozturk  et  al.
2012).
In acute renal failure (ARF), there are reports of elevated CRP levels associating
with poor disease outcome and death, but also reports with no significant difference
in CRP levels between survivors and non-survivors have been published (Simmons
et al. 2004, Wang et al. 2006, Kadiroglu et al. 2007, Perez Valdivieso et al. 2008,
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Xie et al. 2011). However, contrary to the findings in ARF, it has been shown in a
mouse model of systemic lupus erythematosus (SLE) that treatment with CRP
prolongs survival and prevents and ameliorates proteinuria and nephritis (Du Clos et
al. 1994, Rodriguez et al. 2005, Rodriguez et al. 2006). Transgenic SLE-prone mice
expressing human CRP also have less proteinuria and a better life expectancy than
the non-transgenic SLE-prone mice (Szalai et al. 2003). These findings have been
attributed to the ability of CRP to increase the clearance of immune complexes and
to prevent their accumulation in the renal cortex (Szalai et al. 2003). In humans, it
has also been reported that certain genetic factors that associate with reduced CRP
production predispose to the development of SLE (Russell et al. 2004).
In conclusion, CRP is the prototype acute phase protein produced in infection and
inflammation, but also in various other clinical conditions. It plays an important role
in the host innate immune responses against different micro-organisms. CRP is
widely used in clinical practice in order to detect an infection, distinguish bacterial
from viral infections, and to assess the severity and prognosis of different infections
as well as inflammatory disorders.
2.4.2 Pentraxin-3
PTX3 is a multifunctional PRR and the prototype protein of the long pentraxin
group. In contrast to CRP, which is synthesized mainly in the liver, PTX3 is
produced at the site of inflammation mainly by mononuclear phagocytes and
dendritic cells, but also other types of cells, such as endothelial cells and fibroblasts
(Mantovani et al. 2008, Bottazzi et al. 2009, Deban et al. 2009). Also renal epithelial
cells produce PTX3 in response to stimulation (Nauta et al. 2005). Neutrophil
granules can serve as a source of pre-synthesized PTX3, which upon stimulation, is
released rapidly into circulation (Jaillon et al. 2007). The production of PTX3 is
induced by pro-inflammatory signals, such as by bacterial lipopolysaccharide, IL-
??, TNF-?, and TLR engagement, but not by IL-6 (Mantovani et al. 2008, Bottazzi
et al. 2009, Deban et al. 2009). PTX3 has the capacity to bind complement
component  C1q  and  to  activate  the  classical  complement  pathway  (Bottazzi  et  al.
1997). It also interacts with factor H, an alternative pathway regulator thus
preventing exaggerated complement activation (Deban et al. 2008). It interacts with
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several bacteria, fungi, and viruses, promoting their phagocytosis and clearance
(Mantovani et al. 2008, Bottazzi et al. 2009, Deban et al. 2009). In addition, PTX3
has  a  non-redundant  role  in  female  fertility  by  acting  as  a  nodal  point  for  the
assembly of the cumulus oophorus hyaluronan-rich extracellular matrix necessary
for successful ovulation (Garlanda et al. 2005).
PTX3 has been studied in various conditions. PTX3 concentration has been
found to associate with cardiovascular risk factors and act as an early indicator of
acute myocardial infarction (Peri et al. 2000, Jylhävä et al. 2011a). It predicts
mortality in coronary heart disease and myocardial infarction as well as after
ischemic stroke (Latini et al. 2004, Dubin et al. 2012, Ryu et al. 2012). In vasculitis,
it indicates disease activity (Fazzini et al. 2001, Dagna et al. 2011). In addition,
patients with a chronic kidney disease show an increase in PTX plasma levels, with
the highest  levels in patients with the most severe form of the disease (Tong et  al.
2007).
PTX3  has  an  essential  role  in  anti-fungal  innate  immune  response.  PTX3-
deficient mice are highly susceptible to Aspergillus fumigatus infection (Garlanda et
al. 2002). Furthermore, the administration of PTX3 has protective efficacy against
Aspergillus challenge in mice with bone marrow transplants and potentiates the
protective effect of amphotericine B (Garlanda et al. 2002, Gaziano et al. 2004).
In the context of bacterial infections, previous studies have shown that high
PTX3 levels are associated with higher mortality in septicemia and septic shock, as
well as indicate shock in severe meningococcal disease (Sprong et al. 2009, Mauri et
al. 2010, Huttunen et al. 2011a). In addition, high PTX3 is an early predictor of
bacteremia and septic shock in hematologic patients with neutropenic fever (Vänskä
et  al.  2011).  In  critically  ill  patients,  PTX3  correlates  with  disease  severity  and
infection and furthermore, in febrile patients at the emergency department, it
predicts severe disease (Muller et al. 2001, de Kruif et al. 2010). In addition, in
leptospirosis, elevated PTX3 levels predict disease severity and mortality
(Wagenaar et al. 2009). Increased PTX3 levels also associate with active
Mycobacterium tuberculosis infection (Azzurri et al. 2005).
In viral infections, previous clinical studies concerning PTX3 are rare. PTX3 has
been studied in patients with dengue virus infection and the concentrations were
detected to be higher in patients suffering from dengue shock syndrome than in
patients with dengue fever or dengue hemorrhagic fever (Mairuhu et al. 2005). In
44
vitro and in mouse models, PTX3 has been found to have antiviral activity against
influenza virus (Reading et al. 2008) and also to protect from murine and human
cytomegalovirus (CMV) infection (Bozza et al. 2006).
To conclude, PTX3 plays an important role in innate immunity, including
complement activation, opsonization and regulation of inflammation. Pathogen
recognition and elimination are the main functions of PTX3. Moreover, clinical
observations point to PTX3 as a rapidly responding marker of infection and
inflammation, as well as tissue damage.
2.5 Interleukin-6
The IL-6 molecule is a multifunctional cytokine involved in immune responses and
inflammation and also in the regulation of metabolic, regenerative, and neural
processes (Papanicolaou et al. 1998, Scheller et al. 2011). It is mostly regarded as a
pro-inflammatory cytokine, but IL-6 has also many anti-inflammatory activities. It
plays a pivotal role during the transition from innate to acquired immunity (Scheller
et al. 2011). IL-6 is necessary for T cell recruitment and also acts in anti-apoptosis
and differentiation of T cells. Further, it plays a crucial role in B cell proliferation
and  differentiation  as  well  as  in  the  production  of  immunoglobulins.  IL-6  also
activates the production of acute-phase proteins. It is produced by various types of
cells, such as monocytes, macrophages, lymphocytes, fibroblasts, and endothelial
cells (Papanicolaou et al. 1998). IL-6 stimulates the cells via a specific IL-6
receptor.
Plasma IL-6 has been shown to be elevated in several clinical conditions, such as
acute lung injury, acute myocardial infarction, and congestive heart failure and it
was shown to predict morbidity and mortality in these conditions (Parsons et al.
2005, Geppert et al. 2006, Marcucci et al. 2006). Several studies have also shown
plasma IL-6 levels to be elevated in ARF (Himmelfarb et al. 2004, Simmons et al.
2004, Åhlström et al. 2004, Gueret et al. 2009). In addition, high IL-6 levels predict
higher mortality in ARF (Simmons et al. 2004, Kadiroglu et al. 2007). Increased
plasma IL-6 in patients with a critical illness may be due to multiple factors.
Increased IL-6 production by stimulated macrophages in injured organs has been
described (Kielar et al. 2005). ARF may also reduce serum cytokine clearance.
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In the context of infectious diseases, plasma IL-6 has predicted septic shock,
organ dysfunction, and mortality in septic patients (Hack et al. 1989, Oberholzer et
al. 2005, Bozza et al. 2007). Several studies concerning IL-6 in pneumonia have
been carried out and showed high IL-6 levels to predict mortality in this patient
group (Christ-Crain and Opal 2010). In patients with an orthopedic joint prosthesis,
elevated serum IL-6 has predicted periprosthetic infection (Di Cesare et al. 2005). In
active pulmonary tuberculosis, IL-6 level is increased, but during therapy the levels
decrease (Djoba Siawaya et al. 2009). Further, in leptospirosis, high levels of IL-6
were associated with increased mortality (Wagenaar et al. 2009). In invasive
aspergillosis, IL-6 levels are elevated, and persistently high IL-6 levels predict
poorer disease outcome after initiation of treatment (Chai et al. 2010).
IL-6 levels have been detected to be elevated and to predict disease severity and
mortality in several viral infections. However, this is not the case in all viral
infections. In influenza, both plasma and nasal fluid levels of IL-6 have been
associated with higher disease severity (Hayden et al. 1998, Kaiser et al. 2001). In
HIV,  IL-6  is  strongly  related  to  all-cause  mortality  (Kuller  et  al.  2008).  In
Chikungunya virus infection, IL-6 levels are elevated, they associate with a more
severe disease, and remain elevated in chronic cases (Ng et al. 2009, Chopra et al.
2012). Studies on IL-6 in patients with respiratory syncytial virus (RSV), hepatitis B
(HBV), or HCV infection have produced controversial results. Elevated levels have
associated with both a less and a more severe clinical course of RSV infection
(Bennett et al. 2007, Elliott et al. 2007). In children, IL-6 levels did not reflect the
inflammatory activity of HBV infection, while in adults, undetectable IL-6 level at
the early stage of acute exacerbation of HBV infection correlated with a more
favorable long-term outcome (Gora-Gebka et al. 2003, Pan et al. 2011). In HCV
infection, high IL-6 levels have predicted virological response to therapy (Kishida et
al. 2009). However, in HIV/HCV coinfected patients, high plasma IL-6 levels have
predicted failure of the treatment (Guzman-Fulgencio et al. 2012). In tick-borne
encephalitis, the serum IL-6 levels did not correlate with the clinical severity of the
disease, whereas in Japanese encephalitis, the cerebrospinal fluid levels of IL-6 were
higher in non-survivors as compared to survivors (Winter et al. 2004, Toporkova et
al. 2008).
In the context of hemorrhagic fevers, studies on IL-6 have produced controversial
results. In dengue virus infection, high IL-6 levels have predicted severe disease,
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dengue hemorrhagic fever and mortality (Juffrie et al. 2001, Chen et al. 2006, Bozza
et al. 2008). However, a Costa Rican study or another one conducted among
Vietnamese children did not find any significant association of IL-6 levels with the
severity of dengue virus infection (Bethell et al. 1998, Avila-Aguero et al. 2004). In
ebola virus infection, elevated IL-6 levels have predicted both fatal and non-fatal
infection (Baize et al. 2002, Wauquier et al. 2010). These conflicting results may be
due to several factors, such as differences in the timing of sample collection and
classification of the disease severity. A strong correlation between survival and low
IL-6 level has been demonstrated in Lassa fever, while in Crimean-Kongo
hemorrhagic fever, IL-6 level did not differ between severe and mild cases (Papa et
al. 2006, Branco et al. 2011). In hemorrhagic fever-like illness caused by a novel
Bunyavirus, the Huaiyangshan virus, higher IL-6 levels were associated with fatal
outcome (Zhang et al. 2012). Studies concerning IL-6 in hantavirus infections have
been reviewed earlier in this thesis.
To add up, IL-6 is a multifunctional cytokine and one of the most important pro-
inflammatory cytokines responsible for the production of acute phase reactants,
fever and septic shock together with IL-1 and TNF-?. In viral infections, high IL-6
levels have been related to both more and less severe clinical diseases. This may be
due  to  several  factors,  but  differences  in  the  timing  of  sample  collection  and
assigning disease severity may play a role in these controversial results.
2.6 Indoleamine 2,3-dioxygenase enzyme
IDO is an enzyme catalyzing the first and rate-limiting step in the major pathway of
degradation of the essential amino acid tryptophan to kynurenine and its derivatives
(Mellor and Munn 2004, Mellor 2005). Thereby, IDO limits the availability of
tryptophan. IDO is expressed widely in various immune cells, including antigen-
presenting cells, such as monocyte-derived macrophages and dendritic cells (Mellor
and Munn 2004, Mellor 2005). Also other types of cells express IDO, such as
fibroblasts, tumor cells, and TECs (Mellor and Munn 2004, Mellor 2005, Mohib et
al.  2007).  Th1 type  cytokine  IFN-? is  the  strongest  inducer  of  IDO,  however  also
other cytokines and bacterial lipopolysaccharide are capable of inducing it (Mellor
and Munn 2004). Increased IDO activity results in the induction of Tregs and, by a
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positive feedback loop, this can further enhance IDO activity by increased IFN-?
expression (Mellor and Munn 2004, Mulley and Nikolic-Paterson 2008). By
reducing tryptophan, IDO inhibits the replication of various bacteria, intracellular
parasites, and viruses, thus acting as an antimicrobial effector molecule (Mellor and
Munn 2004).
Depletion  of  tryptophan  can  also  lead  to  inhibition  of  T  cell  responses  and
proliferation and thus to immunosuppression and tolerance (Hwu et al. 2000, Mellor
et al. 2002, Mellor and Munn 2004, Mellor 2005). In aged individuals, IDO activity
is increased and predicts mortality, which may be the consequence of suppressed T
cell function (Pertovaara et al. 2006). Placental IDO protects the fetus from rejection
during pregnancy (Munn et al. 1998). IDO may also act as a protective negative
regulator in some autoimmune disorders (Sakurai et al. 2002, Hayashi et al. 2004).
Furthermore, it contributes to the escape of tumor cells from immune surveillance
(Mellor et al. 2002, Uyttenhove et al. 2003).
Enhanced tryptophan degradation or increased IDO activity has been noted in
several conditions, such as infections, autoimmune diseases, malignancies,
neurological disorders, cardiovascular diseases, and depression (Schrocksnadel et al.
2006). In rheumatoid arthritis as well as in primary Sjögren's syndrome, the
overexpression  of  IDO  associates  with  disease  severity  and,  in  SLE,  high  IDO
activity predicts disease activation (Pertovaara et al. 2005, Schroecksnadel et al.
2006, Pertovaara et al. 2007). IDO activity also associates with disease progression
in several malignancies and Alzheimer's disease, as well as with the risk factors for
cardiovascular diseases (Widner et al. 2000, Huang et al. 2002, Niinisalo et al. 2008,
Suzuki et al. 2010).
In the context of bacterial infections, high IDO levels have recently been
documented to associate with severe disease and mortality in sepsis and septic shock
(Huttunen et al. 2010, Tattevin et al. 2010). Also, treatment with granulocyte-
macrophage colony-stimulating factor resulted in reduced IDO levels in severe
sepsis, possibly due to improved antibacterial defense (Schefold et al. 2010).
Previous studies also implicate that enhanced tryptophan degradation may be
associated with poor outcome and the development of sepsis in trauma patients
(Pellegrin et al. 2005, Logters et al. 2009, Ploder et al. 2009). Moreover, IDO
activity predicts poor prognosis in community acquired pneumonia and pulmonary
tuberculosis (Suzuki et al. 2011, Suzuki et al. 2012).
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In the case of viral infections, increased IDO activity has been found in acute
dengue virus infection and chronic HCV infection (Larrea et al. 2007, Becerra et al.
2009). Increased tryptophan degradation has also been found in patients with
chronic Epstein-Barr virus (EBV) and HIV infections (Fuchs et al. 1990, Bellmann-
Weiler et al. 2008). In HIV patients, enhanced tryptophan degradation by IDO was
also associated with disease progression and complications, such as weight loss and
neuropsychiatric disorders (Fuchs et al. 1990, Schroecksnadel et al. 2007).
Furthermore, antiretroviral therapy has reduced tryptophan degradation (Fuchs et al.
1990).
With regard to renal diseases, it has been documented that tryptophan metabolite
levels increase in chronic renal insufficiency, presumably due to an increase in
production and/or decrease in degradation rather than due to a decrease in renal
excretion (Saito et al. 2000, Schefold et al. 2009). In kidney allograft recipients,
increased IDO activity is associated with rejection (Brandacher et al. 2007). In mice,
IDO promotes renal ischemia-reperfusion injury, while, in contrast, it acts as a
protective factor in nephrotoxic serum nephritis, a model of crescentic
glomerulonephritis (Mohib et al. 2008, Hou et al. 2009).
Taken  together,  IDO has  multiple  functions  in  the  immune system.  It  acts  as  a
part of the innate immunity in antimicrobial defense. On the other hand, IDO also
has immunosuppressive functions. However, its precise role in different disease
processes remains currently mostly unclear.
2.7 Cell-free DNA
Detectable amounts of cf-DNA are present in the plasma of healthy individuals
(Zhong et al. 2007a). However, markedly elevated levels of cf-DNA have been
detected in different clinical conditions and circulating nucleic acids have recently
received growing attention. Furthermore, the discovery of fetus- and placenta-
derived nucleic acids in maternal plasma has opened up a new possibility for
prenatal monitoring of pregnancy-associated complications and fetal abnormalities
(Lo et al. 1997, Swarup and Rajeswari 2007).
High levels of cf-DNA have been reported in various conditions, such as in
cancer, autoimmune diseases, myocardial infarction, stroke, pre-eclampsia, organ
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transplant rejection, and trauma (Lo et al. 1999, Lo et al. 2000, Jahr et al. 2001,
Rainer et al. 2003, Antonatos et al. 2006, Gadi et al. 2006, Zhong et al. 2007b,
Mosca  et  al.  2009).  Cf-DNA  has  also  been  proposed  as  a  marker  for  outcome  or
disease severity in these conditions (Butt and Swaminathan 2008). In critically ill
patients, cf-DNA has also predicted in-hospital mortality (Saukkonen et al. 2007). In
addition, a recent study showed that in aged women, cf-DNA levels are elevated
(Jylhävä  et  al.  2011b).  The  current  view  is  that  in  different  diseases,  cf-DNA
originates from apoptotic or necrotic cells and therefore reflects the amount of
cellular damage (Jahr et al. 2001). This hypothesis is corroborated by the frequent
observation of cf-DNA having a nucleosomal (150-200 base pairs (bp) in length) or
ladder-like appearance characteristic of apoptotic cells (Jahr et al. 2001, Langford et
al. 2007).
Concerning infectious diseases, studies in sepsis patients indicate that plasma cf-
DNA levels are elevated in septic patients with poor outcome (Zeerleder et al. 2003,
Rhodes et al. 2006, Saukkonen et al. 2008, Huttunen et al. 2011b). In trauma
patients, cf-DNA has predicted inflammatory second hit and sepsis, while in febrile
patients, it has showed prognostic value in assessing the probability and severity of
infection and sepsis (Margraf et al. 2008, Moreira et al. 2010). In the context of viral
infections, the studies concerning cf-DNA are few. Elevated levels of cf-DNA have
been found in patients with HBV infection (Bhargava et al. 2010). In a recent study
in dengue patients, the cf-DNA levels were elevated as well as they correlated with
the severity of the infection (Ha et al. 2011).
Circulating  DNA can  cross  the  kidney  barrier  (Botezatu  et  al.  2000).  However,
the exact mechanism by which it crosses the glomerular basement membrane is
currently unknown. Urinary cf-DNA has previously been studied in various
conditions. Colorectal cancer patients secrete cf-DNA with K-ras mutations into
urine (Su et al. 2004, Su et al. 2005). Also, fetal Y-chromosomal DNA sequences
have been detected in the urine of pregnant women carrying male fetuses (Koide et
al. 2005, Shekhtman et al. 2009). In hematopoetic stem cell transplant patients,
donor-derived DNA has been detected in urine, whereas in the case of renal
transplantation recipients, donor-derived DNA has been found in urine and also
suggested to be a marker for acute transplant rejection (Zhang et al. 1999, Hung et
al. 2009). With reference to infections, cf-DNA has been demonstrated to be
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elevated  in  the  urine  of  patients  with  urinary  tract  infection  (Garcia  Moreira  et  al.
2009). In viral infections, urinary cf-DNA has not previously been studied.
To conclude, plasma cf-DNA reflects the amount of cellular damage in infection,
inflammation and tissue trauma and it has been suggested as a prognostic marker in
these conditions. Plasma and urinary cf-DNA also present as possible non-invasive
diagnostic tools in different conditions, such as in pregnancy, organ transplantation
and cancer.
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3. AIMS OF THE STUDY
The aims of this study were:
1. To study whether plasma CRP and IL-6 levels are associated with the severity
of NE and whether their levels have prognostic significance (I).
2. To determine whether plasma PTX3 level is associated with disease severity in
NE and to evaluate the possible role of PTX3 in the pathogenesis of NE (II).
3. To evaluate the association of serum IDO concentration with disease severity
and the possible role of IDO in the pathogenesis of NE (III).
4. To assess plasma cf-DNA levels and urinary cf-DNA excretion in acute NE as
well as their associations with the severity of the disease (IV).
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4. SUBJECTS AND METHODS
4.1 Patients
The patients in all Studies I-IV were prospectively collected consecutive patients
treated at the Tampere University Hospital, Finland, for NE. The diagnosis was
serologically confirmed in all cases. The patients were collected as three groups of
patients at different time periods (Table 2).
The patients in Study I (concerning CRP and IL-6) included patients from groups
1 and 2. Group 1 comprised 70 patients and group 2 comprised 61 patients. Thirteen
patients in group 2 were excluded from Study I due to lack of IL-6 determinations.
Finally, 118 patients treated between September 1997 and December 2004
constituted the study cohort in Study I.
The study cohort in Study III (dealing with IDO) consisted of group 2 with 61
patients and group 3 with 41 patients, altogether 102 patients treated between
January 2000 and January 2008.
Group 2, with 61 patients treated between January 2000 and December 2004
comprised the study cohort in Studies II (PTX3-study) and IV (cf-DNA-study).
Thus, 48 patients treated between January 2000 and December 2004 were included
in all Studies I-IV. Furthermore, 172 patients altogether were studied in Studies I-
IV. Table 2 shows the patient groups and study cohorts as well as the time periods
when the patients of each group were hospital-treated for acute NE. The clinical
characteristics of the patients in Studies I-IV are shown in Table 3.
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Table 2. Number of patients in three different patient groups and in Studies I-IV.
The time period, when the patients were collected, is also shown.
Group 1
N=70
Group 2
N=61
Group 3
N=41
Total number
of patients
Hospital
treatment
9/1997-12/1999 1/2000-12/2004 1/2005-1/2008
Study I 70 patients 48 patients 118
Study II 61 patients 61
Study III 61 patients 41 patients 102
Study IV 61 patients 61
Table 3. Clinical characteristics of the patients in Studies I-IV.
Study I Study III Studies II & IV
Patientsa 118 102 61
Male/femalea 86/32 69/33 44/17
Age (years)b 40 (15-71) 46 (22-77) 46 (22-77)
BMI (kg/m2)b 25.0 (17.1-41.9) 26.2 (18.5-37.0) 25.1 (19.8-35.7)
anumber, bmedian (range)
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4.2 Methods
4.2.1 Study protocols
The  patients  in  group  1  were  first  recruited  in  the  study  by  clinical  suspicion  of
acute NE. Patients in group 2-3 were recruited in the study by clinical suspicion and
a positive rapid point-of-care PUUV test (Hujakka et al. 2001). Thereafter, patients
with a negative serological enzyme immunoassay test for PUUV infection
(Vapalahti et al. 1996) were excluded from further analyses in all patient groups. In
addition, patients with no informed consent were excluded from all patient groups.
Group 3 also had other inclusion and exclusion criteria. The inclusion criteria were:
age 16 years or older, history of fever for one week or less, and at least one of the
following criteria: dipstick proteinuria ?2+, serum creatinine >200 ?mol/l, blood
hematocrit ?45 %, or platelet count ?150 x109/l.  The  exclusion  criteria  were:
pregnancy, positive bacterial culture from a sterile body site, clinical diagnosis of a
bacterial infection as etiology of the febrile illness, and underlying, chronic renal
disease.
All patients in Studies I-IV were studied during the acute phase of NE. A detailed
past and current medical history was obtained, and a careful physical examination
was performed. All blood specimens were obtained either on admission or after that
between 7:30-9:30 in the morning. From patients in group 1, the first blood sample
was obtained on the first morning after hospital admission, and from other patients,
on the first weekday morning. Thereafter, blood samples were taken on consecutive
mornings. In Study I, the blood samples were taken on three consecutive mornings
and, in Studies II-IV, on up to five consecutive mornings.
In Study I, urine collection started on the first evening of hospital care and
continued until three days were completed. The nightly collection period was set
from the last voiding at bedtime until the last voiding on rising. The daytime
collection commenced immediately thereafter and was maintained until a total of 24
hours were completed. After completion, the volumes were measured and timing
was recorded for the collection periods.
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In each Study I-IV, the highest and the lowest value of each patient of the various
variables measured during hospitalization were designated as the maximum and
minimum values. In Studies I-III, certain definitions were made. In Study I, high
plasma creatinine, CRP and IL-6 were defined as a value exceeding the median
maximum level among the study population (193 µmol/l, 69 mg/l and 14.05 pg/ml,
respectively) and thrombocytopenia was defined as the minimum platelet count
equal to or lower than the median among the study population (66 x 109/l). In Study
II, clinically significant thrombocytopenia was defined as a minimum platelet count
lower than 50 x 109/l. Finally, in Study III, significant renal insufficiency was
defined as a plasma creatinine value exceeding 250 µmol/l and minimum urinary
output was defined as low if it was equal to or lower than the median in the study
population (1,440 ml/day).
The patients in group 2 were examined at the out-patient clinic 10 and 30 days
after  discharge  from  the  hospital.  The  out-patient  clinic  controls  to  the  patients  in
group 3 were performed 15 days, as well as six and 12 months after the fever
ceased.
4.2.2 Puumala virus serology
A rapid immunogromatographic PUUV IgM test, Point-of-care PUUMALA®
(Reagena, Toivala, Finland) was used at admission to hospital (Hujakka et al. 2001).
However, the serological diagnosis was verified and based on an immunoglobulin
M-capture enzyme immunoassay and PUUV Sotkamo strain full-length N protein
expressed by the baculovirus system in Sf9 insect cells (Vapalahti et al. 1996). In
comparison with various other protocols, the assay has showed optimal sensitivity
and specificity (Sjölander et al. 1997).
4.2.3 C-reactive protein, pentraxin-3 and interleukin-6
determinations
Plasma CRP was analyzed by Hitachi 705 E Analyzer from 1997 to 1998 and, after
that, by the Roche Diagnostics CRP method using Cobas Integra analyzer
(F.Hoffman-La Roche Ltd, Basel, Switzerland).
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Plasma PTX3 concentrations were determined afterwards from frozen samples
stored at ?70°C. The determinations were performed by using a commercially
available human PTX3 immunoassay (Quantikine, R&D Systems, Inc.,
Minneapolis, MN), following the manufacturer’s instructions.
Plasma IL-6 concentrations were determined afterwards from frozen samples
stored at –70 °C by using commercially available enzyme-linked immunosorbent
assays (PeliKine Compact human IL-6 kits; Central Laboratory of the Netherlands,
Red Cross Blood Transfusion Service, Amsterdam, The Netherlands), following the
manufacturer's instructions. The detection limit for the assay was 0.4 pg/ml for IL-6.
None of the 118 patients had values below the detection limit.
4.2.4 Indoleamine 2,3-dioxygenase determinations
Serum tryptophan and kynurenine concentrations were measured afterwards from
frozen samples stored at –70 °C by reverse-phase high-performance liquid
chromatography (HPLC), as previously described (Laich et al. 2002). Tryptophan
was separated with a Shimadzu liquid chromatograph LC-10AD VP (Shimadzu Co,
Kyoto, Japan) using a 50-mm BDS Hypersil C18 5 mm column (Thermo Electron
Co, Bellefonte, PA). It was monitored by fluorescence with a Shimadzu RF-10A XL
detector at 266 nm excitation and 366 nm emission wavelengths. Kynurenine was
separated with a Hewlett Packard 1100 liquid chromatograph (Palo Alto, CA) using
a Merck LiChroCart 55–4,150 mm cartridge containing a Purospher STAR RP-18 3
mm column (Merck Co, Darmstadt, Germany). It was determined by ultraviolet
absorption at 360-nm wavelength with a Hewlett Packard G13144 detector. The rate
of tryptophan degradation reflects the IDO enzyme activity, and IDO level can thus
be measured by determining the ratio of kynurenine to tryptophan
(kynurenine/tryptophan) (Schrocksnadel et al. 2006). The kynurenine/tryptophan
ratio was calculated by relating concentrations of kynurenine to tryptophan, this
allowing estimation of IDO activity.
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4.2.5 Cell-free DNA
4.2.5.1 Quantification analyses of cell-free DNA
The cf-DNA analyses were performed afterwards from frozen samples stored at -70
ºC.  The  amount  of  total  cf-DNA  was  determined  directly  in  plasma  and  urine
without any DNA purification step, using the Quant-iT™ high-sensitivity DNA
assay kit and a Qubit® fluorometer (Invitrogen, Carlsbad, CA, USA), following the
manufacturer’s instructions. Plasma samples were analyzed in duplicate and the
mean of the two values was used as the final value. The assessed intra-day variation
coefficients at the mean plasma cf-DNA levels of 0.673 ?g/ml, 0.876 ?g/ml, and
1.59 ?g/ml were 4.2 %, 1.0 %, and 4.1 %, respectively. The corresponding inter-day
variation coefficients were 5.5 %, 4.3 %, and 6.6 %. Total cf-DNA in urine was
measured in 20/61 patients with quadruple measurements in which the mean of the
four values was used as the final value. The assessed intra-day variation coefficients
at the mean urine levels of 0.307 ?g/ml, 0.769 ?g/ml, and 1.13 ?g/ml were 5.0 %,
4.8 %, and 3.5 %, respectively. The corresponding inter-day variation coefficients
were 10.0 %, 6.5 %, and 10.2 %. Timed overnight urinary excretion of cf-DNA was
calculated as follows: (concentration x total volume)/(time span).
4.2.5.2 Extraction and qualitative analyses of cell-free DNA
Qualitative  analysis  of  plasma  and  urine  cf-DNA  was  performed  for  randomly
selected 10 patients with and without renal insufficiency (defined as maximum
plasma creatinine >370 µmol/l and maximum plasma creatinine <125 µmol/l,
respectively).  Plasma  and  urine  cf-DNA  was  extracted  using  the  NucleoSpin®
Plasma XS Kit (MACHEREY-NAGEL GmbH & Co., Düren, Germany), designed
for isolation of low-molecular-weight (50-1000 bp) cf-DNA. Cf-DNA isolation was
performed according to the manufacturer’s instructions following the high-
sensitivity  protocol.  Extracted  cf-DNA  samples  were  analyzed  with  the  High
Sensitivity DNA assay kit and an Agilent 2100 Bioanalyzer equipped with Expert
2100 software according to the manufacturer’s instructions (Agilent Technologies
Inc., Santa Clara, CA). Agilent 2100 Bioanalyzer uses a lab-on-a-chip technology to
perform gel electrophoresis; nucleic acids are separated analogously to a capillary
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electrophoresis and normalized to a ladder and two DNA markers, after which the
software automatically calculates the size of each band. For each plasma sample, the
appearance and intensity of low-molecular weight cf-DNA was estimated visually
and graded as follows: 1=no visible cf-DNA or extremely weak band intensity,
2=intermediate band intensity, 3=strong band intensity. The researcher responsible
for  analyzing  and  grading  the  cf-DNA samples  was  blinded  to  the  clinical  data  of
the patients. The appearance of cf-DNA in urine was analyzed descriptively.
4.2.6 Complement analyses
The complement analyses were performed at the Department of Bacteriology and
Immunology  of  the  Haartman  Institute  and  at  the  Helsinki  University  Central
Hospital Laboratory. Plasma SC5b-9 measurements were performed using a
commercial ELISA kit (Quidel, San Diego, CA) and plasma C3 concentrations were
measured by nephelometry (Dade Behring, Marburg, Germany). Some samples did
not meet the quality control criteria for the measurements of C3 and SC5b-9 levels
defined by the manufacturer. Thus, these samples were excluded from the respective
analyses.
4.2.7 Analytical methods
Blood cell count was completed by hematological cell counters by Bayer. From
1997 to June 1999, creatinine was determined in serum by Vitros (Johnson &
Johnson, Rochester, NY, USA) and, after that, in plasma by Cobas Integra analyzer.
Creatinine concentrations showed 10 % lower values after June 1999 than during
the earlier years due to the change in the determination method. Therefore, in Study
I the results of serum creatinine concentrations from September 1997 to June 1999
were multiplied by a coefficient of 0.9. Plasma sodium levels were analyzed using a
Cobas Integra analyzer (F.Hoffman-La Roche Ltd., Basel, Switzerland). The 24-
hour urinary protein excretion was measured by the pyrogallolal red molybdate
method (Olli C.; Kone Instruments, Helsinki, Finland) from 1997 to April 1998 and,
after that, by Cobas Integra analyzer.
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4.2.8 Chest X-ray findings
If a chest radiograph revealed heart enlargement, an increase in venous stasis,
interstititial or alveolar edema, a lung infiltration, atelectasis or pleural effusion, it
was defined as pathologic (Paakkala et al. 2004b).
4.2.9 Statistical analyses
In order to describe the data, medians and ranges are given for continuous variables,
and numbers and percentages for categorical variables.
In Study I, the patients were divided into two groups in order to evaluate the
associations of plasma IL-6 and CRP values with the severity of NE, first according
to the maximum IL-6 value and then according to the maximum CRP value. For the
purpose of further evaluation of the patients, they were divided into four groups
using median values of IL-6 and CRP as cut off points: group 1 with low IL-6 and
low CRP (equivalent to or lower than the median), group 2 with low IL-6 and high
CRP (higher than the median), group 3 with high IL-6 and low CRP, and group 4
with both high IL-6 and high CRP. In Studies II and III, the patients were divided
into two groups according to the maximum PTX3 and IDO values to evaluate the
associations of plasma PTX3 and IDO levels, respectively, with the severity of NE.
The  cut  off  points  for  maximum  PTX3  and  IDO  values  were  determined  with
receiver operating characteristics (ROC) analyses (Boyd 1997).
Groups were compared using the Mann-Whitney U-test or Kruskal-Wallis test, as
appropriate. Categorical data were analyzed by the x2 test or the Fisher's exact test.
Correlations were calculated by means of Spearman's rank correlation coefficient.
Wilcoxon’s test was used to compare two related samples.
Logistic regression analyses were also performed in Studies I and III. In Study I,
the analyses were performed with high serum creatinine, thrombocytopenia, or
hospitalization exceeding seven days (median in the study population) as dependent
factors and high plasma IL-6 and high plasma CRP as independent factors for the
purpose of further examination of the associations of these factors with the severity
of the disease. Age was also included in these models. In Study III, a logistic
regression analysis with significant renal insufficiency (creatinine >250 mmol/l) as a
dependent factor and high IDO and low urinary output as independent factors was
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performed as to further examine the associations of these factors with significant
renal insufficiency. Age and sex were also included in this model. Adjusted odds
ratios (OR) and their 95 % confidence intervals (95 % CI) are given.
All tests were two-sided, and statistically significant P-values are given. All
analyses were made with the SPSS (version 7.5 and 18) statistical software package.
4.2.10 Ethical considerations
All patients gave a written informed consent before participation in the study. All
study protocols were approved by the Ethics Committee of Tampere University
Hospital.  The  study  protocol  of  Study  II  was  also  approved  by  the  University  of
Massachusetts Medical School.
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5. RESULTS
5.1 Characteristics of the study material (Studies I-IV)
5.1.1 Clinical data
The clinical findings in patients participating in Studies I-IV are presented in Table
4. The clinical picture did not differ between the studies, except for the occurrence
of shock in three patients in Study I. In the other studies shock was not observed in
any of the patients. In addition, chest radiographs revealed pathologic findings in 30
patients (32 %, n=96) in Study I, 33 patients (41 %, n=81) in Study III, and 13
patients (30 %, n=44) in Studies II and IV. No secondary bacterial infections were
detected and all blood cultures were negative. All patients recovered.
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Table 4. Clinical findings in patients in Studies I-IV.
Study I (n=118) Study III (n=102) Studies II&IV (n=61)
Patients in
shocka
3 (3 %) 0 (0 %) 0 (0 %)
Patients
requiring
dialysisa
6 (5 %) 5 (5 %) 4 (7 %)
Duration of
fever before
hospital
admission
(days)b
4 (1-14) 4 (1-15) 4 (1-15)
Hospitalization
(days)b
7 (2-15) 6 (2-15) 6 (2-15)
Duration of
fever (days)b
5 (2-15) 6 (2-19) 6 (2-19)
Change in
body weight
(kg)b
2.6 (0-12.0) 2.1 (0-12.0) 2.7 (0-12.0)
Urinary output
min (ml/day)b
1,520 (50-7,000) 1,440 (50-4,940) 1,600 (50-4,940)
SBP min
(mmHg)b
112 (82-162) 113 (74-170) 112 (82-162)
anumber (percent), bmedian (range).
Abbreviations: min=minimum, SBP=systolic blood pressure
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5.1.2 Laboratory variables
The laboratory findings in patients participating in Studies I-IV are presented in
Table 5. The laboratory findings did not differ significantly between the groups. In
addition, 24-hour urinary protein excretion was measured from 72 patients in Study
I. The median maximum excretion was 1.80 g/day (range 0.14-17.78 g/day).
Table 5. Laboratory findings in patients in Studies I-IV.
Study I (n=118) Study III (n=102) Studies II&IV (n=61)
Creatinine
max (µmol/l)
193 (65-1,285) 176 (52-1,285) 175 (65-1,285)
Leukocytes
max (x109/l)
10.0 (3.9-31.2) 10.1 (3.9-31.2) 9.9 (3.9-31.2)
Platelets min
(x109/l)
66 (3-238) 61 (9-238) 68 (9-238)
Hematocrit
min
0.36 (0.25-0.45) 0.36 (0.25-0.44) 0.36 (0.25-0.43)
CRP max
(mg/l)
69 (11-269) 80 (16-269) 69 (17-269)
The values are presented as median (range).
Abbreviations: max=maximum, min=minimum, CRP=C-reactive protein
5.2 Plasma C-reactive protein and interleukin-6 levels
and the outcome of nephropathia epidemica
(Study I)
5.2.1  C-reactive protein
The median maximum plasma CRP in Study I was 69 mg/l. The patients were
divided into two groups according to the maximum CRP value. The median age was
higher in patients with high CRP (CRP>69 mg/l) than in patients with low CRP
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??69 mg/l) (46 years, range 25-71 vs 38 years, range 15-64, P <0.001). The
proportion of males and females did not differ between these two groups. Forty-two
(72 %) of the patients with high CRP levels were males compared to 44 (73 %) of
the patients with low CRP (P = 0.911). In addition, BMI did not differ between the
two groups (median 26.2 kg/m2, range 18.9-41.9 vs median 24.8 kg/m2, range 17.1-
37.2, high vs low CRP, P=0.298). The clinical and laboratory values reflecting the
severity of the disease did not differ between patients with high and low CRP with
the exception of minimum urinary output (Table 6). Furthermore, the occurrence of
a pathologic chest radiograph had no significant association with high CRP values.
Eighteen patients (37 %) with high CRP had a pathologic chest radiograph
compared with 12 patients (26 %) with low CRP (P = 0.265).
Table 6. The clinical and laboratory parameters in 118 patients with acute NE
divided into two groups according to the maximum plasma CRP value.
CRP?69 mg/l CRP>69 mg/l P-value
Duration of
hospital stay
(days)
6 (2-15) 7 (3-14) 0.222
Change in body
weight (kg)
2.4 (0-12.0) 2.7 (0-9.9) 0.564
Urinary output min
(ml/day)
1,700 (50-7,000) 1,400 (50-4,940) 0.035
SBP min 112 (82-162) 112 (86-158) 0.381
Urinary protein
excretion max
(g/day)
2.24 (0.14-10.00) 1.78 (0.30-17.78) 0.474
Creatinine max
(µmol/l)
241 (65-1,285) 141 (68-1,156) 0.193
Leukocytes max
(x109/l)
9.5 (3.9-31.2) 10.4 (5.4-26.8) 0.303
Platelets min
(x109/l)
70 (3-238) 62 (13-187) 0.133
The values are presented as median (range).
Abbreviations: CRP=C-reactive protein, SBP=systolic blood pressure,
min=minimum, max=maximum
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5.2.2 Interleukin-6
The median of the maximum plasma IL-6 levels was 14.05 pg/ml. The patients were
divided into two groups according to their maximum IL-6 value. The median age
did not differ between the patients with plasma IL-6>14.05 pg/ml (high IL-6) and
the patients with plasma IL-6?14.05 pg/ml (low IL-6) (41 years, range 15-65 vs 39
years, range 17-71, P = 0.741). The proportion of males and females did not differ
between the groups either. Forty-four (75 %) of the patients with high IL-6 were
males compared with 42 (71 %) of the patients with low IL-6 (P = 0.679). In
addition, BMI did not differ between these two groups (24.1 kg/m2, range 17.1-37.2
vs 26.2 kg/m2, range 19.2-41.9, high vs low IL-6 groups, P=0.179). The maximum
level of plasma IL-6 associated with most variables reflecting the severity of the
disease (Table 7). The occurrence of a pathologic chest radiograph had no
significant associations with high IL-6. Twenty patients (38 %) with high IL-6 had a
pathologic chest radiograph as compared to 10 patients (24 %) with low IL-6 (P =
0.147).
Table 7. The clinical and laboratory parameters in 118 patients with acute NE
divided into two groups according to the maximum plasma IL-6 value.
IL-6?14.05 pg/ml IL-6>14.05 pg/ml P-value
Duration of
hospital stay
(days)
6 (2-15) 8 (3-14) <0.001
Change in body
weight (kg)
2.0 (0-9.9) 3.2 (0-12.0) 0.008
Urinary output min
(ml/day)
2,180 (200-7,000) 1,040 (50-4,900) <0.001
SBP min 115 (82-162) 110 (85-158) 0.034
Urinary protein
excretion max
(g/day)
1.68 (0.14-5.59) 2.51 (0.30-17.78) 0.017
Creatinine max
(µmol/l)
140 (65-917) 242 (70-1,285) 0.057
Leukocytes max
(x109/l)
9.0 (3.9-31.2) 11.9 (5.1-26.8) 0.001
Platelets min
(x109/l)
80 (3-238) 55 (9-187) <0.001
The values are presented as median (range).
Abbreviations: IL-6=interleukin-6, SBP=systolic blood pressure, min=minimum,
max=maximum
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5.2.3 C-reactive protein and interleukin-6
The patients in Study I were also divided into four groups according to the
maximum CRP and IL-6 values. Patients in group 1 had both low CRP and IL-6,
group 2 consisted of patients with high CRP and low IL-6, group 3 consisted of
patients with low CRP and high IL-6, and patients in group 4 had both high CRP
and IL-6. It was discovered that significantly fewer patients in group 2 with high
CRP and low IL-6 had high creatinine level (>193 µmol/l) compared to the patients
in the other three groups (group 2 vs group 1, 23 % vs 49 %, P =0.048; group 2 vs
group 3, 23 % vs 70 %, P = 0.002; group 2 vs group 4, 23 % vs 53 %, P= 0.024).
Furthermore, none of the patients in group 2 required dialysis treatment.
Logistic regression analyses were then performed to evaluate the association of
high CRP and IL-6 values with high serum creatinine levels (>193 µmol/l),
thrombocytopenia (?66 x 109/l) or hospitalization exceeding seven days. Age was
also included in these models. High plasma CRP was found to be a protective factor
for renal function in this model (Table 8). High plasma CRP did not have a
significant association with thrombocytopenia or hospitalization exceeding seven
days  (data  not  shown).  High  plasma  IL-6,  on  the  contrary,  was  found  to  be  an
independent risk factor for high serum creatinine (Table 8). High IL-6 was also
revealed as an independent risk factor for thrombocytopenia and hospitalization
exceeding seven days (OR 3.6, 95 % CI 1.6-8.0, P=0.002, and OR 4.5, 95 % CI 1.9-
10.8, P<0.001, respectively).
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Table 8. Multivariate analysis of risk factors for serum creatinine level >193 µmol/l
among 118 hospitalized patients with NE.
Creatinine?193
µmol/l (n=60)
Creatinine>193
µmol/l (n=58)
OR 95 % CI
Age (years) 38 42 1.0 0.99-1.06
High CRP
-No 26 34 1 Reference
-Yes 34 24 0.3 0.13-0.74
High IL-6
-No 36 23 1 Reference
-Yes 24 35 3.2 1.41-7.35
Abbreviations: CRP=C-reactive protein, IL-6=interleukin-6, OR=odds ratio,
CI=confidence interval
5.3 Pentraxin-3 and the severity of NE (Study II)
The acute phase maximum PTX3 values were significantly higher as compared to
the control values seen after hospitalization (median 42.0 ng/ml, range 3.9–1251.4
ng/ml vs. 1.1 ng/ml, range 0.4–6.6 ng/ml, P<0.001). The control samples were taken
median 41 days (range 18-83 days) after the onset of fever.
To evaluate the association of PTX3 level with the parameters reflecting the
severity of NE, correlations between different parameters were first calculated. A
strong inverse correlation between the maximum plasma PTX3 level and the
minimum blood platelet count was found (r=?0.567, P<0.001). Inverse correlations
were also found between maximum PTX3 level and minimum C3 as well as
minimum hematocrit levels (r=?0.365, P=0.006, and r=?0.282, P=0.028,
respectively). The maximum PTX3 level correlated positively with the maximum
blood leukocyte count (r=0.477, P<0.001) and the maximum hematocrit level
(r=0.390, P=0.002), as well as with the maximum plasma IL-6 (r=0.643, P<0.001),
serum IDO (r=0.287, P=0.025), and plasma SC5b-9 (r=0.454, P<0.001) levels.
68
Furthermore, the change in patient weight and the length of hospital stay (r=0.315,
P=0.013, and r=0.401, P=0.001, respectively) correlated positively with the
maximum PTX3 level.
ROC  curves  were  then  used  to  examine,  whether  the  maximum  plasma  PTX3
level could act as an indicator of significant thrombocytopenia (minimum blood
platelet value <50×109/l). A maximum PTX3 level >101.6 ng/ml showed a
sensitivity of 71 % and a specificity of 89 % for detecting significant
thrombocytopenia, with an area under curve (AUC) value of 0.78 (95 % confidence
interval [CI] 0.63–0.94). This cut-off point was used to divide the patients into two
groups. In the low PTX3 group, the patients had a PTX3 maximum level ?101.6
ng/ml, and in the high PTX3 group, the PTX3 maximum level was >101.6 ng/ml.
When comparing high and low PTX3 groups, high PTX3 level was found to
associate also with several other parameters reflecting the severity of the disease
(Table 9). However, in both groups two patients needed dialysis treatment and the
proportion of such patients was not significantly different between the two groups
(13 % vs 14 % high vs low PTX3 groups, P=0.251). Age and BMI did not differ
between these two groups (median 45 years, range 25-60 vs median 47 years, range
22-77, P=0.657 and 28 kg/m2, range 20-30 vs median 24 kg/m2, range 20-36,
P=0.579, high vs low PTX3 groups, respectively). Also the proportion of males and
females did not differ between the two groups (70 % male vs 80 % male, P=0.524).
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Table 9. The clinical and laboratory findings in 61 patients with NE divided into two
groups according to the maximum PTX3 level.
PTX3 max ?101.6
ng/ml (n=46)
PTX3 max >101.6
ng/ml (n=15)
P-value
Hospital stay
(days)
5 (2-15) 8 (4-14) 0.015
SBP min (mmHg) 110 (82-162) 112 (86-152) 0.585
Change in body
weight (kg)
2.0 (0-10.1) 3.8 (0.5-12.0) 0.014
CRP max (mg/l) 68.4 (16.7-269.2) 75.3 (19.7-214.0) 0.331
IL-6 max (pg/ml)
(n=48)
9.0 (1.3-44.8) 16.9 (6.8-96.6) 0.007
IDO max
(µmol/mmol)
196.9
(46.6-1,044.7)
338.3
(119.2-3,679.2)
0.009
C3 min (g/l)
(n=55)
1.29 (0.8-2.11) 1.07 (0.65-1.56) 0.017
SC5b-9 max
(ng/ml) (n=57)
468.0
(103.5-903.5)
679.4
(238.4-1,034.0)
0.008
Platelets min
(10E9/l)
77 (24-238) 36 (9-84) <0.001
Leukocytes max
(10E9/l)
9.7 (3.9-20.0) 16.1 (8.1-31.2) <0.001
Hematocrit min 0.37 (0.30-0.43) 0.34 (0.25-0.38) 0.045
Hematocrit max 0.43 (0.35-0.57) 0.48 (0.34-0.54) 0.010
Creatinine max
(µmol/l)
124 (65-1,156) 282 (113-1,285) 0.007
Sodium min
(mmol/l)
132 (120-139) 129 (115-136) 0.028
Values are expressed as median (range).
Abbreviations: PTX=pentraxin-3, SBP=systolic blood pressure, CRP=C-reactive
protein, IL-6=interleukin-6, IDO=indoleamine 2,3-dioxygenase, min=minimum,
max=maximum
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In  order  to  examine  the  kinetics  of  the  changes  in  the  plasma  PTX3  and  blood
platelet  levels,  their  daily medians in relation to the day of the onset of fever were
depicted. PTX3 level was at its highest (92.5 ng/ml) at the median time of hospital
admittance, i.e., 4 days after the onset of fever, and, thereafter, it declined. The
lowest platelet level (59×109/l), in turn, was also observed at the median time of
admittance and the level rose thereafter (Figure 1).
Figure 1. Daily median pentraxin-3 (ng/ml) and blood platelet (x109/l) levels in relation to
the onset of fever (day 0). (Adapted from Study II)
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5.4 Indoleamine 2,3-dioxygenase and the degree of
renal insufficiency (Study III)
The acute phase maximum IDO values were significantly higher than the
convalescent phase values (median 199.3 µmol/mmol, range 46.6-3679.2 vs median
64.7 µmol/mmol, range 23.9-350.6, P<0.001). The control samples were taken
median 22 (range 14-32) days after the onset of fever.
To evaluate the association of serum IDO level with the variables reflecting the
severity of NE, correlations were calculated. A strong positive correlation was found
between maximum serum IDO and creatinine levels as well as maximum IDO level
and change in body weight (r=0.672, P<0.001, and r=0.526, P<0.001, respectively).
Maximum IDO level and minimum urinary output were inversely correlated (r=-
0.385, P<0.001). There was a positive correlation between maximum IDO level and
the length of hospital stay as well as between maximum IDO and the maximum
blood leukocyte count (r =0.494, P<0.001, and r=0.508, P<0.001, respectively).
The ability of maximum serum IDO level to function as an indicator of plasma
creatinine level >250 µmol/l was evaluated using ROC curves. A maximum
IDO>202 µmol/mmol  showed a  sensitivity  of  85  % and  a  specificity  of  75  % for
detecting maximum plasma creatinine levels >250 µmol/l and the AUC was 0.84
(95 % CI 0.76–0.91). This cut-off point was then used to divide patients into two
groups. Patients with a low IDO level had maximum IDO?202 µmol/mmol and
patients with a high IDO level had maximum IDO>202 µmol/mmol.
When comparing high and low IDO groups, a high IDO level was found to
associate also with several other variables reflecting the severity of the disease
(Table 10). Furthermore, all five patients who needed dialysis treatment were in the
high IDO group (P=0.025). The patients in the high IDO group were older than the
patients in the low IDO group (50 years, range 25-74 vs 38 years, range 22-77,
P=0.002), while BMI did not differ between these two groups (27.1 kg/m2, range
20.9-37.0 vs 24.8 kg/m2, range 18.5-34.6, high vs low IDO groups, P=0.149). The
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proportion of males and females did not differ between the two groups (70 % male
vs 65 % male, high vs low IDO groups, P=0.618).
Table 10. The clinical and laboratory variables in 102 patients with NE divided into
two groups according to the maximum IDO level.
IDO max ?202
µmol/mmol (n=52)
IDO max >202
µmol/mmol (n=50)
P-value
Hospital stay
(days)
5 (2-15) 8 (3-14) <0.001
Urinary output min
(ml/day) (n=94)
1,900 (200-4,940) 1,100 (50-4,900) <0.001
Change in body
weight (kg)
1.0 (0-10.0) 3.5 (0-12.0) <0.001
Creatinine max
(µmol/l)
102 (52-537) 379 (75-1,285) <0.001
CRP max (mg/l) 72.1 (15.9-176.0) 104.1 (19.7-269.2) 0.029
Leukocytes max
(109/l)
9.0 (3.9-24.0) 11.9 (6.3-31.2) <0.001
Hematocrit min 0.38 (0.31-0.44) 0.33 (0.25-0.40) <0.001
Platelets min
(109/l)
53 (14-172) 67 (9-238) 0.202
Values are expressed as median (range).
Abbreviations: IDO=indoleamine 2,3-dioxygenase, CRP=C-reactive protein,
min=minimum, max=maximum
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A logistic regression analysis was also performed in order to assess the association
of high IDO level with significant renal insufficiency (plasma creatinine >250
µmol/l) when adjusted for age, sex and low urinary output (minimum urinary output
?1,440 ml/day). Low urinary output was included in this model in order to detect
the possible effect of decrease in renal excretion of kynurenine. High IDO level was
revealed as an independent risk factor for significant renal insufficiency in this
model (OR 17.57, 95 % CI 5.25-58.77, P<0.001). Age, sex or low urinary output
did not have significant association with significant renal insufficiency in this
analysis (data not shown).
Maximum kynurenine and tryptophan values were also analyzed separately by
calculating correlations with the variables reflecting the severity of NE. Maximum
kynurenine level was positively correlated with the maximum serum creatinine level
and change in body weight (r=0.785, P<0.001, and r=0.517, P<0.001, respectively),
as well as with the length of hospital stay and maximum blood leukocyte value
(r=0.517, P<0.001 and r=0.516, P<0.001, respectively). It was inversely correlated
with the minimum urinary output (r=-0.357, P<0.001). Maximum tryptophan level
had only a weak positive correlation with the minimum urinary output (r=0.230,
P=0.026), and a weak inverse correlation with the change in body weight, maximum
blood leukocyte and maximum CRP values (r=-0.201, P=0.044; r=-0.244, P=0.014,
and r=-0.256, P=0.009, respectively).
In  order  to  analyze  the  kinetics  of  the  changes  in  serum  IDO  and  plasma
creatinine levels, their daily medians in relation to the onset of fever were depicted.
It was revealed that both variables first gradually increased to their peak values,
after which they started to decline. Median IDO hit its peak value 243,9 µmol/mmol
9 days after the onset of fever and median creatinine was at its highest (265 µmol/l)
one day later (Figure 2).
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Figure 2. Daily median serum IDO (?mol/mmol) and creatinine (?mol/l) levels in relation to
the onset of fever (day 0). (adapted from Study III)
5.5 Cell-free DNA in acute Puumala virus infection
(Study IV)
The median of the maximum total plasma cf-DNA levels during the acute phase was
1.33 µg/ml, range 0.94-3.29. It was significantly higher than the median of the
control values (0.77 µg/ml, range 0.55-0.99 µg/ml, P<0.001). The median maximum
urinary excretion of cf-DNA during the hospitalization period was 0.68 µg/min
(range 0.34-1.38). It was not increased as compared to the control values (median
0.62 µg/min, range 0.19-1.15, P=0.43). The control samples were taken median 41
(range 18-83) days after the onset of fever.
Correlations were calculated to evaluate the association of plasma cf-DNA with
the variables reflecting the severity of NE. The maximum plasma cf-DNA levels
correlated positively with the maximum blood leukocyte count, maximum plasma
PTX3 levels, and the length of the hospital treatment (Table 11). There was also an
inverse correlation between the maximum plasma cf-DNA levels and minimum
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blood platelet count (Table 11). The maximum plasma cf-DNA levels did not
correlate with the maximum plasma creatinine levels, minimum urinary output,
minimum hematocrit, maximum plasma CRP, IL-6 or serum IDO levels (Table 11).
There was no correlation between plasma cf-DNA and age (r=0.093, P=0.477).
Furthermore, the plasma cf-DNA levels did not differ significantly between men
and women (median 1.30 µg/ml, range 0.94-3.29 vs median 1.36 µg/ml, range 1.05-
2.50, male vs female, P=0.303).
Table 11. The correlations of maximum plasma cell-free DNA with variables
reflecting the severity of the disease in 61 patients with acute NE.
Variable R P-value
Duration of hospital stay  0.376 0.003
Platelets min -0.297 0.020
Leukocytes max 0.388 0.002
Hematocrit min -0.120 0.359
PTX3 max 0.513 <0.001
CRP max -0.015 0.907
IL-6 max 0.202 0.168
IDO max 0.228 0.077
Creatinine max 0.101 0.436
Urinary output min -0.063 0.636
Abbreviations: PTX3=pentraxin-3, CRP=C-reactive protein, IL-6=interleukin-6,
IDO=indoleamine 2,3-dioxygenase, min=minimum, max=maximum
The maximum urinary excretion did not correlate with any of the variables
reflecting disease severity, plasma cf-DNA level or age. The level of maximum
urinary excretion did not differ between men and women (data not shown).
In  the  qualitative  analysis  of  plasma  cf-DNA,  it  was  revealed  that  during  the
acute phase of the disease, cf-DNA showed a low-molecular weight pattern in most
patients, corresponding to the size of apoptotic DNA fragments (150-200 bp) (IV,
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Figure 1A and 1B). This was observed independent of renal insufficiency. The
visually graded maximum cf-DNA band intensity correlated positively with the
maximum level of total plasma cf-DNA (r=0.513, P=0.021). However, the
maximum  cf-DNA  band  intensity  did  not  correlate  with  any  of  the  clinical  or
laboratory variables reflecting the severity of the disease. In control samples, taken
four weeks after the release from the hospital, the low-molecular weight cf-DNA
band was either absent or it was markedly weakened in all patients (IV, Figures 1A
and 1B).
In the qualitative analysis of urine-cf-DNA, it was found that no distinguished
low-molecular weight (150-200 bp) appearance of cf-DNA was detected during the
acute phase of the disease, with the exception of two patients with renal
insufficiency (patients No. 5 and 7) (IV, Figure 2). In addition, two patients (patients
No. 3 and 20) had random-sized cf-DNA fragments in their convalescent phase
urine samples (IV, Figure 2). In Figures 3A and 3B, the qualitative analysis data of
plasma cf-DNA and of urine cf-DNA is shown from four patients as examples.
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Figure legend for Figure 3 on page 78:
Figure 3. Qualitative analysis of plasma cf-DNA in 2 patients with maximum
plasma creatinine >370 µmol/l (patients 1 and 5) and 2 patients with maximum
plasma creatinine <125 µmol/l (patients 17 and 19) after NucleoSpin® Plasma XS
kit extraction (A). Panel B shows qualitative analysis of urine cf-DNA in 3 patients
with maximum plasma creatinine >370 µmol/l (patients 3, 5, and 7) and in a patient
with maximum plasma creatinine <125 mmol/l  (patient  20).  Analyses  were
performed  with  Agilent’s  High  Sensitivity  Lab-on-a-chip  DNA  assay.  Green  lines
indicate the low weight (35 bp) DNA marker and purple lines the high weight
(10,380 bp) DNA marker. The intensity of low-molecular weight cf-DNA band was
graded as follows: 1=no visible band or weak band intensity, 2=intermediate band
intensity, 3=strong band intensity.
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6. DISCUSSION
6.1 Clinical picture
The clinical picture of the disease was typical of NE in all Studies I-IV. In Study I,
the patients were hospital-treated during the years 1997-2004, and 3 % of the
patients suffered a clinical shock. In Studies II-IV, the patients were treated later,
during the years 2000-2008, and none of the patients were in shock. Otherwise, the
clinical course of the disease did not differ between the four studies as judged by the
disease severity. All patients had fever and the median duration of fever was 5-6
days in Studies I-IV. It is noteworthy that in all studies the median duration of fever
before admission to hospital was 4 days. Thus, the clinical and laboratory variables
have been obtained median 4 days after the onset of the disease in all studies.
Transient dialysis treatment was needed for 5-7 % of the patients in Studies I-IV. No
deaths occurred in any of the studies and all patients recovered. Considering the
typical laboratory findings of NE, the median of the maximum creatinine levels was
175-193 ?mol/l in Studies I-IV. The median of the minimum platelet levels varied
from 61 to 68 x109/l in Studies I-IV, while the lowest platelet level was less than 10
x109/l in all studies. The median of the maximum leukocyte counts and CRP levels
were both moderately elevated in all Studies I-IV (9.9-10.1 x109/l and 69-80 mg/l,
respectively). It should be noted that the highest leukocyte count as well as the
highest CRP value in all studies (31.2 x109/l and 269 mg/l, respectively) were
comparable to values seen in severe invasive bacterial infections Thus, these
variables are not informative in clinical practice in differential diagnostics between
PUUV and bacterial infections. All these findings are in concordance with previous
studies concerning the clinical picture of NE (Settergren et al. 1989, Mustonen et al.
1994a, Braun et al. 2010).
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6.2 C-reactive protein and pentraxin-3
Pentraxin family members are acute phase proteins produced in response to various
inflammatory and infectious signals and they are considered as a part of the innate
immune system (Garlanda et al. 2005). CRP, the prototype short pentraxin produced
in the liver, was studied in Study I, whereas PTX3, the prototype long pentraxin
produced at the site of inflammation, was studied in Study II.
Study I  shows that the severity of acute NE is not associated with plasma CRP
levels. The clinical or laboratory values reflecting the severity of the disease did not
differ between patients having high or low CRP levels (>69 mg/l and ?69 mg/l,
respectively) with the exception of minimum urinary output. Furthermore, the
occurrence of a pathologic chest radiograph had no significant association with high
CRP levels. Instead, in multivariate analysis, high plasma CRP was found to be a
protective factor against high serum creatinine (>193 ?mol/l) (OR 0.3, 95 % CI
0.1?0.7, P=0.009) when examined together with age and high plasma IL-6. Age did
not have an effect on high serum creatinine in this model, although the median age
was higher in patients with high plasma CRP as compared to patients with low CRP
levels.
Study I revealed that high CRP associates with preserved kidney function. This is
the first report suggesting that CRP might act as a protective factor for kidney
function in an infectious disease. Previously, it has been reported in a mouse model
of SLE that administration of CRP prevents and reverses proteinuria and nephritis
(Du Clos et al. 1994, Rodriguez et al. 2005, Rodriguez et al. 2006). It has also been
shown that genetic factors associated with decreased CRP production predispose to
SLE (Russell et al. 2004). These findings have been credited to the ability of CRP to
enhance the clearance of immune complexes and to inhibit their accumulation in the
renal cortex (Szalai et al. 2003). It should be noted that immune complexes have
also been found in patients with PUUV infection (Penttinen et al. 1981). Reduced
deposition and increased clearance of immune complexes could be the mechanism
of high CRP to protect renal function in acute PUUV infection.
Previous studies concerning CRP and the severity or prognosis of viral infections
have  provided  controversial  results.  In  children,  high  CRP  levels  do  not  associate
with a more severe disease in influenza or adenovirus infection (Appenzeller et al.
2002, Edelbauer et al. 2006). However, in influenza A H1N1pdm09 virus infection
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and SARS, high CRP has been shown to be related to a more severe course of the
disease (Wang et al. 2004, Zimmerman et al. 2010). Although in two studies
concerning dengue virus infection, CRP levels associated with the severity of the
infection, in another study carried out among Vietnamese children with dengue
hemorrhagic fever, no association of CRP with disease severity was found (Bethell
et al. 1998, Juffrie et al. 2001, Levy et al. 2010). In addition, high CRP has been
shown as  a  predictor  for  a  more  severe  clinical  course  of  the  disease  and  death  in
Crimean-Congo hemorrhagic fever (Yilmaz et al. 2010, Ozturk et al. 2012).
Previous studies with negative results concerning CRP and its association with the
prognosis of viral infections have been conducted with children. However, in Study
I,  no  association  of  CRP  with  disease  severity  could  be  detected  in  acute  PUUV
infection in adults.
Study II shows that PTX3 levels are elevated during acute PUUV infection. The
median maximum PTX3 level during the acute phase was 42.0 ng/ml, while during
the convalescent phase the median PTX3 level was 1.1 ng/ml (P<0.001). In normal
conditions, PTX3 blood level is <2 ng/ml in humans (Garlanda et al. 2005). In a
study dealing with PTX3 in dengue virus infection, median PTX3 level was 80.8
ng/ml 2-3 days after the onset of symptoms (Mairuhu et al. 2005). Interestingly, the
median of the maximum PTX3 levels was higher in patients with dengue virus
infection and in Study II in patients with PUUV infection than in a previous study
carried out with bacteremic patients (7.8 ng/ml) (Huttunen et al. 2011a). The reason
for higher PTX3 levels in these viral infections as compared to bacteremic
infections is unclear.
Study  II  also  shows that  high  PTX3 levels  are  associated  with  a  severe  clinical
course of acute PUUV infection and especially with thrombocytopenia. A maximum
PTX3 level >101.6 ng/ml showed in ROC analysis a sensitivity of 71 % and a
specificity of 89 % for detecting significant thrombocytopenia (platelet level <50
x109), with an AUC value of 0.78 (95 % CI 0.63–0.94). A high PTX3 level (>101.6
ng/ml) associated also with a higher maximum blood leukocyte count, plasma IL-6,
creatinine and serum IDO values, as well as more severe anemia and longer hospital
stay. Further, a high PTX3 level was associated with higher maximum hematocrit,
lower minimum sodium level and greater change in body weight during
hospitalization. It is noteworthy that hemoconcentration, fluid volume overload and
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decreased sodium level are all considered signs of capillary leakage, which is the
central pathogenetic feature in hantavirus infections.
There is only one previous clinical study concerning PTX3 in a viral infection. In
dengue virus infection, PTX3 levels were found to be higher in patients with a
severe form of the infection, dengue shock syndrome, compared to levels found in
patients with milder diseases, dengue fever or dengue hemorrhagic fever (Mairuhu
et al. 2005). Contrary to this clinical finding, in cell culture and in mouse models,
PTX3 has been found to have antiviral activity against influenza virus and to protect
from murine and human CMV infection (Bozza et al. 2006, Reading et al. 2008).
Previous studies have also found that high PTX3 levels predict higher fatality in
septicemia and septic shock (Mauri et al. 2010, Huttunen et al. 2011a, Vänskä et al.
2011).  In  Study  II,  a  high  PTX3 level  was  shown to  associate  with  a  more  severe
clinical course of acute PUUV infection, which is in concordance with the findings
in dengue or septic patients.
In  Study  II,  plasma  PTX3  levels  also  correlated  positively  with  terminal
complement complex SC5b-9 and inversely with complement component C3 levels.
Elevated SC5b-9 levels reflect the overall activation of the complement system,
while C3 concentrations reflect the consumption during complement activation.
Previously, it has been shown that complement activation is common in PUUV
infection and the activation of both classical and alternative pathways has been
associated with a severe disease (Paakkala et al. 2000, Sane et al. 2011). It has also
been shown that PTX3 interacts with both the classical and alternative pathways of
the complement system (Bottazzi et al. 1997, Deban et al. 2008). In Study II, it was
shown that PTX3 levels correlate with the activation of the complement system and
thrombocytopenia. These findings bring up the possibility that PTX3 is involved in
the pathogenesis of thrombocytopenia in acute PUUV infection through the
activation of the complement system. The activated complement cascade is able to
activate the coagulation system and this in turn may lead to thrombocytopenia
through the consumption of platelets (Peerschke et al. 2008). Supporting this idea, it
has been shown that thrombocytopenia associates with decreased plasma
anticoagulant levels, shortened thrombin time and enhanced fibrinolysis in acute
PUUV infection (Laine et al. 2010). In Study II, the highest PTX3 levels were
measured four days after the onset of fever, i.e. at the time of admission to the
hospital  simultaneously  with  the  lowest  platelet  levels.  Thereafter,  PTX3  levels
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declined and platelet levels rose. Possibly the PTX3 peak and the most severe
thrombocytopenia occurred already before the admission to the hospital. Based on
this analysis it is not possible to say, whether the peak PTX3 level preceded the
most severe thrombocytopenia or not.
To  conclude,  the  short  pentraxin  CRP does  not  reflect  a  clinically  severe  acute
PUUV infection, whereas the long pentraxin PTX3 does. Moreover, CRP was
shown to protect kidney function in Study I, possibly by reducing the deposition and
enhancing  the  clearance  of  immune  complexes.  PTX3  in  turn,  associated  strongly
with  thrombocytopenia  and  also  with  the  activation  of  the  complement  system  in
Study II. PTX3 could act in the pathogenesis of thrombocytopenia in acute PUUV
infection  through  the  activation  of  the  complement  system.  Finally,  plasma  PTX3
determinations offer a potential diagnostic tool for assessing the severity and
outcome of acute NE, whereas CRP level is not informative in this viral infection.
6.3 Interleukin-6
IL-6 is a multifunctional cytokine and one of the most important cytokines
responsible for the production of acute phase reactants, fever, and septic shock
together with IL-1 and TNF-?.
Study I showed that high plasma IL-6 is associated with clinically severe acute
PUUV infection. High maximum plasma IL-6 levels (>14.05 pg/ml) were found to
associate with blood leukocytosis, thrombocytopenia, greater urinary protein
excretion and change in body weight during hospitalization, lower minimum urinary
output and systolic blood pressure, as well as with longer duration of
hospitalization. In multivariate analysis, high IL-6 was found to be an independent
risk factor for impaired renal function, thrombocytopenia, and longer
hospitalization, when examined together with high CRP and age.
Previously, increased cytokine levels have been detected in plasma, urine, and
various tissues of hantavirus infection patients (Linderholm et al. 1996, Temonen et
al. 1996, Mori et al. 1999, Mäkelä et al. 2004). Concerning IL-6 in hantavirus
infections, a Swedish study detected elevated IL-6 plasma levels in all patients with
acute PUUV infection and found also a correlation between maximum levels of IL-6
and serum creatinine (Linderholm et al. 1996). Two Finnish studies have also found
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IL-6 levels to be elevated in NE (Takala et al. 2000, Mäkelä et al. 2004). The first
study found a negative correlation of serum IL-6 concentrations with mean arterial
pressure and minimum platelet count (Takala et al. 2000). The second study found
also  urinary  excretion  of  IL-6  to  be  increased.  However,  there  was  no  correlation
between plasma and urinary IL-6 levels, implying that IL-6 is possibly locally
produced in the kidneys (Mäkelä et al. 2004). A German study detected significantly
elevated levels of IL-6 in acute NE and the disease severity judged by elevated
creatinine and low platelet counts correlated with high IL-6 levels (Sadeghi et al.
2011). Finally, a Brazilian study showed the levels of IL-6 to be elevated and to
correlate with the severity of the disease in HCPS, and furthermore, very high IL-6
levels were seen in the fatal cases (Borges et al. 2008). In Study I, high IL-6 levels
were found to associate with a severe clinical course of PUUV infection and also to
be a risk factor for impaired renal function in concordance with previous findings in
hantavirus infections. In other viral infections, studies concerning IL-6 and the
severity of infection have produced controversial results relating high IL-6 levels to
both more and less severe clinical diseases (Avila-Aguero et al. 2004, Bennett et al.
2007, Elliott et al. 2007, Bozza et al. 2008). This may be due to various factors, such
as differences in the timing of sample collection and measuring disease severity.
The pathogenesis of hantavirus infections is currently not completely understood.
Immunological factors, mainly abundantly expressed cytokines together with T cell
activation, probably play an important role. More recent studies concerning
cytokines in hantavirus infections have brought up the possibility that an imbalance
in the production of pro-inflammatory and anti-inflammatory cytokines might be
associated with the severity of the disease (Sadeghi et al. 2011, Saksida et al. 2011).
In Study I, it was detected that the production of the pro-inflammatory cytokine IL-6
was associated with a clinically severe PUUV infection. However, other cytokines
were not examined in this study.
To conclude, IL-6 is one of the most important pro-inflammatory cytokines. In
the pathogenesis of hantavirus infections, cytokines probably play an important role
and, possibly, an imbalance in the production of pro-inflammatory and regulatory
cytokines is important. In Study I, it was shown that high IL-6 is associated with a
clinically more severe acute PUUV infection. It was also shown that high IL-6 is an
independent risk factor for renal insufficiency in acute PUUV infection. These
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findings are in good agreement with previous findings concerning hantavirus
infections.
6.4 Indoleamine 2,3-dioxygenase
IDO is an enzyme catalyzing the first and rate-limiting step in the catabolism of the
essential amino acid tryptophan to kynurenine and its derivatives and thus limiting
the availability of tryptophan (Mellor and Munn 2004, Mellor 2005). This leads to
inhibition of microbial growth, but also inhibition of T cell responses and
proliferation (Mellor and Munn 2004, Mellor 2005). Thereby IDO acts not only as a
part of the innate immunity in antimicrobial defense, but also as an
immunosuppressive agent.
Study III showed that IDO levels are elevated during acute PUUV infection. The
median of the maximum IDO levels in the study was 199.3 ?mol/mmol during the
acute infection, while the median level in the convalescent phase was 64.7
?mol/mmol (P<0.001). In a previous Finnish study carried out in SLE patients, the
median IDO level in healthy controls was 25.9 µmol/mmol (Pertovaara et al. 2007).
In Study III, the IDO levels were lower during the convalescent phase than during
the acute phase, but still higher than the values published for the healthy controls.
Interestingly, in another Finnish study with bacteremic patients, the median of the
maximum IDO levels was lower (89.9 ?mol/mmol) than in Study III in patients with
acute PUUV infection (Huttunen et al. 2010).
Study III  also shows that high IDO levels are associated with increased disease
severity of acute PUUV infection and especially renal impairment. A maximum
IDO level >202 µmol/mmol showed in ROC analysis a sensitivity of 85 % and a
specificity of 75 % for detecting maximum plasma creatinine levels >250 µmol/l
and the AUC was 0.84 (95 % CI 0.76–0.91). A high IDO level, defined as a
maximum IDO level >202 µmol/mmol, was found to be an independent risk factor
for maximum serum creatinine level exceeding 250 ?mol/l, when examined together
with low urinary output, age, and sex. The other factors did not show significant
association with significant renal insufficiency (creatinine>250 µmol/l) in this
model. Thus, the finding of high IDO (kynurenine/tryptophan ratio) being a risk
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factor for significant renal insufficiency is not explained by the possible decrease in
the excretion of kynurenine. It was further detected that a high IDO level was
associated not only with renal insufficiency, but also with higher blood leukocyte
count  and  greater  change  in  body  weight  during  hospitalization,  as  well  as  with
lower urinary output and blood hematocrit. It also associated with longer duration of
hospitalization.
In previous studies dealing with IDO in viral infections, enhanced IDO activity
has been detected in dengue virus infection and chronic HCV infection (Larrea et al.
2007, Becerra et al. 2009). Patients with chronic EBV infection or HIV infection
have also been shown to have increased tryptophan degradation (Fuchs et al. 1990,
Bellmann-Weiler et al. 2008). In the studies concerning dengue virus, HCV or EBV
infection, the association between IDO level and the severity or progression of the
disease was not studied. However, enhanced tryptophan degradation was also
associated  with  progression  of  the  disease  and  with  complications,  such  as  weight
loss and neuropsychiatric disorders, in HIV (Fuchs et al. 1990, Schroecksnadel et al.
2007). Furthermore, antiretroviral therapy reduced tryptophan degradation (Fuchs et
al. 1990). High IDO levels have also predicted severe disease and fatality in sepsis
and septic shock (Huttunen et al. 2010, Tattevin et al. 2010). In concordance with
the findings in HIV infection and sepsis, a high IDO level was associated with
increased severity of PUUV infection in Study III.
Concerning renal diseases, it has previously been demonstrated that the levels of
tryptophan metabolites increase in chronic renal insufficiency apparently not due to
a decrease in renal excretion, but due to an increase in production and/or decrease in
degradation (Saito et al. 2000, Schefold et al. 2009). In mice, it has been shown that
IDO enhances renal ischemia-reperfusion injury (Mohib et al. 2008). On the
contrary, in a mouse model of crescentic glomerulonephritis, IDO acts as a
protective factor (Hou et al. 2009). The latter finding might be explained by the
immunosuppressive  function  of  IDO.  In  Study  III,  a  high  IDO  level  was  strongly
associated with renal impairment in acute PUUV infection.
Whether IDO is merely a marker of severe disease in PUUV infection, or has a
pathogenetic role in it, is not known. However, it is possible that IDO is involved in
the pathogenesis of renal failure in NE. It has previously been demonstrated that
increased IDO activity promotes TEC apoptosis and inhibition of IDO enhances
TEC  survival  (Mohib  et  al.  2007).  In  Study  III,  it  was  found  that  high  IDO  was
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strongly associated with significant renal failure. IDO levels were also found to peak
before creatinine levels, which supports the idea of IDO being involved in the
pathogenesis of renal failure in acute PUUV infection. The pathogenetic mechanism
could be promotion of TEC apoptosis. Noteworthy is that signs of epithelial cell
apoptosis have previously been detected in patients with PUUV infection
(Klingström et al. 2006). Another pathogenetic mechanism could be enhancement of
the infection by inducing immunosuppression through T cell suppression and
apoptosis.
Taken  into  account  its  effects  on  T  cells,  IDO  is  an  interesting  enzyme  in  the
context of hantavirus infections. Although the pathogenesis of hantaviral infections
is currently still not completely understood, immunological factors, especially T cell
activation together with cytokines probably play an important role. It has been
suggested that virus-specific CD8+ cells are important in the development of
endothelial cell dysfunction and capillary leakage in hantavirus infections (Terajima
et al. 2007). In kidney biopsies of patients with NE, there is an increased amount of
infiltrating cells in the peritubular areas including plasma cells,
monocyte/macrophages, polymorphonuclear leukocytes, as well as lymphocytes,
predominantly CD8+ T cells (Temonen et al. 1996). It has also been shown that the
severity  of  the  histopathological  changes  is  associated  with  the  clinical  severity  of
renal failure. These findings are indicative of an important role of cell-mediated
cytotoxicity in the pathogenesis of renal failure in PUUV infection.
To add up, IDO has multiple functions in the immune system. It has an inhibitory
effect on T cells, which have an important role in the pathogenesis of hantavirus
infections. In the present study, it was shown that a high IDO level associates with
clinically severe acute PUUV infection and especially with the severity of renal
insufficiency. IDO may have a pathogenetic role in the development of renal failure
in PUUV infection through its enhancive functions on TEC apoptosis or inhibitory
functions on T cells.
6.5 Cell-free DNA
The current view is that, in clinical conditions, cf-DNA originates from apoptotic or
necrotic cells and therefore its plasma levels reflect the amount of cellular damage
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(Jahr et al. 2001). Hantaviruses have been considered noncytopathic (Yanagihara et
al. 1985, Temonen et al. 1993), although under certain conditions Tula hantavirus
induces apoptosis in cultured cells (Li et al. 2004, Li et al. 2005). Also, a Swedish
study in PUUV-infected patients showed that epithelial cell apoptosis is induced
during the acute infection (Klingström et al. 2006).
Study IV showed that plasma cf-DNA levels are elevated during acute PUUV
infection, but the urinary excretion of cf-DNA is not. The median of the maximum
cf-DNA levels during the acute phase was 1.33 µg/ml, while during the
convalescent phase, the median cf-DNA level was 0.77 µg/ml (P<0.001).  In  a
previous study with bacteremic patients, the median of the maximum cf-DNA levels
was 2.03 µg/ml in nonsurvivors and 1.26 µg/ml in survivors (Huttunen et al. 2011b).
In  Study  IV,  the  median  of  the  maximum  plasma  cf-DNA  levels  in  acute  PUUV
infection equals with the level seen in survived bacteremia patients. The urinary
excretion of cf-DNA was not increased during the acute phase compared to urinary
excretion during the convalescent phase.
Study  IV also  showed that  plasma cf-DNA level  correlates  with  the  severity  of
acute PUUV infection, whereas urine cf-DNA excretion does not. The total plasma
cf-DNA level and blood platelet count showed a negative correlation. In addition,
plasma cf-DNA levels correlated positively with blood leukocyte count and the
length of the hospital stay. The latter is probably the best variable reflecting the
overall severity of the disease. Plasma cf-DNA levels also correlated with plasma
PTX3 levels. This is explained by the fact that PTX3 contributes to the opsonization
and clearance of apoptotic and necrotic cells (Bottazzi et al. 2009), which are
regarded as the origin of cf-DNA. There was no statistically significant correlation
between  plasma  cf-DNA  and  IDO  levels,  despite  the  fact  that  IDO  promotes
apoptosis  of  TECs.  The  total  plasma  cf-DNA  level  did  not  correlate  with  the
severity of renal insufficiency. Moreover, maximum urine cf-DNA secretion did not
correlate  with  any  clinical  or  laboratory  variables  reflecting  the  severity  of  the
infection. Neither did maximum urine cf-DNA excretion correlate with maximum
plasma cf-DNA levels.
In the qualitative analysis of plasma cf-DNA, it was revealed that, during the
acute phase of the disease, cf-DNA displayed a low-molecular weight pattern in
most patients, corresponding to the size of apoptotic DNA fragments (150-200 bp).
After recovery, such cf-DNA pattern was not observed. It is therefore plausible that
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the detected low-molecular weight cf-DNA originated from apoptotic cells during
the acute phase of the disease. An earlier study detecting signs of epithelial cell
apoptosis during acute PUUV infection supports this idea (Klingström et al. 2006).
Furthermore, Study IV showed that the maximum total plasma cf-DNA
concentration and the apoptotic cf-DNA band intensity correlated, which also
supports the hypothesis that the increase in plasma cf-DNA is due to apoptosis.
Similar results concerning apoptotic cf-DNA pattern have been observed also in
bacteremic patients (Huttunen et al. 2011b). However, in Study IV, the plasma cf-
DNA apoptotic band intensity was not associated with the severity of PUUV
infection. It should be noted, however, that the qualitative analysis was performed
only for twenty patients. This may have been too small a sample size to detect
possible correlations between the band intensity and the disease severity reflecting
variables.
In the qualitative analysis of urine cf-DNA, no low-molecular weight pattern of
cf-DNA that could be attributed to the disease severity was detected. However, two
patients with renal insufficiency had a clear low-molecular weight cf-DNA band in
their urine during the acute phase of the disease, possibly indicating increased
apoptosis in the renal system.
In viral infections, previous studies concerning plasma cf-DNA are scarce. In
patients with occult HBV infection, the levels of cf-DNA have been detected to be
elevated (Bhargava et al. 2010). In a recent study, the cf-DNA levels were elevated
and they correlated with the severity of the infection in dengue patients (Ha et al.
2011). Also, in septic patients, elevated plasma cf-DNA levels have predicted poor
clinical outcome (Zeerleder et al. 2003, Rhodes et al. 2006, Saukkonen et al. 2008,
Huttunen et al. 2011b). In agreement with previous studies in patients with dengue
virus infection or sepsis, Study IV showed that, in acute PUUV infection, plasma cf-
DNA levels are elevated and they correlate with the severity of the disease, although
not with the degree of renal insufficiency.
The  urinary  excretion  of  cf-DNA  did  not  correlate  with  the  severity  of  acute
PUUV infection in Study IV, whereas total plasma cf-DNA did. This discrepancy
between the correlations of urine and plasma cf-DNA suggests that the cf-DNA
detected in urine may not be clinically relevant and does not reflect the degree of
inflammation in the kidneys. Previous studies concerning urinary cf-DNA support
these findings. In hematopoetic stem cell transplant patients, the quantity of donor-
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derived DNA does not correlate with the quantity of plasma cf-DNA and the
predominant cf-DNA fragment size also differs between plasma and urine (Hung et
al. 2009). A similar DNA fragment size difference between plasma and urine has
also been detected in pregnant women carrying male fetuses (Koide et al. 2005).
Previously, cf-DNA has been shown to be elevated in the urine of patients with
urinary tract infection (Garcia Moreira et al. 2009). On the other hand, in colorectal
cancer patients, urine secreted cf-DNA contains tumor-derived K-ras mutations (Su
et al. 2004, Su et al. 2005). In addition, fetal Y-chromosomal DNA sequences have
been found in the urine of pregnant women carrying male fetuses (Koide et al. 2005,
Shekhtman et al. 2009). These findings indicate that urinary cf-DNA probably
consists of a heterogeneous mixture of cf-DNA fragments originating from dying
cells in the renal system and from the pool of plasma cf-DNA. It is known that cf-
DNA  can  cross  the  kidney  barrier  (Botezatu  et  al.  2000).  However,  the  exact
mechanism by which it crosses the glomerular basement membrane is unclear. The
maximum urinary excretion of cf-DNA has been thought to be influenced by renal
function. However, the results of Study IV do not support this hypothesis since no
correlation between urinary secretion of cf-DNA and renal function was detected.
To conclude, the elevated levels of cf-DNA in different diseases originate from
apoptotic  or  necrotic  cells.  In  Study  IV,  it  was  shown  that  the  maximum  total
plasma cf-DNA level is elevated during acute PUUV infection and it correlates with
the  severity  of  the  disease,  although  not  with  the  degree  of  renal  insufficiency.  It
was  also  shown  that  the  maximum  total  plasma  cf-DNA  level  correlates  with  the
apoptotic cf-DNA band intensity, suggesting that the increase in plasma cf-DNA is
due to apoptosis. This finding supports the previous findings indicative of epithelial
cell apoptosis in acute PUUV infection. The urinary excretion of cf-DNA, in turn,
does not reflect the degree of inflammation in the kidneys.
6.6 Future considerations
In the present study, CRP, PTX3, IL-6, IDO, and cf-DNA were analyzed in acute
PUUV infection as markers of disease severity, but also their possible pathogenetic
role in the disease was evaluated. The precise mechanisms in the pathogenesis of
PUUV as well as other hantavirus infections are still not completely understood.
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Central clinical findings in acute NE are thrombocytopenia and acute renal
insufficiency together with the vascular permeability syndrome.
Thrombocytopenia is a characteristic phenomenon of NE, causing sometimes
even fatal bleedings. In Study II, it was revealed that high plasma PTX3 levels
associate  strongly  with  thrombocytopenia  as  well  as  with  the  activation  of  the
complement system. It is postulated that PTX3 might be involved in the
pathogenesis of thrombocytopenia in acute NE through the complement system,
which in turn would activate the coagulation system and lead to the consumption of
platelets. In concordance with this idea are the findings that thrombocytopenia
associates with decreased plasma anticoagulant levels, shortened thrombin time and
enhanced fibrinolysis in NE (Laine et al. 2010). It has been suggested that the
interaction of platelets with endothelium, their activation, and P-selectin expression
could provide mechanisms of thrombocytopenia during hantavirus infection (Laine
et al. 2010). Furthermore, it has been proposed that enhanced platelet adhesion and
activation could result in platelet consumption and thrombocytopenia (Laine et al.
2011). However, further studies concerning platelets and the coagulation system are
needed to establish the exact mechanisms of thrombocytopenia in HFRS. Moreover,
the association of PTX3 with other elements of the coagulation system have not
been studied in hantavirus infections. Studies elucidating the association of PTX3
with different elements of the coagulation system might clarify the role of PTX3 in
the development of thrombocytopenia in HFRS.
In Study III, high IDO was identified as a predictive factor for severe clinical
course of NE and as an independent risk factor for significant renal insufficiency.
Increased IDO activity is known to promote TEC apoptosis and this could provide a
possible pathogenetic mechanism for the development of renal failure in NE (Mohib
et  al.  2007).  However,  IDO  is  also  known  to  inhibit  T  cell  responses  and
proliferation and thus lead to immunosuppression. Therefore, IDO could be
involved in the pathogenesis of NE also via impaired cellular immunity.
Furthermore,  CD8+  T  cells  are  considered  important  in  the  pathogenesis  of
hantavirus infection including the capillary leakage syndrome. In addition, an
imbalance between effector T cells and Tregs possibly has a role in the
pathogenesis. Noteworthy is that IDO also inducts Tregs. Future studies concerning
the role and significance of Tregs in hantavirus infections are needed. Moreover, the
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association of IDO and T cell functions in hantavirus infection require further
studies in order to establish the role of IDO in the infection.
Capillary leakage is the central phenomenon in the pathogenesis of hantavirus
infection explaining many clinical signs and symptoms of the disease. However, the
mechanisms behind this phenomenon remain currently still to be elucidated. VEGF
is an interesting factor quite recently studied in the context of hantavirus infections.
It has been demonstrated that pathogenic hantaviruses enhance the permeability of
endothelial cells in response to VEGF (Gavrilovskaya et al. 2008). Moreover,
hantavirus-directed permeability has been inhibited by antibodies to VEGF2
(Gavrilovskaya et al. 2008). Antibodies to VEGF as well as VEGF2 are already
commercially available and in clinical use in oncology. These agents could offer a
therapeutic possibility also in hantavirus infections. However, this type of therapy
has shown common adverse vascular effects that may limit its clinical use (Hayman
et al. 2012). Nevertheless, further clinical studies concerning VEGF and its role in
the pathogenesis of capillary leakage syndrome in hantavirus infections are
warranted.
Finally, there were no control patient groups in any of the studies in this thesis. In
further studies, control individuals with other viral infections would help to clarify
the specificity of the findings to PUUV/hantavirus infection instead of more
generally to viral infections.
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7. SUMMARY AND CONCLUSIONS
The association of CRP, PTX3, IL-6, IDO, and cf-DNA with the severity of acute
PUUV  infection,  and  their  possible  role  in  the  pathogenesis  of  NE  can  be
summarized as follows:
I High plasma CRP level is not associated with a severe clinical course of NE.
On the contrary, high CRP level was revealed as a possible protective factor against
renal failure.
II PTX3 level is elevated during acute NE. High plasma PTX3 level is
associated with a more severe course of NE and especially thrombocytopenia. In
addition, PTX3 level associates with the activation of the complement system.
These findings bring up the possibility that PTX3 is involved in the pathogenesis of
thrombocytopenia in NE through the complement system.
III High IL-6 level is associated with clinically severe NE. High IL-6 is also an
independent risk factor for impaired renal function in NE.
IV IDO is upregulated during acute NE. A high IDO level is associated with
clinically severe acute NE and, most of all, impaired renal function. IDO is an
independent risk factor for significant renal insufficiency and may be involved in
the pathogenesis of renal failure either through its effects on TECs or T-cells.
V Total plasma cf-DNA level is elevated during acute NE and it associates
with the severity of NE, but not with the degree of renal insufficiency. Furthermore,
the plasma cf-DNA level and the apoptotic band intensity correlate, indicating that
the increase in plasma cf-DNA is likely due to cellular apoptosis. The urinary
excretion of cf-DNA, in turn, is not increased during acute NE and does not
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correlate with the severity of the disease indicating that the urinary excretion of cf-
DNA does not reflect the degree of inflammation in the kidneys.
In  conclusion,  high  plasma  PTX3,  IL-6,  cf-DNA,  and  serum  IDO  levels  are
associated  with  a  severe  clinical  course  of  NE,  although cf-DNA is  not  associated
with  the  severity  of  renal  failure.  PTX3  correlates  most  of  all  with
thrombocytopenia. Since it also correlates with the activation of the complement
system, it is possible that PTX3 is involved in the pathogenesis of thrombocytopenia
in  NE  through  the  activation  of  the  complement  cascade.  IDO  activity,  in  turn,  is
associated especially with significant renal insufficiency. As IDO is known to
promote TEC apoptosis, it is possible that it is involved in the pathogenesis of renal
impairment in NE through TEC apoptosis. Furthermore, the suppressive effect of
IDO on T cells may induce immunosuppression and promote renal insufficiency by
this mechanism. The results of the qualitative analysis of plasma cf-DNA indicate
that apoptosis occurs during acute NE. Urinary excretion of cf-DNA, however, does
not reflect the degree of inflammation in the kidneys. Finally, high CRP does not
indicate a clinically severe NE. On the contrary, it may protect the kidneys, possibly
by enhancing the clearance of immune complexes.
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using plasma interleukin-6 than C-reactive protein 
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Abstract
Background: Nephropathia epidemica (NE) is a Scandinavian type of hemorrhagic fever with renal syndrome caused 
by Puumala hantavirus. The clinical course of the disease varies greatly in severity. The aim of the present study was to 
evaluate whether plasma C-reactive protein (CRP) and interleukin (IL)-6 levels associate with the severity of NE.
Methods: A prospectively collected cohort of 118 consecutive hospital-treated patients with acute serologically 
confirmed NE was examined. Plasma IL-6, CRP, and creatinine, as well as blood cell count and daily urinary protein 
excretion were measured on three consecutive days after admission. Plasma IL-6 and CRP levels higher than the 
median were considered high.
Results: We found that high IL-6 associated with most variables reflecting the severity of the disease. When compared 
to patients with low IL-6, patients with high IL-6 had higher maximum blood leukocyte count (11.9 vs 9.0 × 109/l, P = 
0.001) and urinary protein excretion (2.51 vs 1.68 g/day, P = 0.017), as well as a lower minimum blood platelet count (55 
vs 80 × 109/l, P < 0.001), hematocrit (0.34 vs 0.38, P = 0.001), and urinary output (1040 vs 2180 ml/day, P < 0.001). They 
also stayed longer in hospital than patients with low IL-6 (8 vs 6 days, P < 0.001). In contrast, high CRP did not associate 
with severe disease.
Conclusions: High plasma IL-6 concentrations associate with a clinically severe acute Puumala hantavirus infection, 
whereas high plasma CRP as such does not reflect the severity of the disease.
Background
Nephropathia epidemica (NE) is a Scandinavian type of
hemorrhagic fever with renal syndrome. The causative
agent, Puumala virus (PUUV), is a member of the genus
Hantavirus in the family Bunyaviridae [1]. Other hanta-
viruses causing more severe forms of HFRS include Han-
taan, Seoul, and Dobrava viruses [2]. Many hantaviruses
in North and South America, e.g. Sin Nombre, Andes,
and Black Creek Canal viruses, cause hantavirus pulmo-
nary syndrome (HPS) [2]. The natural host of PUUV is
the bank vole (Myodes glareolus) [3].
Nephropathia epidemica is prevalent in Finland, else-
where in Scandinavia, in Western Russia, in the Balkan
region and also in many parts of Western Europe [2,4].
Approximately 1000 serological diagnoses of PUUV
infection are made in Finland annually [5]. However, the
seroprevalence in the Finnish population is 5%, implying
that most infections are subclinical or undiagnosed [5].
The clinical severity of NE varies greatly. Host genetics
have been shown to influence the clinical picture [6,7]. It
is clinically characterized by acute fever, headache, back
and abdominal pains, myalgia, nausea, vomiting, and
transient myopia, while hemorrhages are uncommon
[8,9]. Renal involvement causes proteinuria, hematuria
and oliguria, followed by polyuria [8,9]. A minority of
patients needs transient dialysis treatment [8], but com-
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acute phase, an increase in the serum creatinine concen-
tration, thrombocytopenia, anemia, leukocytosis, as well
as moderately elevated erythrocyte sedimentation rate
and C-reactive protein (CRP) values are typical labora-
tory findings [8,9]. In addition, radiological pulmonary
manifestations have been detected in 16-53% of the
patients, and they have been associated with the degree of
acute renal insufficiency [8-12].
The pathogenesis of NE is not completely understood.
An important feature in hantavirus infections is univer-
sally increased capillary permeability [13], but the mecha-
nisms of vascular leakage are unclear. PUUV causes no
cytopathic effects in cultured cells but has a wide cell sus-
ceptibility in vitro [14]. It has been suggested that immu-
nological factors including cytokines are involved in the
pathogenesis of NE [2]. Increased cytokine levels have
been found in the plasma, urine, and tissues of hantavirus
infection patients [15-18]. Infection of cynomolgus
macaques by PUUV also results in increased serum levels
of several cytokines [19]. We have previously found
plasma and urinary levels of interleukin (IL)-6, tumor
necrosis factor-α, IL-1, and IL-1-receptor antagonist to
be increased during the acute phase of NE, so that the
observed levels of IL-6 were exceptionally high [15].
The IL-6 molecule is a multifunctional cytokine
involved in immune responses and inflammation. IL-6 is
the main inducer of CRP production in vitro in cultured
human hepatoma cells [20], but data about the associa-
tions of IL-6 and CRP in vivo is scarce. The known main
functions of CRP are complement activation, enhance-
ment of phagocytosis, and induction of cytokine synthe-
sis. Although plasma CRP level is widely used as an
indicator of the severity of the disease in various infec-
tions, there are no reports associating high CRP levels to
a severe disease in NE or other viral infections. On the
other hand, IL-6 level has been found to be associated to
the severity of the disease in some viral infections, e.g.
influenza [21,22]. Therefore, we studied whether plasma
IL-6 or CRP levels are associated with the severity of NE,
in order to evaluate if IL-6 or CRP are good markers for
disease severity in NE.
Methods
Patients
The study cohort originally consisted of 131 prospec-
tively collected consecutive patients with acute NE
treated at Tampere University Hospital, Finland, between
September 1997 and December 2004. We have previously
studied urinary IL-6 excretion in 70 NE patients treated
during the years 1997-1999 [15], these patients were also
included in the present material. Now plasma IL-6 levels
were measured altogether from 118 patients, who com-
prised the final cohort of the present study, as we did not
have plasma samples for IL-6 determinations from 13
subjects. The median patient age was 40 (ranging 15-71)
years, and 86 (73%) were males.
Thirty-seven (31%) patients had one or more of the fol-
lowing diseases before NE: essential hypertension in 10,
dyslipidemia in six, hypothyreosis in five, coronary artery
disease in four, and bronchial asthma in three; atrial
fibrillation, celiac disease, chronic inflammatory bowel
disease, and hyperplasia of the prostate in two; sick sinus
syndrome treated with pacemaker, diabetes mellitus,
osteoporosis, ankylosing spondylarthritis, aortic valve
disease, mitral valve disease, epilepsy, fibromyalgia, sar-
coidosis, multiple sclerosis, operated melanoma, oper-
ated cancer of vocal cords, operated meningeoma, and
sequelae of renal tuberculosis in one patient each.
The diagnosis of acute PUUV infection was serologi-
cally confirmed in all cases [23]. All subjects gave
informed consent before participation and the study was
approved by the Ethics Committee of Tampere University
Hospital.
Study protocol
All 118 patients were studied during the acute phase of
NE. A detailed past and current medical history was
obtained, and a careful physical examination was per-
formed. Blood samples to analyze plasma IL-6 and CRP,
serum creatinine, and blood cell count, as well as daily
urinary protein excretion were collected on three consec-
utive mornings after hospital admission. Other blood
samples were taken according to the clinical needs of the
patient. The highest and the lowest value of each patient
of the various variables measured during hospitalization
were designated as the maximum and minimum values.
In this study, we have defined high serum creatinine as a
value exceeding the median maximum creatinine among
the study population (193 μmol/l) and thrombocytopenia
as the minimum platelet count equal to or lower than the
median among the study population (66 × 109/l). High
plasma CRP was defined as the maximum CRP value
above the median in the study population (69 mg/l) and
high plasma IL-6 as the maximum IL-6 value higher than
14.05 pg/ml (the median in the study population).
Methods
All blood specimens were obtained between 7:30-9:30 in
the morning. Plasma CRP was analyzed by Hitachi 705 E
Analyzer from 1997 to 1998 and after that by the Roche
Diagnostics CRP method using Cobas Integra analyzer (F.
Hoffman-La Roche Ltd, Basel, Switzerland). Blood cell
count was completed by hematological cell counters by
Bayer. From 1997 to June 1999, serum creatinine was
determined by Vitros (Johnson & Johnson, Rochester,
NY, USA) and after that by Cobas Integra analyzer. Serum
creatinine concentrations showed 10% lower values after
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in the determination method. Therefore, in this study the
results of serum creatinine concentrations from Septem-
ber 1997 to June 1999 were multiplied by the coefficient
0.9. Plasma IL-6 concentrations were determined after-
wards from frozen samples by using commercially avail-
able enzyme-linked immunosorbent assays (PeliKine
Compact human IL-6 kits; Central Laboratory of the
Netherlands, Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands), following the manufac-
turer's instructions. Detection limit for the assay was 0.4
pg/ml for IL-6. The patients in this study did not have val-
ues below the detection limit. The 24-hour urinary pro-
tein excretion was measured by the pyrogallolal red
molybdate method (Olli C.; Kone Instruments, Helsinki,
Finland) from 1997 to April 1998 and after that by Cobas
Integra analyzer, from a total of 72 patients. One chest
radiograph was obtained during hospitalization from 77
patients, two from 16 and three from two patients.
Statistical Analysis
In order to describe the data, medians (ranging) were
given for continuous variables and numbers and percent-
ages for categorical variables.
To evaluate the associations of plasma IL-6 and CRP
values with the severity of NE, we divided the patients
into two groups, first according to the maximum IL-6
value and then according to the maximum CRP value. For
the purposes of further evaluating the effect of plasma IL-
6 and plasma CRP on the severity of the disease, we
divided the patients into four groups: group 1 with low
IL-6 and low CRP (equivalent to or lower than the
median), group 2 with low IL-6 and high CRP (higher
than the median), group 3 with high IL-6 and low CRP,
and group 4 with both high IL-6 and high CRP.
Groups were compared using the Mann-Whitney U-
test or Kruskal-Wallis test, as appropriate. Categorical
data were analyzed by the x2 test or the Fisher's exact test.
Correlations were calculated by means of Spearman's
rank correlation coefficient. We also performed logistic
regression analyses with high serum creatinine, thrombo-
cytopenia, or hospitalization exceeding seven days as
dependent factors and high plasma IL-6 and high plasma
CRP as independent factors in order to further examine
the association of these factors with the severity of the
disease. Age was also included in these models as a con-
tinuous variable. Adjusted odds ratios (OR) and their 95%
confidence intervals (95% CI) were given. All tests were
two-sided, and statistically significant P-values are given.
All analyses were made with the SPSS (version 7.5) statis-
tical software package.
Results
The clinical and laboratory characteristics of the patients
are shown in Table 1. Three (3%) of the total 118 patients
were in clinical shock at admission, and six (5%) required
dialysis treatment during hospital care. Thirty-four of the
patients (29%) had a plasma CRP value higher than 100
mg/l, 59 (50%) had a leukocyte count higher than 10.0 ×
109/l, 34 (29%) had a platelet count lower than 50 × 109/l,
and 88 (75%) had a serum creatinine value higher than
100 μmol/l during the hospital stay. Thirty patients (32%)
presented with pathologic findings in a chest radiograph.
Everyone recovered completely. The median duration of
fever before admission to the hospital was four (ranging
1-14) days.
Table 1: The clinical and laboratory findings in 118 patients with acute Puumala hantavirus infection.
Symptoms and findings Median Ranging
Duration of fever (days) 5 2-15
Duration of hospital stay (days) 7 2-15
SBP min (mmHg) 112 82-162
Change in weight during hospital stay (kg) 2.6 0-12.0
Urinary output min (ml/day) 1520 50-7000
Urinary protein max (g/day) 1.80 0.14-17.78
Creatinine max (μmol/l) 193 65-1285
Platelets min (109/l) 66 3-238
Hematocrit min 0.36 0.25-0.46
Leukocytes max (109/l) 10.0 3.9-31.2
CRP max (mg/l) 69 11-269
IL-6 max (pg/ml) 14.05 1.31-107.00
SBP = systolic blood pressure, min = minimum, max = maximum, CRP = C-reactive protein, IL-6 = interleukin-6.
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high plasma IL-6 and patients with low IL-6 (41 years,
ranging 15-65 vs 39 years, ranging 17-71, P = 0.741).
Forty-four (75%) of the patients with high IL-6 were
males compared with 42 (71%) of the patients with low
IL-6 (P = 0.679). In patients with high plasma CRP, the
median age was higher than in patients with low CRP (46
years, ranging 25-71 vs 38 years, ranging 15-64, P <
0.001). Forty-two (72%) of the patients with high CRP
were males compared with 44 (73%) of the patients with
low CRP (P = 0.911).
The maximum level of plasma IL-6 associated strongly
with several variables reflecting the severity of the disease
(Figures 1 and 2). Patients who had high IL-6 had lower
minimum urinary output (1040 vs 2180 ml/day, Figure
1A), lower minimum systolic blood pressure (110 vs 115
mmHg, Figure 1B), and a greater change in weight during
hospital care (3.2 vs 2.0 kg, Figure 1C), and they also
stayed longer in hospital than patients with low IL-6 (8 vs
6 days, Figure 1D). Furthermore, patients with high IL-6
had numerically (but not statistically significantly) higher
maximum serum creatinine levels (242 vs 140 μmol/l,
Figure 2A), higher maximum urinary protein excretion
(2.51 vs 1.68 g/day, Figure 2B), higher maximum leuko-
cyte count (11.9 vs 9.0 × 109/l, Figure 2C), lower mini-
mum platelet count (55 vs 80 × 109/l, Figure 2D), and
lower minimum hematocrit (0.34 vs 0.38, P = 0.001) than
patients with low IL-6. The clinical or laboratory vari-
ables between the patients with high and low CRP did not
differ (Figures 1F-H, 2E-H) with the exception of mini-
mum urinary output. Patients with high CRP had slightly
lower minimum urinary output when compared to
patients with low CRP (1400 vs 1700 ml/day, Figure 1E).
The occurrence of a pathologic chest radiograph had
no significant associations with high IL-6 or high CRP.
Twenty patients (38%) with high IL-6 had a pathologic
chest x-ray compared with 10 patients (24%) with low IL-
6 (P = 0.147). Eighteen patients (37%) with high CRP had
a pathologic chest x-ray compared with 12 patients (26%)
with low CRP (P = 0.265).
There was a positive correlation between plasma CRP
and plasma IL-6 levels (r = 0.323, P < 0.001). We also
found a slight positive correlation between maximum
plasma IL-6 and serum creatinine concentrations (r =
0.238, P = 0.010), whereas no correlation was found
between maximum plasma CRP and serum creatinine
levels.
Figure 1 The associations of various clinical variables with maximum plasma interleukin-6 and C-reactive protein concentrations in pa-
tients with Puumala hantavirus infection. Data are given as median (thick line), 25th-75th percentile (box), and range (whiskers); outliers have been 
omitted from the figure.
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ables reflecting the severity of the disease with plasma IL-
6 and CRP levels in patients divided into four groups
according to maximum IL-6 and CRP values. Table 2
shows that especially patients with an IL-6 value higher
than the median, with or without high CRP (groups 3 and
4), had more severe disease as measured with several
clinical parameters. Table 3 shows the occurrence of
shock, dialysis treatment, pathologic findings in a chest x-
ray, high serum creatinine, thrombocytopenia, and hospi-
talization longer than seven days (median) in these four
groups. Significantly fewer patients in group 2 (low IL-6
and high CRP) had high serum creatinine levels com-
pared to the other three groups (group 2 vs group 1, P =
0.048; group 2 vs group 3, P = 0.002; group 2 vs group 4, P
= 0.024). Furthermore, none of the patients in group 2
required dialysis treatment.
Logistic regression analyses were then carried out to
evaluate the associations of high CRP and high IL-6 with
high serum creatinine, thrombocytopenia, or hospitaliza-
tion exceeding seven days. High plasma IL-6 was revealed
as an independent risk factor for high serum creatinine
(OR 3.2, 95% CI 1.4-7.3, P = 0.005), whereas high plasma
CRP was found to be a protective factor (OR 0.3, 95% CI
0.1-0.7, P = 0.009) in this model. High plasma IL-6 was
also found to be an independent risk factor for thrombo-
cytopenia and hospitalization exceeding seven days (OR
3.6, 95% CI 1.6-8.0, P = 0.002, and OR 4.5, 95% CI 1.9-
10.8, P < 0.001, respectively) in models including high
plasma IL-6, high plasma CRP, and age. High plasma CRP
did not have a significant association with these factors
(data not shown).
As the patients with NE sought medical assistance at
different time intervals from the onset of fever, the
plasma CRP and IL-6 samples were also taken at different
periods from the onset. From the majority of patients
(66%) we had both CRP and IL-6 samples taken 5 days
from the onset of fever. In this subgroup of 78 patients
the main results remained the same: when compared to
patients with low IL-6, patients with high IL-6 had higher
creatinine levels, higher leukocyte count, greater change
in weight, as well as a lower platelet count, hematocrit,
and urinary output. They also stayed longer in hospital
than patients with low IL-6. High CRP five days after the
onset of fever had no associations with the variables
reflecting the severity of NE (data not shown).
Figure 2 The associations of laboratory variables with maximum plasma interleukin-6 and C-reactive protein concentrations in patients 
with Puumala hantavirus infection. Data are given as median (thick line), 25th-75th percentile (box), and range (whiskers); outliers have been omitted 
from the figure.
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The present study with 118 consecutive prospectively
collected hospitalized patients is by far the largest study
concerning inflammatory parameters, i.e. IL-6 and CRP,
in acute Puumala hantavirus infection. The present data
showed that high plasma IL-6 is associated with clinically
severe NE. High IL-6 was found to be an independent risk
factor for impaired renal function, thrombocytopenia,
and longer hospitalization, when examined together with
high CRP and age. Surprisingly, the results also suggested
that high plasma CRP might have a protective effect on
renal function, but the data must be interpreted with cau-
tion.
We found that maximum plasma IL-6 was associated
with the severity of renal insufficiency, blood leukocyto-
sis and thrombocytopenia. It also associated strongly
with the duration of hospitalization. We have previously
studied plasma IL-6 concentrations in a cohort of 70 NE
patients and found IL-6 levels to be increased [15]. In that
earlier study, there was no correlation between plasma
IL-6 levels and serum creatinine, but in the present larger
study we did find a correlation between the levels of these
two variables.
Previously, Linderholm and co-workers have studied 15
NE patients and detected elevated IL-6 plasma levels in
all cases [17]. They also found a significant correlation
between maximum levels of IL-6 and serum creatinine in
concordance with our results. Takala and co-workers
have studied 19 NE patients and 13 patients with other
viral infections and detected an inverse correlation of
Table 2: The clinical and laboratory variables in patients with Puumala hantavirus infection divided into four groups 
according to maximum plasma interleukin-6 and C-reactive protein levels.
Group 1 (N = 37)
CRP ≤ 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 2 (N = 22)
CRP > 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 3 (N = 23)
CRP ≤ 69 mg/l
IL-6 > 14.05 pg/ml
Group 4 (N = 36)
CRP > 69 mg/l
IL-6 > 14.05 pg/ml
P-value
Age (years) 38 (17-63) 51 (26-71) 36 (15-64) 45 (25-65) 0.013
Hospital stay (days) 6 (2-15) 6 (3-10) 7 (4-13) 8 (3-14) 0.003
SBP min (mmHg) 117 (82-162) 112 (93-149) 110 (85-140) 112 (86-158) 0.092
Change in weight (kg) 2.1 (0-9.9) 1.3 (0-4.7) 2.8 (0-12.0) 3.3 (0-9.9) 0.023
Urinary output min (ml/day) 2230 (350-7000) 2050 (200-4940) 1040 (50-4900) 1045 (50-3325) < 0.001
Urinary protein max (g/day) 1.43 (0.14-5.59) 2.03 (0.57-4.31) 6.05 (0.30-10.00) 1.72 (0.30-17.78) 0.003
Creatinine max (μmol/l) 193 (65-917) 114 (68-878) 256 (88-1285) 230 (70-1156) 0.073
Platelets min (109/l) 80 (3-238) 84 (19-159) 59 (9-139) 54 (13-187) 0.001
Hematocrit min 0.38 (0.29-0.43) 0.38 (0.29-0.44) 0.34 (0.25-0.43) 0.35 (0.25-0.46) 0.007
Leukocytes max (109/l) 9.0 (3.9-31.2) 9.2 (5.4-18.6) 11.0 (5.1-23.2) 12.2 (7.1-26.8) 0.011
Values are expressed as medians (ranging). SBP = systolic blood pressure, min = minimum, max = maximum, CRP = plasma C-reactive protein, IL-
6 = plasma interleukin-6.
Table 3: Categorical variables associated with the severity of the disease in nephropathia epidemica patients, divided into 
four groups according to maximum plasma interleukin-6 and C-reactive protein levels.
Group 1 (N = 37)
CRP ≤ 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 2 (N = 22)
CRP > 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 3 (N = 23)
CRP ≤ 69 mg/l
IL-6 > 14.05 pg/ml
Group 4 (N = 36)
CRP > 69 mg/l
IL-6 > 14.05 pg/ml
P-value
Gender (males) 28 (76%) 14 (64%) 16 (70%) 28 (78%) 0.645
Shock 0 (0%) 0 (0%) 1 (4%) 2 (6%)
Dialysis treatment 1 (3%) 0 (0%) 2 (9%) 3 (8%)
Pathologic chest x-ray 6 (23%) 4 (25%) 6 (30%) 14 (42%) 0.390
Hospital stay > 7 days 7 (19%) 5 (23%) 11 (48%) 19 (53%) 0.007
Creatinine max > 193 μmol/l 18 (49%) 5 (23%) 16 (70%) 19 (53%) 0.017
Platelets min ≤ 66 × 109/l 14 (38%) 7 (32%) 13 (57%) 27 (75%) 0.002
Values are expressed as numbers and percentages. CRP = plasma C-reactive protein, IL-6 = plasma interleukin-6, max = maximum, min = 
minimum.
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arterial pressure and minimum platelet count [24].
Plasma levels of IL-6 have been reported to associate with
the severity of the disease also in influenza and Japanese
encephalitis [21,22,25]. Studies of IL-6 in respiratory syn-
cytial virus infection and Dengue virus infection have
produced controversial results [26-29]. In acute renal fail-
ure, it has been demonstrated that plasma IL-6 levels are
elevated and that high levels predict mortality [30,31].
As far as we know, this is the first report suggesting that
CRP might act as a protective factor for renal function in
infectious diseases. Previously, it has been shown in mice
that CRP prevents and reverses proteinuria in accelerated
nephrotoxic nephritis [32-34]. It has also been reported
that genetics associated with reduced CRP production
predispose to the development of systemic lupus
erytematosus [35]. This has been attributed to the ability
of CRP to prevent the deposition of immune complexes
and enhance their phagocytosis. It should be noted that
immune complexes have also been found in NE patients
[36]. Reduced deposition and enhanced phagocytosis of
immune complexes could be the mechanism by which
high CRP protects renal function in NE. In viral infec-
tions, there are no reports of CRP concentrations affect-
ing the severity of the disease. In bacteremia and sepsis,
the results concerning CRP as a predictor of clinical out-
come are controversial. A year 2005 review concludes
that the ability of CRP level to reflect the severity of sep-
sis may be limited [37].
Finally, there was a positive correlation between maxi-
mum IL-6 and CRP levels in the present study, which can
be explained by the fact that IL-6 induces the production
of CRP. However, high IL-6 concentration was associated
with more severe disease, whereas high CRP level, in con-
trast, was associated with less severe renal impairment.
This finding can probably be explained by the diverse bio-
logical influences of IL-6 and CRP.
Conclusions
High plasma IL-6 concentration is associated with clini-
cally severe acute NE and could be used as a marker of
the severity of the disease. On the other hand, high CRP
as such does not indicate a severe form of NE.
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Abstract Our aim was to investigate whether plasma levels
of the long pentraxin-3 (PTX3) associate with the severity
of Puumala hantavirus-induced nephropathia epidemica
(NE). Sixty-one prospectively identified consecutively
hospitalized NE patients were examined. Plasma PTX3,
interleukin (IL)-6, terminal complement complex SC5b-9,
complement component C3, C-reactive protein (CRP),
creatinine, sodium, kynurenine, and tryptophan levels, as
well as the blood cell count, were determined for up to five
consecutive days after hospitalization. Receiver operating
characteristic (ROC) analysis revealed that the maximum
PTX3 level >101.6 ng/ml (high PTX3) showed a sensitivity
of 71% and a specificity of 89% for detecting platelet level
<50×109/l, with an area under the curve (AUC) value of
0.78 (95% confidence interval [CI] 0.63–0.94). High PTX3
level was also associated with several other variables
reflecting the severity of the disease: patients with high
PTX3 level had higher maximum blood leukocyte (16.1 vs.
9.7×109/l, p<0.001), plasma IL-6 (16.9 vs. 9.0 pg/ml, p=
0.007), and creatinine (282 vs. 124 μmol/l, p=0.007) levels
than patients with low maximum PTX3 level. They also
had longer hospital stays (8 vs. 5 days, p=0.015) compared
to patients with low PTX3 level. High plasma PTX3 levels
are associated with thrombocytopenia and the overall
severity of NE.
Introduction
Puumala hantavirus (PUUV) causes a mild hemorrhagic
fever with renal syndrome (HFRS), called nephropathia
epidemica (NE) [1]. The natural carrier rodent of PUUV is
the bank vole (Myodes glareolus) [2]. Other HFRS-causing
hantaviruses are Hantaan, Dobrava, Saaremaa, and Seoul
viruses [1]. In the Americas, many hantaviruses, e.g., Sin
Nombre, Andes, and Black Creek Canal viruses, cause
hantavirus cardiopulmonary syndrome (HCPS) [3]. NE is
prevalent in Finland, elsewhere in Scandinavia, European
Russia, and many parts of Central-Western Europe [1]. In
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Finland, 1,000–3,000 serological PUUV infection diagnoses
are made annually (http://www3.ktl.fi).
The clinical picture of NE varies greatly in severity. The
usual symptoms are sudden high fever, headache, gastrointes-
tinal symptoms, back pain, and visual disturbances [4, 5].
Hemorrhagic manifestations or signs of increased bleeding
tendency are present in about 10% of PUUV infection cases
[1]. Renal involvement causes proteinuria, hematuria, and
oliguria, which is followed by polyuria [4, 5]. During the
oliguric phase, about 5% of hospitalized patients need
transient hemodialysis treatment [1]. Complete recovery is
the usual outcome in NE, but in rare cases, the disease can be
fatal [6]. Common laboratory findings include leukocytosis,
thrombocytopenia, anemia, and elevation of plasma C-
reactive protein (CRP) and creatinine levels [5, 7]. However,
in our earlier studies, high plasma CRP levels did not
indicate clinically severe NE, whereas high plasma interleu-
kin (IL)-6 and serum indoleamine 2,3-dioxygenase (IDO)
levels were associated with a severe disease [8, 9]. Both the
classical and the alternative pathway of the complement
system have also been shown to be activated in acute NE
and to be associated with a severe disease [10, 11].
Pentraxins are a family of acute-phase proteins, which
are characterized by a cyclic multimeric structure [12]. CRP
and serum amyloid P component are two short pentraxins
produced mainly in the liver in response to inflammatory
signals [12, 13]. Pentraxin-3 (PTX3) is the prototype
protein of the long pentraxin group. It is produced by a
variety of peripheral tissues and cells, mainly by mononu-
clear phagocytes and myeloid-derived dendritic cells, in
response to proinflammatory signals, such as IL-1β, tumor
necrosis factor-α, and Toll-like receptor activation [12–14].
Neutrophil granules serve as a source of pre-synthesized
PTX3 [15], which, upon its release, can interact with a
number of bacteria, fungi, and viruses, promoting phago-
cytosis and the clearance of the microbes [16]. PTX3 has
the capacity to bind complement component C1q and
activate the classical pathway [17]. It also interacts with
factor H, an alternative pathway regulator [18]. PTX3 is
presumed to play a role in the tuning of inflammation,
extracellular matrix deposition, and female fertility [14, 16].
The aim of the current study was to investigate whether
the circulating level of the long pentraxin PTX3 is
associated with disease severity in NE and to evaluate the
possible role of PTX3 in the pathogenesis of NE.
Patients and methods
Patients
Sixty-one prospectively identified consecutive patients with
acute NE comprised the study cohort. The patients were
treated at the Tampere University Hospital, Finland,
between September 2000 and December 2004. The diagnosis
of acute PUUV infection was serologically confirmed in all
cases [19]. The median patient age was 46 (range 22–77)
years, and 44 (72%) were males. We have previously studied
IL-6 and CRP in 118 NE patients [8], as well as IDO in 102
NE patients [9]. Forty-eight of the patients in the present
study were also included in the IL-6 and CRP study, and all
61 patients in the present study were also included in the
IDO study. We have also previously studied complement
activation in NE in the same cohort of 61 patients [11].
Furthermore, 19 of the patients in the present study were also
included in a study that examined the activation of
coagulation and fibrinolysis in NE [20].
Twenty-four (39%) patients had one or more of the
following diseases before NE: essential hypertension in
eight; dyslipidemia in six; atrial fibrillation in three;
coronary artery disease, bronchial asthma, hypothyreosis,
chronic inflammatory bowel disease, and hyperplasia of the
prostate in two patients each; and diabetes mellitus, sick
sinus syndrome treated with a pacemaker, Sjögren’s
syndrome, mitral valve disease, epilepsy, fibromyalgia,
sarcoidosis, multiple sclerosis, operated atrial septal defect,
and operated melanoma were present in one patient each.
All subjects gave an informed consent before participation
and the study was approved by the Ethics Committee of the
Tampere University Hospital.
Study protocol
All 61 patients were studied during the acute phase of NE.
A detailed past and current medical history was obtained,
and a careful physical examination was performed. Blood
samples were collected for up to five consecutive days after
hospitalization. They were used for the analysis of plasma
PTX3, IL-6 (from 48 patients), CRP, creatinine, and
sodium, as well as serum kynurenine (Kyn), tryptophan
(Trp), terminal complement complex SC5b-9 (SC5b-9), and
complement component C3 (C3) levels, and also for the
blood cell counts. Other blood samples were taken
according to the clinical needs of the patient. The highest
and the lowest values of the various variables measured
during hospitalization for each patient were designated as
the maximum and minimum values. In this study, a
clinically significant thrombocytopenia was defined as a
minimum platelet value lower than 50×109/l.
Methods
All blood specimens were obtained between 7:30–9:30 in
the morning. Plasma PTX3 concentrations were determined
afterwards from frozen samples stored at −70°C. The
determinations were performed by using a commercially
Eur J Clin Microbiol Infect Dis
available human PTX3 immunoassay (Quantikine, R&D
Systems, Inc., Minneapolis, MN), following the manufac-
turer’s instructions. Plasma CRP, creatinine, and sodium
levels were analyzed using a Cobas Integra analyzer (F.
Hoffman-La Roche Ltd., Basel, Switzerland). The blood
cell count was completed by hematological cell counters by
Bayer. Plasma IL-6 concentrations were determined as
previously described [21]. The IDO level can be measured
by determining the ratio of kynurenine to tryptophan (Kyn/
Trp) in serum [22] by reverse-phase high-performance liquid
chromatography (HPLC), as previously described [23]. The
Kyn/Trp ratio was calculated by relating concentrations of
Kyn to Trp. Plasma IL-6 as well as serum Kyn and Trp
concentrations were measured afterwards from frozen
samples. All laboratory variables mentioned above were
determined at the Laboratory Center of the Pirkanmaa
Hospital District. The complement analyses were per-
formed at the Department of Bacteriology and Immu-
nology of the Haartman Institute and at the Helsinki
University Central Hospital Laboratory. Plasma SC5b-9
measurements were performed using a commercial
ELISA kit (Quidel, San Diego, CA) and plasma C3
concentrations were measured by nephelometry (Dade
Behring, Marburg, Germany). Some samples did not
meet the quality control criteria for the measurements of
C3 and SC5b-9 levels defined by the manufacturer.
Thus, these samples were excluded from the respective
analyses.
Statistical analysis
In order to describe the data, medians and ranges were
given for continuous variables, and numbers and percen-
tages for categorical variables. To evaluate the associations
of PTX3 levels with different variables, we divided the
patients into two groups according to the maximum PTX3
value. Groups were compared using the Mann–Whitney
U-test. Categorical data were analyzed by the χ2 test or
Fisher’s exact test, as appropriate. Correlations were
calculated by Spearman’s rank correlation test. Wilcoxon’s
test was used to compare two related samples. All tests
were two-sided, and all p-values were given. A receiver
operating characteristic (ROC) analysis was also made in
order to evaluate if the maximum PTX3 level could
function as an indicator of significant thrombocytopenia.
All analyses were made with the SPSS (version 18)
statistical software package.
Results
The clinical and laboratory findings of the 61 NE patients
are shown in Table 1. The median duration of fever before
admission to the hospital was 4 days (range 1–15 days).
None of the patients was in clinical shock at the time of
admission. Four of the 61 NE patients (7%) needed dialysis
treatment during hospital stay. All patients recovered
completely.
The maximum PTX3 values taken during hospitalization
for acute NE were significantly higher than the control
values taken after the hospitalization period (median
42.0 ng/ml, range 3.9–1251.4 ng/ml vs. 1.1 ng/ml, range
0.4–6.6 ng/ml, p<0.001). The control values were obtained
41 days (median, range 18–83 days) after the onset of fever
from 52 patients.
There was a strong inverse correlation between the
maximum plasma PTX3 level and the minimum blood
platelet count (r=−0.567, p<0.001). The maximum PTX3
levels also correlated inversely with the minimum C3 and
the minimum hematocrit levels (r=−0.365, p=0.006, and
r=−0.282, p=0.028, respectively). The maximum PTX3
level correlated positively with the maximum blood
leukocyte (r=0.477, p<0.001) and the maximum hematocrit
(r=0.390, p=0.002) levels, as well as with the maximum
plasma IL-6 (r=0.643, p<0.001), serum IDO (r=0.287, p=
0.025), and plasma SC5b-9 levels (r=0.454, p<0.001). Also,
the change in patient weight (reflecting fluid retention during
Table 1 The clinical and laboratory characteristics of the 61 patients
with Puumala hantavirus (PUUV)-induced nephropathia epidemica
(NE)
Median Range
Clinical findings
BMI (kg/m2) 25.1 19.8–31.2
Hospital stay (days) 6 2–15
Duration of fever (days) 6 2–19
SBP min. (mmHg) 112 82–162
Change in weight (kg) 2.7 0–12.0
Immunological variables
PTX3 max. (ng/ml) 42.0 3.9–1,251.4
CRP max. (mg/l) 69.2 16.7–269.2
IL-6 max. (pg/ml) (n=48) 11.5 1.3–96.6
IDO max. (μmol/mmol) 212.3 46.6–3,679.2
Laboratory variables
Platelets min. (109/l) 68 9–238
Leukocytes max. (109/l) 9.9 3.9–31.2
Hematocrit min. 0.36 0.25–0.43
Hematocrit max. 0.44 0.34–0.57
Creatinine max. (μmol/l) 175 65–1,285
Sodium min. (mmol/l) 131 115–139
BMI = body mass index, SBP = systolic blood pressure, min. =
minimum, max. = maximum, PTX3 = pentraxin-3, CRP = C-reactive
protein, IL-6 = interleukin-6, IDO = indoleamine 2,3-dioxygenase
Change in weight reflects fluid retention during the oliguric phase
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the oliguric phase) (r=0.315, p=0.013) and the length of
hospital stay (r=0.401, p=0.001) correlated positively with
the maximum PTX3 level.
We used ROC curves to examine if the maximum plasma
PTX3 level could function as an indicator of significant
thrombocytopenia (minimum blood platelet value <50×109/l)
[24]. A maximum PTX3 level >101.6 ng/ml showed a
sensitivity of 71% and a specificity of 89% for detecting
significant thrombocytopenia, with an area under the curve
(AUC) value of 0.78 (95% confidence interval [CI] 0.63–
0.94) (Fig. 1). This cut-off point was used to divide the
patients into two groups, so that patients with low PTX3 had
a maximum level ≤101.6 ng/ml and patients with high PTX3
had a maximum level >101.6 ng/ml.
The maximum plasma PTX3 level was also associated
with several other variables reflecting disease severity
(Table 2). Patients with high maximum PTX3 level had
higher maximum blood leukocyte and maximum hemato-
crit, as well as plasma IL-6 and serum IDO levels,
compared to patients with low maximum PTX3 level. They
also had a higher maximum plasma creatinine level and a
greater change in weight compared to patients with low
maximum PTX3 level. They also stayed longer in the
hospital compared to patients with low PTX3 level. In
addition, patients with high PTX3 had lower minimum
hematocrit and minimum plasma sodium levels compared
to patients with high PTX3.
The median age of the patients or the proportion of
males and females did not differ between patients with high
PTX3 level and patients with low PTX3 level (70% male
vs. 80% male, p=0.524). Furthermore, the BMI did not
differ between these two groups. In both groups, two
patients needed dialysis during the hospital treatment, while
the proportion of such patients was not significantly
different between the high and low PTX3 level groups
(13% vs. 4%, p=0.251).
In order to examine the kinetics of the changes in the
plasma PTX3 and blood platelet levels, we depicted their
daily medians in relation to the day of the onset of fever.
Figure 2 shows that the PTX3 level was at its highest
(92.5 ng/ml) at the median time of hospital admittance, i.e.,
4 days after the onset of fever, and, thereafter, it declined.
The lowest platelet level (59×109/l), in turn, was also
observed at the median time of admittance and the level
rose thereafter.
Discussion
The present data show that PTX3 levels are clearly elevated
during acute PUUV-induced NE, as the maximum PTX3
values during acute NE were significantly higher than the
control values after the hospitalization. The median
maximum PTX3 level was also markedly higher in our
patients (42.0 ng/ml) compare to in patients with acute
bacteremia (7.8 ng/ml) in a study carried out in our hospital
[25]. To our knowledge, there is only one previous clinical
study on PTX3 during a viral infection, which showed that
the median PTX3 level was 80.8 ng/ml 2–3 days after the
onset of symptoms during dengue virus infection [26].
Under normal conditions, the plasma PTX3 level is <2 ng/ml
in humans [27].
In the present study, high PTX3 levels were associated
especially with thrombocytopenia, a characteristic finding
in most NE patients, which may sometimes even cause fatal
bleedings. Maximum PTX3 level >101.6 ng/ml showed a
good sensitivity and specificity for detecting significant
thrombocytopenia (platelet level <50×109). The highest
PTX3 levels were measured 4 days after the onset of fever,
i.e., at the time of admittance to the hospital, in parallel
with the lowest observed platelet levels. Thereafter, the
PTX3 levels declined and the platelet levels rose.
High PTX3 levels were also associated with higher
maximum blood leukocyte count, plasma IL-6, creatinine,
and serum IDO values, as well as with anemia and longer
hospital stays, which all reflect the overall severity of the
disease. Moreover, high PTX3 levels were associated with
higher maximum hematocrit level, lower minimum sodium
level, and greater change in weight during hospitalization.
Hemoconcentration, fluid volume overload, and decreased
sodium level are all considered to be signs of capillary
leakage, an important feature in the pathogenesis of
hantaviral infections [3].
Studies concerning PTX3 in viral infections are scarce.
In the study on dengue virus infection cited above [26], the
PTX3 levels were higher in patients suffering from dengue
shock syndrome compared with the levels found in patients
Fig. 1 Receiver operating characteristic (ROC) curve for maximum
plasma pentraxin-3 (PTX3) level in relation to blood platelet level
<50×109/l in 61 patients with nephropathia epidemica (NE)
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with dengue fever and dengue hemorrhagic fever. In mouse
models and in vitro studies, PTX3 has been found to exhibit
antiviral activity against the influenza virus [28] and also to
protect from murine and human cytomegalovirus infection
[29].
In leptospirosis, high levels of PTX3 are associated with
mortality and disease severity [30]. Active Mycobacterium
tuberculosis infection is also associated with increased
PTX3 plasma levels [31]. In patients with severe meningo-
coccal disease, PTX3 was found to be an early indicator of
shock [32] and high PTX3 levels have also been associated
with mortality in septicemia and septic shock [25, 33]. In
critically ill patients, the PTX3 levels correlate with disease
severity and infection [34]. Furthermore, in febrile patients
admitted to the emergency department, PTX3 predicts
bloodstream infection and severe disease [35].
On the other hand, PTX3-deficient mice are highly
susceptible to Aspergillus fumigatus infection [36]. The
administration of PTX3 protected against Aspergillus
challenge in mice with bone marrow transplants [36] and
potentiated the protective effect of amphotericin B [37].
In the present study, the plasma PTX3 levels also
correlated positively with the terminal complement com-
plex SC5b-9 and inversely with the complement component
C3 levels. Elevated SC5b-9 levels reflect the overall
activation of the complement system. Decreased C3
concentrations, in turn, reflect the consumption occurring
during complement activation. Previously, it has been
shown that complement activation is common in NE, and
Fig. 2 Daily median PTX3 (solid squares) and blood platelet (open
squares) levels in relation to the onset of fever (day 0). Days 1–3 as
well as day 10 and onwards were omitted because there were less than
ten values available for those days
Table 2 The clinical and laboratory findings in 61 patients with PUUV-induced NE divided into two groups according to the maximum plasma
pentraxin-3 (PTX3) level
PTX3 max. ≤101.6 ng/ml, n=46 PTX3 max. >101.6 ng/ml, n=15 p-value
Clinical findings
Age (years) 47 (22–77) 45 (25–60) 0.657
BMI (kg/m2) 24 (20–36) 28 (20–30) 0.579
Hospital stay (days) 5 (2–15) 8 (4–14) 0.015
SBP min. (mmHg) 110 (82–162) 112 (86–152) 0.585
Change in weight (kg) 2.0 (0–10.1) 3.8 (0.5–12.0) 0.014
Immunological variables
CRP max. (mg/l) 68.4 (16.7–269.2) 75.3 (19.7–214.0) 0.331
IL-6 max. (pg/ml) (n=48) 9.0 (1.3–44.8) 16.9 (6.8–96.6) 0.007
IDO max. (μmol/mmol) 196.9 (46.6–1,044.7) 338.3 (119.2–3,679.2) 0.009
C3 min. (g/l) (n=55) 1.29 (0.8–2.11) 1.07 (0.65–1.56) 0.017
SC5b-9 max. (ng/ml) (n=57) 468 (103.5–903.5) 679.4 (238.4–1,034) 0.008
Laboratory variables
Platelets min. (109/l) 77 (24–238) 36 (9–84) <0.001
Leukocytes max. (109/l) 9.7 (3.9–20.0) 16.1 (8.1–31.2) <0.001
Hematocrit min. 0.37 (0.30–0.43) 0.34 (0.25–0.38) 0.045
Hematocrit max. 0.43 (0.35–0.57) 0.48 (0.34–0.54) 0.010
Creatinine max. (μmol/l) 124 (65–1,156) 282 (113–1,285) 0.007
Sodium min. (mmol/l) 132 (120–139) 129 (115–136) 0.028
Values are expressed as median (range)
PTX3 = pentraxin-3, BMI = body mass index, SBP = systolic blood pressure, CRP = C-reactive protein, IL-6 = interleukin-6, IDO = indoleamine
2,3-dioxygenase, min. = minimum, max. = maximum
Change in weight reflects fluid retention during the oliguric phase
Eur J Clin Microbiol Infect Dis
activation of the classical pathway is associated with a
severe disease [10]. Recently, complement activation also
via the alternative pathway, observed as elevated levels of
SC5b-9 and decreased levels of C3, was found to correlate
with the disease severity [11].
The present study shows that PTX3 levels correlate with
the activation of the complement system in NE. High PTX3
levels were also associated with thrombocytopenia. PTX3
could be involved in the pathogenesis of thrombocytopenia
in NE through the activation of the complement system,
which, in turn, activates the coagulation system and leads to
thrombocytopenia through the consumption of the platelets
[38]. Recently, it has been shown that thrombin formation
and fibrinolysis are enhanced in NE [20].
In conclusion, high plasma PTX3 levels are associated
with a more severe disease and significant thrombocytopenia
in PUUV-induced NE. PTX3 could even be involved in the
pathogenesis of thrombocytopenia in NE. As PTX3 is an
acute-phase reactant, PTX3 determinations could be useful in
the evaluation of disease severity during acute NE.
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Nephropathia epidemica (NE) is a hemorrhagic
fever with renal syndrome caused by Puumala
hantavirus. The severity of NE varies greatly.
The aim of the present study was to evaluate
whether serum indoleamine 2,3-dioxygenase
(IDO) activity is associated with the severity of
NE. A prospectively collected cohort of 102 con-
secutive patients with acute serologically con-
ﬁrmed NE was examined. Serum kynurenine,
tryptophan, creatinine, CRP, and blood cell count
were measured for up to 5 consecutive days
after admission. The kynurenine to tryptophan
(kyn/trp) ratio reﬂecting IDO activity was calcu-
lated.Amaximumkyn/trp ratio>202 mmol/mmol
had a sensitivity of 85% and a speciﬁcity of
75% for detecting maximum serum creatinine
values >250 mmol/L by receiver operating char-
acteristic (ROC) analysis. A maximum kyn/trp
ratio >202 mmol/mmol (high IDO level) was also
associated with other parameters reﬂecting
the severity of the disease and renal impair-
ment. Patients with high IDO levels had higher
maximum serum creatinine (379 vs. 102 mmol/L,
P < 0.001), plasma C-reactive protein (104.1 vs.
72.1 mg/L, P ¼ 0.029), and blood leukocyte
values (11.9 vs. 9.0  109/L, P < 0.001) compared
to patients with kyn/trp ratio 202 mmol/mmol.
They also had lower minimum urinary output
(1,100 vs. 1,900 ml/day, P < 0.001) and longer
hospital stays (8 vs. 5 days, P < 0.001). In
conclusion, high serum IDO activity was associ-
ated with increased disease severity and renal
impairment in NE. J. Med. Virol. 83:731–
737, 2011.  2011 Wiley-Liss, Inc.
KEY WORDS: Puumala hantavirus; nephro-
pathia epidemica; kynurenine;
tryptophan; indoleamine 2,3-
dioxygenase
INTRODUCTION
Nephropathia epidemica (NE) is a mild type of hem-
orrhagic fever with renal syndrome (HFRS), caused by
Puumala virus (PUUV) [Vapalahti et al., 2003]. The
virus is amember of theHantavirus genus in theBunya-
viridae family and is carried by bank voles (Myodes
glareolus) [Vapalahti et al., 2003]. NE is prevalent in
Finland, elsewhere in Scandinavia, in the Balkan
region, and also in many parts of Western Europe
[Kanerva et al., 1998; Vapalahti et al., 2003]. Approxi-
mately 1,000–3,000 serological diagnoses of PUUV
infection are made in Finland annually (http://
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www3.ktl.ﬁ/), and the seroprevalence in the population
is 5% [Brummer-Korvenkontio et al., 1999]. Other
hantaviruses causingHFRS includeHantaan,Dobrava,
Saaremaa, and Seoul viruses; while in the Americas,
Sin Nombre, Andes, and Black Creek Canal viruses
cause hantavirus cardiopulmonary syndrome (HCPS)
[Vapalahti et al., 2003].
The clinical severity of NE varies greatly and host
genetics have been shown to inﬂuence the clinical pic-
ture [Mustonen et al., 1996; Ma¨kela¨ et al., 2002]. The
usual symptoms are high fever, headache, backache,
abdominal pain and nausea, while hemorrhagic mani-
festations are uncommon [La¨hdevirta, 1971; Mustonen
et al., 1994a; Settergren, 2000]. Renal involvement is
manifested by proteinuria, hematuria, and oliguria fol-
lowed by polyuria. A minority of patients require tran-
sient dialysis treatment [La¨hdevirta, 1971; Mustonen
et al., 1994a; Settergren, 2000]. The characteristic his-
topathologic renal ﬁnding is acute tubulointerstitial
nephritis [Mustonen et al., 1994b]. Complete recovery
is the usual outcome [La¨hdevirta, 1971; Mustonen
et al., 1994a; Settergren, 2000]. Typical laboratory ﬁnd-
ings in NE are leukocytosis, thrombocytopenia, anemia,
and elevation of plasma C-reactive protein (CRP) and
creatinine concentrations [Mustonen et al., 1994a;
Settergren, 2000]. In addition radiological pulmonary
manifestations have been detected in 16–53% of hospi-
talized patientswithNE [La¨hdevirta, 1971; Linderholm
et al., 1992;Mustonen et al., 1994a;Kanerva et al., 1996;
Paakkala et al., 2004].
Indoleamine 2,3-dioxygenase (IDO) is an enzyme cat-
alyzing the ﬁrst and rate-limiting step in the major
pathway of tryptophan (trp) catabolism to kynurenine
(kyn) and its derivatives [Mellor, 2005]. IDO is
expressed widely in various immune cells, including
monocyte-derived macrophages and dendritic cells
[Mellor and Munn, 2004]. It is also expressed in other
types of cells, such as certain tumor-cells, ﬁbroblasts,
and renal tubular epithelial cells (TEC) [Burke et al.,
1995; Jalili et al., 2007; Mohib et al., 2007]. Interferon
(IFN)-g is the strongest inducer of IDO [Mellor and
Munn, 2004]. Increased IDO activity results in the
depletion of trp and this can lead to inhibition of T-cell
responses and proliferation and thus to immunosup-
pression [Hwuet al., 2000;Mellor et al., 2002].Depletion
of trp is also thought to be themechanism by which IDO
activity inhibits the replication of various bacteria,
intracellular parasites, and viruses [Takikawa, 2005].
In the present study, we investigated whether serum
IDO concentrations are associatedwith disease severity
and renal insufﬁciency in Puumala hantavirus-induced
HFRS.
MATERIALS AND METHODS
Patients
The study cohort consisted of 102 prospectively
identiﬁed consecutive patients with acute NE treated
at Tampere University Hospital, Finland, between
September 2000 and January 2008. Themedian patient
age was 46 (range 22–77) years, and 69 (68%) were
males.
Thirty-eight (37%) patients had one or more of the
following diseases before NE: essential hypertension in
12, dyslipidemia in eight, arthritis rheumatoides and
atrial ﬁbrillation/ﬂuctuation in four, and coronary
artery disease and bronchial asthma in three patients;
hypothyreosis, chronic inﬂammatory bowel disease, dia-
betes mellitus, psychiatric disorder, migraine and
hyperplasia of the prostate in two patients; sick sinus
syndrome treated with pacemaker, osteoporosis, psor-
iasis, Sjo¨gren’s syndrome, mitral valve disease, epi-
lepsy, ﬁbromyalgia, sarcoidosis, multiple sclerosis,
polyneuropathia, chronic gastritis, transient ischaemic
attack, congenital hearing impairment, operated atrial
septal defect, and operated melanoma in one patient
each.
The diagnosis of acute PUUV infection was serologi-
cally conﬁrmed in all cases [Vapalahti et al., 1996]. All
subjects gave informed consent before participation
and the study was approved by the Ethics Committee
of Tampere University Hospital and the University of
Massachusetts Medical School.
Study Protocol
All 102 patients were studied during the acute phase
of NE. A detailed past and current medical history was
obtained, and a careful physical examination was per-
formed. Blood samples to analyze serum trp and kyn,
creatinine, CRP, and blood cell count were collected for
up to 5 consecutive days after hospitalization. Other
blood sampleswere taken according to the clinical needs
of the patient. The highest and the lowest value of each
patient of the various variables measured during hos-
pitalization were designated as themaximumandmini-
mum values. In this study, we have deﬁned signiﬁcant
renal insufﬁciency as a serum creatinine value exceed-
ing 250 mmol/L. Minimum urinary output was deﬁned
as low if it was equal or lower than the median value in
the study population (1,440 ml/day) and high if it was
>1,440 ml/day.
METHODS
All blood specimens were obtained between 7:30 and
9:30 in the morning. Plasma CRP was analyzed by the
Roche Diagnostics CRP method using Cobas Integra
analyzer (F. Hoffman-La Roche Ltd, Basel, Switzer-
land). Blood cell count was completed by hematological
cell counters by Bayer. Serum creatinine was deter-
mined by Cobas Integra analyzer.
The rate of trp degradation reﬂects the IDO enzyme
activity, and IDO level can thus be measured by deter-
mining the ratio of kynurenine to tryptophan (kyn/trp)
in sera [Schrocksnadel et al., 2006]. Serum trp and kyn
concentrations were measured afterwards from frozen
samples by reverse-phase high-performance liquid
chromatography (HPLC), as previously described
[Laich et al., 2002]. Trp was separated with a Shimadzu
liquid chromatograph LC-10AD VP (Shimadzu Co,
J. Med. Virol. DOI 10.1002/jmv
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Kyoto, Japan) using a 50-mm BDS Hypersil C18 5 mm
column (Thermo Electron Co, Bellefonte, PA). It was
monitored by ﬂuorescence with a Shimadzu RF-10A
XL detector at 266 nm excitation and 366 nm emission
wavelengths. Kyn was separated with a Hewlett Pack-
ard 1100 liquid chromatograph (Palo Alto, CA) using a
Merck LiChroCart 55–4,150 mm cartridge containing a
Purospher STARRP-18 3 mmcolumn (Merck Co, Darm-
stadt, Germany). It was determined by ultraviolet
absorption at 360-nm wavelength with a Hewlett Pack-
ard G13144 detector. The kyn/trp ratio was calculated
by relating concentrations of kyn to trp, this allowing
estimation of IDO activity.
Statistical Analysis
In order to describe the data, medians and ranges
were given for continuous variables and numbers and
percentages for categorical variables. To evaluate the
associations of plasma IDO levels with the severity of
NE,we divided the patients into two groups according to
the maximum IDO value. Groups were compared using
the Mann–Whitney U-test. Categorical data were ana-
lyzed by the x2 test or the Fisher’s exact test. Corre-
lations were calculated by means of Spearman’s rank
correlation coefﬁcient. Wilcoxon’s test was used to com-
pare two related samples. We also performed a logistic
regression analysis with signiﬁcant renal insufﬁciency
(creatinine >250 mmol/L) as a dependent factor and
high IDOand lowurinary output as independent factors
in order to further examine the associations of these
factors with signiﬁcant renal insufﬁciency. Age and
sex were also included in these models. Odds ratios
(OR) and their 95% conﬁdence intervals (95% CI) were
given. All tests were two-sided, and statistically signiﬁ-
cantP values are given.All analysesweremadewith the
SPSS (version 7.5) statistical software package.
RESULTS
The clinical and laboratory characteristics of the NE
patients are shown in Table I. The median duration of
symptoms before admission to the hospital was 4 days
(range 1–15 days). None of the patients was in clinical
shock at the time of admission. Five of the 102 NE
patients (5%) eventually needed dialysis treatment
during hospital stay. The median duration of fever
was six days (range 2–19 days). Everyone recovered
completely.
The ability of maximum serum kyn/trp ratio to
predict serum creatinine levels >250 mmol/L was eval-
uated using receiver operating characteristics (ROC)
curves [Boyd, 1997]. A maximum kyn/trp >202 mmol/
mmol showed a sensitivity of 85% and a speciﬁcity
of 75% for detecting maximum serum creatinine levels
>250 mmol/L and the area under curve (AUC) was 0.84
(95%CI 0.76–0.91; Fig. 1). This cut-off point was used to
divide patients into two groups. Patients with low IDO
valuehadmaximumkyn/trp ratio202 mmol/mmol and
patients with high IDO value had maximum kyn/trp
ratio>202 mmol/mmol. IDO values during acute illness
and hospitalization were signiﬁcantly higher (median
maximum kyn/trp 199.3, range 46.6–3,679.2 mmol/
mmol) than convalescent values taken 14–32 days
(median 22 days) after the onset of fever (median
64.7, range 23.9–350.6 mmol/mmol, P < 0.001).
The proportion of males and females did not differ
between patients with high serum IDO levels and
patients with low IDO levels (70% male vs. 65% male,
high vs. low IDO groups, respectively, P ¼ 0.618). Forty
six (45%) of thepatientswere smokers. Theproportion of
smokers also did not differ between high and low IDO
groups (52% smokers vs. 44% smokers, high vs. low IDO
groups, P ¼ 0.404). All ﬁve patients, who needed dialy-
sis treatment were in the high IDO group (P ¼ 0.025).
The maximum level of IDO was associated with several
other parameters reﬂecting disease severity and renal
impairment (Table II). Patients with high IDO levels
TABLE I. Clinical and Laboratory Findings in 102 Patients
With Acute Nephropathia Epidemica
Median Range
BMI (kg/m2) (n ¼ 83) 26.2 18.5–37.0
Urinary output min (ml/day)
(n ¼ 94)
1,440 50–4,940
Change in weight (kg) 2.1 0–12.0
Hospital stay (days) 6 2–15
IDO max (mmol/mmol) 199.3 46.6–3,679.2
Creatinine max (mmol/L) 176 52–1,285
CRP max (mg/L) 79.8 15.9–269.2
Leukocytes max (109/L) 10.1 3.9–31.2
Hematocrit min 0.36 0.25–0.44
Platelets min (109/L) 61 9–238
BMI, body mass index; min, minimum; max, maximum; IDO, serum
kynurenine/tryptophan ratio; CRP, plasma C-reactive protein.
Fig. 1. Receiver operating characteristics (ROC) curve formaximum
kynurenine/tryptophan ratio in relation to serum creatinine value
>250 mmol/L in 102 patients with nephropathia epidemica.
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were older than patientswith low IDO levels, while BMI
did not differ between these two groups. There was a
strong positive correlation between maximum serum
IDO and creatinine levels (r ¼ 0.672, P < 0.001), as
well as maximum IDO level and change in weight,
which reﬂects ﬂuid retention during renal impairment
(r ¼ 0.526, P < 0.001). Maximum IDO levels and
minimum urinary output were inversely correlated
(r ¼ 0.385, P < 0.001). There was a positive corre-
lation between maximum IDO levels and the length of
hospital stay (r ¼ 0.494, P < 0.001). Maximum IDO
levels and the maximum blood leukocyte count were
positively correlated (r ¼ 0.508, P < 0.001). We also
performed a logistic regression analysis in order to
evaluate the association of high IDO levels with signiﬁ-
cant renal insufﬁciency (creatinine > 250 mmol/L)
when adjusted for age, sex, and low urinary output
(Table III). A high IDO level was an independent risk
factor for signiﬁcant renal insufﬁciency in this model.
We also analyzed maximum kyn and trp values sep-
arately in relation to parameters reﬂecting the severity
ofNE.Maximumkyn levelwas positively correlatedwith
maximum serum creatinine (r ¼ 0.785, P < 0.001)
and change in weight (r ¼ 0.517, P < 0.001). It was
inversely correlated with minimum urinary output
(r ¼ 0.357, P < 0.001). There was also a positive
correlation between maximum kyn level and the length
of hospital stay (r ¼ 0.517, P < 0.001) and the maxi-
mum blood leukocyte value (r ¼ 0.516, P < 0.001).
Maximum trp level had a slight positive correlation
with minimum urinary output (r ¼ 0.230, P ¼ 0.026),
and a slight inverse correlation with change in weight
(r ¼ 0.201, P ¼ 0.044), the maximum blood leukocyte
value (r ¼ 0.244, P ¼ 0.014) and maximum CRP
(r ¼ 0.256, P ¼ 0.009).
As the patients with NE sought medical assistance at
different time intervals from the onset of fever, the
serum trp and kyn samples were also taken at different
periods from the onset. From the majority of patients
(80%)we had trp and kyn samples taken 6 days from the
onset of fever. Themedian kyn/trp level on that day was
191.9, range 40.9–2,442.5 mmol/mmol. In this subgroup
of 82 patients, the main results remained the same.
Patients with high IDO (kyn/trp >202 mmol/mmol)
6 days after the onset had higher maximum blood leu-
kocytes (median 12.3, range 6.3–31.2  109/L vs.
median 9.1, range 5.1–24.0  109/L, P ¼ 0.001), higher
maximum serum creatinine (median 445, range 79–
1,285 mmol/L vs. median 113 g range 60–615 mmol/L,
P < 0.001), greater change inweight (median 3.5, range
TABLE II. Clinical andLaboratoryFindings in 102PatientsWithNephropathiaEpidemicaDivided IntoTwoGroupsAccording
to Maximum Serum Kynurenine/Tryptophan Ratio
IDO max 202 mmol/mmol IDO max >202 mmol/mmol
Pn ¼ 52 n ¼ 50
Age (years) 38 (22–77) 50 (25–74) 0.002
BMI (kg/m2) (n ¼ 83) 24.8 (18.5–34.6) 27.1 (20.9–37.0) 0.149
Urinary output min (ml/day) (n ¼ 94) 1,900 (200–4,940) 1,100 (50–4,900) <0.001
Change in weight (kg) 1.0 (0–10.0) 3.5 (0–12.0) <0.001
Hospital stay (days) 5 (2–15) 8 (3–14) <0.001
Creatinine max (mmol/L) 102 (52–537) 379 (75–1,285) <0.001
CRP max (mg/L) 72.1 (15.9–176.0) 104.1 (19.7–269.2) 0.029
Leukocytes max (109/L) 9.0 (3.9–24.0) 11.9 (6.3–31.2) <0.001
Hematocrit min 0.38 (0.31–0.44) 0.33 (0.25–0.40) <0.001
Platelets min (109/L) 53 (14–172) 67 (9–238) 0.202
Values are expressed asmedians (range). BMI, bodymass index;min,minimum;max,maximum; IDO, serumkynurenine/tryptophan ratio; CRP,
plasma C-reactive protein.
TABLE III. Multivariate Analysis of Risk Factors for Serum Creatinine Level >250 mmol/L Among 94 Hospitalized Patients
With Nephropathia Epidemica
Creatinine 250 mmol/L,
N ¼ 53
Creatinine >250 mmol/L,
N ¼ 41 OR 95% CI
Age (years) 43 48 0.98 0.94–1.03
Sex
Female 18 9 1 Reference
Male 35 32 2.70 0.80–9.09
Low urinary output
No 33 14 1 Reference
Yes 20 27 1.96 0.65–5.87
High IDO
No 39 6 1 Reference
Yes 14 35 17.57 5.25–58.77
Continuous variables are expressed asmedians. Category variables are expressed as numbers. IDO, kynurenine/tryptophan ratio; OR, odds ratio.
CI, conﬁdence interval.
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0–12.0 kg vs. median 1.6, range 0–9.9 kg, P < 0.001),
and longer hospital stay (median 7, range 3–14 days vs.
median 5, range 2–10 days, P < 0.001) than patients
with low IDO. They also had lower minimum urinary
output (median 1,085, range 50–4,900 ml vs. median
1,555, range 200–4,940 ml, P ¼ 0.042) than patients
with low IDO.
In order to analyze the kinetics of the changes in
serum IDOand creatinine levels,we depicted their daily
medians in relation to the day of the onset of fever.
Figure 2 shows that both variables ﬁrst gradually
increased to their peak values, and thereafter they
started to decline. Median IDO peaked to 243.9 mmol/
mmol 9 days after the onset of fever, whereas median
creatinine was at its highest (265 mmol/L) 10 days after
the onset of fever.
DISCUSSION
The present study with 102 consecutive and pros-
pectively identiﬁedhospitalizedpatients is to ourknowl-
edge the ﬁrst study on IDO during a hantavirus
infection. Our data show that IDO levels are elevated
during acute Puumala hantavirus infection. The
median maximum kyn/trp ratio in our study was
199.3 mmol/mmol during acute NE. Previous studies
on IDO levels in patients with systemic lupus erythe-
matosus (SLE) and in bacteremic patients have been
carried out in Tampere University Hospital using the
same laboratory as in the present study. InSLEpatients
the median IDO levels were 39.1–43.0 mmol/mmol
during different seasons [Pertovaara et al., 2007]. In
the same study the median kyn/trp ratio was also ana-
lyzed in 309 healthy controls and was found to be
25.9 mmol/mmol. Interestingly, in bacteremic patients,
the median maximum kyn/trp ratio was lower
(89.9 mmol/mmol) than in our patients with Puumala
virus infection (199.3 mmol/mmol) [Huttunen et al.,
2010]. In the present study, the IDO levels were lower
during the convalescent phase (14–32 days after the
onset of fever) than during the acute phase, but still
higher than the values published earlier for the healthy
controls. It was not possible to standardize dietary
intake of the essential amino acid trp in our study.
However, it seems unlikely that dietary intake would
have affected serumkyn/trp levels, since kyn/trp ratio is
not affected by the dietary intake of trp [Schrocksnadel
et al., 2006].
In the present study, high IDO levels were associated
with increased disease severity, especially renal impair-
ment in acute Puumala hantavirus infection. A high
IDO level was found to be an independent risk factor
for maximum serum creatinine exceeding 250 mmol/L,
when examined together with low urinary output, age,
and sex. We found that high IDO levels were associated
with signiﬁcant renal insufﬁciency and higher blood
leukocyte count as well as with lower urinary output
and blood hematocrit. It also associated strongly with
the duration of hospitalization.
IDOhas not beenwidely studied in patientswith viral
infections. Increased IDO activity has been found in
acute dengue virus infection and chronic hepatitis C
virus infection [Larrea et al., 2007; Becerra et al.,
2009]. Also increased trp degradation has been found
in chronic Epstein–Barr virus infection [Bellmann-
Weiler et al., 2008]. In those studies the association
between IDO level and the severity or progression of
the disease was not studied. However, in human immu-
nodeﬁciency virus infection enhanced trp degradation
by IDO was associated with disease progression and
complications, for example, weight loss and neuro-
psychiatric disorders [Schroecksnadel et al., 2007].High
IDO levels were also associated with severe disease and
mortality in bacteremic patients [Huttunen et al., 2010].
Treatment with granulocyte-macrophage colony-stimu-
lating factor resulted in reduced IDO levels in severe
sepsis, possibly due to improved antibacterial defence
[Schefold et al., 2010]. In the present study, a high IDO
level was associated with increased severity of Puumala
hantavirus infection.
Studies of IDO in humans with kidney diseases are
also scarce. It has been demonstrated that concen-
trations of trp metabolites increase in chronic renal
insufﬁciency [Saito et al., 2000; Schefold et al., 2009].
This is presumeddue to an increase in production and/or
decrease in degradation, rather than a decrease in renal
excretion [Saito et al., 2000]. In our study, the level of trp
metabolite, kyn, positively correlated with the severity
of acute renal insufﬁciency. This may suggest that the
increased production of kyn reﬂecting the activity of
IDO is important. In kidney allograft recipients, upre-
gulation of IDO is associatedwith rejection [Brandacher
et al., 2007]. In mice, it has been shown that IDO
promotes renal ischemia-reperfusion injury [Mohib
et al., 2008]. On the other hand, in nephrotoxic serum
Fig. 2. Daily median serum kynurenine/tryptophan (kyn/trp) ratios
and creatinine levels in relation to the onset of fever. Kyn/trpmedian is
presented as solid line and creatinine median as dashed line. IDO,
serum kynurenine/tryptophan ratio; crea, serum creatinine.
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nephritis, amodel of crescentic glomerulonephritis, IDO
acts as a protective factor [Hou et al., 2009].
The pathogenesis of NE is notwell understood. PUUV
has no direct cytopathic effect on cultured cells
[Temonen et al., 1993]. Therefore, it is unlikely that
direct viral cytotoxicity is the primary cause of pathol-
ogy in NE. PUUV causes acute tubulointerstitial neph-
ritis and the severity of histological changes in NE
has been found to be related to the clinical severity of
renal failure as measured by the highest serum creati-
nine level [Mustonen et al., 1994b]. In kidney biopsies
of patients with NE, there is an increased amount of
inﬁltrating cells in the peritubular areas [Temonen
et al., 1996]. The inﬁltrating cells include plasma cells,
monocytes/macrophages, and lymphocytes, as well as
polymorphonuclear cells, mainly eosinophils and neu-
trophils. CD8þ T-cells predominate the lymphocyte
inﬁltrate [Temonen et al., 1996]. This is thought to
indicate that cell-mediated cytotoxicity is important
in the kidney involvement in NE.
Macrophages express IDO when exposed to IFN-g.
Increased IDO activity in turn results in T-cell supres-
sionand the inductionofT-regulatory cells (T-regs).Bya
positive feedback loop, T-regs can further enhance IDO
activity by stimulating increased IFN-g expression
[Mulley and Nikolic-Paterson, 2008]. It has been dem-
onstrated that increased IDO activity promotes TEC
apoptosis and inhibition of IDO augments TEC survival
[Mohib et al., 2007]. We found that high IDO was
strongly associated with signiﬁcant renal failure. We
also found that IDO levels peaked before creatinine
levels, which might suggest that IDO could be in fact
involved in the pathogenesis of renal failure in NE. One
pathogenetic mechanism could be TEC apoptosis. Pre-
viously signs of epithelial cell apoptosis have been
detected in patients with PUUV infection [Klingstro¨m
et al., 2006]. Increased IDO levels could also contribute
to immunosuppression through T-cell suppression and
apoptosis.
In conclusion, a high serum kyn/trp level reﬂecting
increased IDO activity was associated with clinically
severe PUUV-induced interstitial nephritis and we
suggest that it might even be involved in the pathogen-
esis of renal failure in NE.
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Plasma Cell-Free DNA Levels Are Elevated in Acute
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Abstract
Introduction: Puumala hantavirus (PUUV) causes a hemorrhagic fever with renal syndrome called nephropathia epidemica
(NE). The aim of the present study was to evaluate plasma cell-free DNA (cf-DNA) levels and urinary cf-DNA excretion in
acute NE as well as their associations with the severity of the disease.
Methods: Total plasma cf-DNA was quantified directly in plasma of 61 patients and urine of 20 patients with acute NE. We
also carried out a qualitative high-sensitivity lab-on-a-chip DNA assay in 20 patients to elucidate the appearance of cf-DNA
in plasma and urine.
Results: The maximum plasma cf-DNA values taken during acute NE were significantly higher than the control values taken
after the hospitalization period (median 1.33 mg/ml, range 0.94–3.29 mg/ml vs. median 0.77 mg/ml, range 0.55–0.99 mg/ml,
P,0.001). The maximum plasma cf-DNA levels correlated positively with maximum blood leukocyte count (r= 0.388,
P= 0.002) and the length of hospital stay (r= 0.376, P= 0.003), and inversely with minimum blood platelet count (r=20.297,
P= 0.020). Qualitative analysis of plasma cf-DNA revealed that in most of the patients cf-DNA displayed a low-molecular
weight appearance, corresponding to the size of apoptotic DNA (150–200 bp). The visually graded maximum cf-DNA band
intensity correlated positively with the maximum quantity of total plasma cf-DNA (r= 0.513, P= 0.021). Maximum urinary
excretion of cf-DNA in turn was not markedly increased during the acute phase of NE and did not correlate with any of the
variables reflecting severity of the disease or with the maximum plasma cf-DNA level.
Conclusions: The plasma levels of cf-DNA are elevated during acute PUUV infection and correlate with the apoptotic cf-
DNA-band intensity. The plasma cf-DNA concentration correlates with some variables reflecting the severity of the disease.
The urinary excretion of cf-DNA does not reflect the degree of inflammation in the kidney.
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Introduction
Puumala hantavirus (PUUV) is a rodent-borne zoonotic virus
carried by the bank vole, Myodes glareolus [1]. PUUV causes a mild
hemorrhagic fever with renal syndrome called nephropathia
epidemica (NE) [2]. Numerous hantaviruses cause hemorrhagic
fever with renal syndrome in Eurasia and hantavirus cardiopul-
monary syndrome in the Americas [2]. In Finland, 1000–3000
serological NE diagnoses are made annually (http://www3.ktl.fi).
The severity of PUUV infection varies from subclinical disease
to rare fatal cases [3]. Host genetics have been shown to influence
the clinical picture [4]. After an incubation period of 2–6 weeks,
the disease begins with sudden high fever, headache, back and
abdominal pains, nausea and visual disturbances [5–6]. Signs of
renal involvement are proteinuria and hematuria, as well as
oliguria followed by polyuria [5–6]. Five per cent of hospitalized
patients need transient hemodialysis treatment [2]. Typical
laboratory findings during the acute phase are leukocytosis,
thrombocytopenia, anemia, and elevation of plasma C-reactive
protein (CRP) and creatinine levels [6]. Radiological pulmonary
manifestations have been detected in about one-third of NE
patients [7–9]. In addition, over half of patients have abnormal
cardiac findings [10].
The pathogenesis of NE is not completely understood. An
important feature in hantaviral infections is capillary leakage due
to increased capillary permeability. The mechanisms behind this
phenomenon are unclear, but complement activation may be
involved [11–13]. Immunological responses rather than direct
cytotoxicity of the virus have been suggested to be important in the
pathogenesis of hantaviral infections. One reason for this
hypothesis is that hantaviruses are considered noncytopathic
[14–15], although under certain conditions Tula hantavirus
induces apoptosis in cultured cells [16–17]. Increased cytokine
levels have been found in the plasma, urine and tissues in patients
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with hantaviral infection [18–21], and in our previous study, high
interleukin (IL)-6 levels also associated with a clinically severe
course of NE [22]. In addition, high levels of indoleamine 2,3
dioxygenase (IDO) and pentraxin-3 (PTX3), elements of the
innate immunity, were associated with a clinically severe NE in
our previous studies [23–24]. Although no direct viral cytopathy
has been detected, increased levels of serum lactate dehydroge-
nase, aspartate aminotransferase, and alanine aminotransferase
have been observed in patients with hantaviral infection,
indicating that the cellular membrane integrity is disturbed [25].
A recent study in PUUV-infected patients showed that epithelial
cell apoptosis is induced during acute infection and suggests that
the tissue damage is due to immune reaction [26].
Circulating cell-free DNA (cf-DNA) has recently been studied in
various acute and chronic clinical disorders. Elevated levels of cf-
DNA have been reported in cancer, autoimmune diseases, stroke,
myocardial infarction, trauma patients and sepsis [27–34]. It has
also been proposed that cf-DNA could be used as a predictor of
outcome or disease severity in these conditions [35]. Detectable
levels of cf-DNA are present also in the plasma of healthy
individuals, but the concentrations are low [36]. However, a
recent study showed cf-DNA concentrations to be elevated in
elderly women [37]. The current view is that in clinical conditions
cf-DNA originates from apoptotic or necrotic cells and therefore
reflects the amount of cellular damage [27].
Studies on plasma cf-DNA in viral infections are scarce and
urine levels of cf-DNA have not previously been studied in
infectious diseases. In the present study, our aim was to assess cf-
DNA plasma levels and urine excretion in patients with acute
PUUV infection. We aimed to evaluate the associations of plasma
cf-DNA levels with the clinical severity of the disease. We also
wanted to assess whether the excretion of cf-DNA is associated
with the severity of the infection or renal insufficiency. In addition
to measuring total cf-DNA levels directly in plasma and urine, we
carried out a qualitative high-sensitivity lab-on-a-chip DNA assay
to elucidate the appearance of cf-DNA in plasma and urine during
the course of the infection.
Materials and Methods
Patients
The study cohort consisted of 61 prospectively collected
consecutive adult patients with acute NE. The diagnosis of acute
PUUV infection was serologically confirmed in all cases [38]. The
patients were treated at the Tampere University Hospital
(Tampere, Finland) from September 2000 to December 2004.
The median patient age was 46 (range 22–77) years, and 44 (72%)
were males. We have previously studied IL-6 and CRP in 118 NE
patients [22], as well as IDO in 102 NE patients [23]. Forty-eight
of the patients in the present study were also included in the IL-6
and CRP study, and all 61 patients in the present study were also
included in the IDO study. We have also previously studied
complement activation as well as PTX3 in NE in the same cohort
of 61 patients [13,24]. Furthermore, 19 of the patients in the
present study were also included in studies examining the
activation of coagulation and fibrinolysis as well as platelet ligands
and endothelial involvement in NE [39–40].
The following diseases before NE were prevalent in 24 (39%)
patients: essential hypertension in eight; dyslipidemia in six; atrial
fibrillation in three; coronary artery disease, bronchial asthma,
hypothyreosis, chronic inflammatory bowel disease, and hyper-
plasia of the prostate in two patients each; diabetes mellitus, sick
sinus syndrome treated with pacemaker, Sjo¨gren’s syndrome,
mitral valve disease, epilepsy, fibromyalgia, sarcoidosis, multiple
sclerosis, operated atrial septal defect, and operated melanoma
were present in one patient each.
All subjects gave an informed consent before participation and
the study was approved by the Ethics Committee of Tampere
University Hospital.
Study protocol
All 61 patients were examined during the acute phase of NE. A
detailed past and current medical history was obtained, and a
careful physical examination was performed. Blood samples were
collected between 7:30–9:30 in the morning for up to five
consecutive days after hospitalization. They were used for the
analysis of plasma cf-DNA, PTX3, IL-6 (from 48 patients), CRP,
and creatinine, as well as serum kynurenine (Kyn) and tryptophan
(Trp) levels, and also for the blood cell counts. Other blood
samples were taken according to the clinical needs of the patient.
The nightly urine collection was performed during two
consecutive nights after hospitalization. The nightly collection
period was set from the time of the last voiding at bedtime until the
last voiding on rising. After completion, volume was measured and
timing was recorded for the collection period.
The highest and the lowest values of the various variables
measured during hospitalization for each patient were designated
as the maximum and minimum values.
One to three chest radiographs were obtained from 38 patients
(62%).
Fifty-three (87%) of the 61 patients were also studied at the out-
patient clinic four weeks after the hospital period. The plasma and
urine samples taken four weeks after the hospital treatment were
regarded and assessed as control/recovery samples.
Methods
Quantification analyses of plasma and urine cf-DNA
The cf-DNA analyses were performed afterwards from frozen
samples stored at 270uC. The amount of total cf-DNA was
determined directly in plasma and urine without any DNA
purification step, using the Quant-iTTM high-sensitivity DNA
assay kit and a QubitH fluorometer (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions. Plasma samples
were analysed in duplicate and the mean of the two values was
used as the final value. The assessed intra-day variation
coefficients at the mean plasma cf-DNA levels of 0.673 mg/ml,
0.876 mg/ml and 1.59 mg/ml were 4.2%, 1.0% and 4.1%,
respectively. The corresponding inter-day variation coefficients
were 5.5%, 4.3% and 6.6%. Total cf-DNA in urine was
measured in 20/61 patients with quadruple measurements in
which the mean of the four values was used as the final value.
The assessed intra-day variation coefficients at the mean urine
levels of 0.307 mg/ml, 0.769 mg/ml and 1.13 mg/ml were 5.0%,
4.8% and 3.5%, respectively. The corresponding inter-day
variation coefficients were 10.0%, 6.5% and 10.2%. Timed
overnight urinary excretion of cf-DNA was calculated as follows:
(concentration6total volume)/(time span).
Extraction and qualitative analysis of cf-DNA in plasma
and urine
Qualitative analysis of plasma and urine cf-DNA was performed
for randomly selected 10 patients with and without renal
insufficiency (defined as maximum plasma creatinine .370 mmol/l
and maximum plasma creatinine ,125 mmol/l, respectively).
Plasma and urine cf-DNA was extracted using the NucleoSpinH
Plasma XS Kit (MACHEREY-NAGEL GmbH & Co., Du¨ren,
Germany), designed for isolation of low-molecular-weight (50–
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1000 bp) cf-DNA. Cf-DNA isolation was performed according to
the manufacturer’s instructions following the high-sensitivity proto-
col. Extracted cf-DNA samples were analyzed with the High
Sensitivity DNA assay kit and an Agilent 2100 Bioanalyzer equipped
with Expert 2100 software according to the manufacturer’s
instructions (Agilent Technologies Inc., Santa Clara, CA). Agilent
2100 Bioanalyzer uses a lab-on-a-chip technology to perform gel
electrophoresis; nucleic acids are separated analogously to a capillary
electrophoresis and normalized to a ladder and two DNA markers,
after which the software automatically calculates the size of each
band. For each plasma sample, the appearance and intensity of low-
molecular weight cf-DNA was estimated visually and graded as
follows: 1 = no visible cf-DNA or extremely weak band intensity,
2 = intermediate band intensity, 3 = strong band intensity. The
researcher responsible for analysing and grading the cf-DNA
samples was blinded for the clinical data of the patients. The
appearance of cf-DNA in urine was analyzed descriptively.
Plasma CRP and creatinine levels were analyzed using Cobas
Integra analyzer (F. Hoffman-La Roche Ltd, Basel, Switzerland).
Blood cell count was completed by hematological cell counters by
Bayer. Plasma IL-6 concentrations were determined as previously
described [21]. IDO level can be measured by determining the
ratio of Kyn to Trp in serum [41] by reverse-phase high
performance liquid chromatography (HPLC) as previously
described [42]. The Kyn/Trp ratio was calculated by relating
concentrations of Kyn to Trp. Plasma PTX3 determinations were
performed by using a commercially available human pentraxin-3
immunoassay (Quantikine, R&D Systems, Inc., Minneapolis,
MN), following the manufacturer’s instructions. Plasma IL-6 and
PTX3 as well as serum Kyn and Trp concentrations were
measured afterwards from frozen samples. All laboratory variables
mentioned above were determined at the Laboratory Center of
Pirkanmaa Hospital District.
Statistical Analyses
In order to describe the data, medians and ranges were given for
continuous variables and numbers and percentages for categorical
variables. Groups were compared using the Mann-Whitney U-
test. Categorical data were analyzed by the x2 test or the Fisher’s
exact test, as appropriate. Correlations were calculated by the
Spearman’s rank correlation test. Wilcoxon’s test was used to
compare two related samples. All tests were two-sided, and
statistically significant P-values are given. All analyses were made
with the SPSS (version 18) statistical software package.
Results
The clinical characteristics of the 61 patients are shown in
Table 1 and the laboratory variables in Table 2. None of the
patients was in clinical shock at the time of admission. Four
patients (7%) needed hemodialysis treatment during the hospital
stay. Eleven patients had pathologic findings in chest radiograph,
i.e. 29% of the 38 patients with radiograph performed. No deaths
occurred.
The maximum total plasma cf-DNA values taken during acute
NE were significantly higher than the control values taken after the
hospitalization period (median 1.33 mg/ml, range 0.94–3.29 mg/
ml vs. median 0.77 mg/ml, range 0.55–0.99 mg/ml, P,0.001).
Maximum urinary excretion of cf-DNA was not increased during
the acute phase of NE when compared with the control values
after the hospitalization (median 0.68 mg/min, range 0.34–
1.38 mg/min vs. median 0.62 mg/min, range 0.19–1.15 mg/ml,
P = 0.43). The control values were taken median 41 (range 18–83)
days after the onset of fever.
The maximum plasma cf-DNA levels correlated positively with
maximum blood leukocyte count (r= 0.388, P = 0.002), maximum
plasma PTX3 levels (r= 0.513, P,0.001), and the length of
hospital stay (r= 0.376, P = 0.003). There was also an inverse
correlation between maximum plasma cf-DNA levels and
minimum blood platelet count (r=20.297, P = 0.020). The
maximum plasma cf-DNA levels did not correlate with maximum
plasma creatinine levels or minimum urinary output (r = 0.101,
P = 0.436 and r=20.063, P = 0.636; respectively). Neither did the
maximum cf-DNA levels correlate with minimum hematocrit,
maximum plasma CRP, IL-6 or serum IDO levels (r =20.120,
P = 0.359; r=20.015, P = 0.907; r= 0.202, P = 0.168 and
r = 0.228, P = 0.077; respectively). There was no correlation
between plasma cf-DNA and age (r = 0.093, P = 0.477).
There was no significant difference in maximum plasma cf-
DNA levels between patients with normal or pathologic chest
radiograph, or between patients who needed hemodialysis
treatment and those who managed without hemodialysis. Also,
the plasma cf-DNA levels did not differ between men and women
(data not shown).
The maximum urinary excretion of cf-DNA did not correlate
with any of the variables reflecting severity of the disease, and it
did not correlate with age or maximum plasma cf-DNA, either
(data not shown).
Qualitative analysis of plasma cf-DNA revealed that during the
acute phase of the disease, in most patients cf-DNA displayed a
low-molecular weight appearance, corresponding to the size of
apoptotic DNA fragments (150–200 bp) (Figures 1A and 1B). This
phenomenon was observed in patients with and without renal
Table 1. Clinical data for 61 patients with Puumala hantavirus
infection.
Median Range
Age (years) 46 22–77
BMI (kg/m2) 25.1 19.8–35.7
Duration of fever before hospital
admission (days)
4 1–15
Duration of fever (days) 6 2–19
Length of hospital stay (days) 6 2–15
Urinary output min (ml/day) 1600 50–4940
BMI = body mass index, min =minimum, max =maximum
doi:10.1371/journal.pone.0031455.t001
Table 2. Laboratory data for 61 patients with Puumala
hantavirus infection.
Median Range
Creatinine max (mmol/l) 175 65–1285
Platelets min (10E9/L) 68 9–238
Hematocrit min 0.36 0.25–0.43
Leukocytes max (10E9/L) 9.9 3.9–31.2
CRP max (mg/l) 69.2 16.7–269.2
IL-6 max (pg/ml) (n = 48) 11.5 1.3–96.6
IDO max (mmol/mmol) 212.3 46.6–3679.2
Min =minimum, Max =maximum, CRP =plasma C-reactive protein, IL-
6 = plasma inteleukin-6, IDO= serum kynurenine/tryptophan ratio.
doi:10.1371/journal.pone.0031455.t002
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insufficiency. The visually graded maximum cf-DNA band
intensity correlated positively with the maximum quantity of total
plasma cf-DNA (r= 0.513, P = 0.021). However, the maximum cf-
DNA band intensity did not correlate with any of the clinical or
laboratory parameters. In control samples, which were taken four
weeks after the hospital period, the low-molecular weight cf-DNA
band was either completely absent or markedly weakened in all
patients (Figures 1A and 1B).
Qualitative analysis of urine-cf-DNA revealed that in contrast to
plasma, no distinguishable low-molecular weight (150–200 bp)
Figure 1. Qualitative analysis of plasma cf-DNA in 10 patients with maximum plasma creatinine .370 mmol/l (A) and 10 patients
with maximum plasma creatinine ,125 mmol/l (B) after NucleoSpinH Plasma XS kit extraction. Analyses were performed with Agilent’s
High Sensitivity Lab-on-a-chip DNA assay. Green lines indicate the low weight (35 base pairs (bp)) DNA marker and purple lines the high weight
(10 380 bp) DNA marker. The intensity of low-molecular weight cf-DNA band was graded as follows: 1 = no visible cf-DNA or weak band intensity,
2 = intermediate band intensity, 3 = strong band intensity.
doi:10.1371/journal.pone.0031455.g001
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pattern of cf-DNA was detected during the acute phase of the
disease, with the exception of two patients with renal insufficiency
(patients no 5 and 7 with maximum plasma creatinine
.370 mmol/l) (Figure 2). In addition, two patients (no 3 and 20)
had random-sized cf-DNA fragments in their control urine
samples (Figure 2). The tracings of patients no 11 and 14 are
shown as examples of the 16 patients who had no findings in the
urinary cf-DNA fragment analyses (Figure 2).
Discussion
The data presented here show that plasma cf-DNA levels are
elevated during acute PUUV infection. The cf-DNA values
measured during the acute phase were markedly higher than the
values measured after the hospitalization. Previously, in bacter-
emia patients the median maximum cf-DNA levels were 2.03 mg/
ml in nonsurvivors and 1.26 mg/ml in survivors [34]. In the
present study, the median maximum plasma cf-DNA levels
(1.33 mg/ml) were close the level of survived bacteremia patients.
In the study presented here, the total plasma cf-DNA levels did not
correlate with the severity of renal insufficiency. However, there
was an inverse correlation between plasma cf-DNA level and
blood platelet count. In addition, plasma cf-DNA levels correlated
positively with blood leukocyte count and the length of hospital
stay, which is probably one of the best variables reflecting the
overall severity of the disease as all patients fully recovered. Plasma
cf-DNA levels also correlated with plasma PTX3 levels. This is
logical as PTX3 contributes to the opsonization and clearance of
Figure 2. Qualitative analysis of urine cf-DNA after NucleoSpinH Plasma XS kit extraction. Analyses were performed with Agilent’s High
Sensitivity Lab-on-a-chip DNA assay. Green lines indicate the low weight (35 base pairs (bp)) DNA marker and purple lines the high weight
(10 380 bp) DNA marker. During the acute phase of the disease low-molecular weight (150–200 bp) pattern of cf-DNA was detected only in patients
no 5 and 7, while patients no 3 and 20 had random-sized cf-DNA fragments in their control urine samples. Data from patients no 11 and 14 are
depicted as examples of the 16 subjects who had no findings in the urinary cf-DNA fragment analyses.
doi:10.1371/journal.pone.0031455.g002
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apoptotic or necrotic cells [43], which are regarded as the origin of
cf-DNA. In contrast, urine maximum cf-DNA excretion did not
correlate with any clinical or laboratory parameters or maximum
plasma cf-DNA.
Qualitative analysis of plasma cf-DNA revealed that, during the
acute phase of infection, cf-DNA displayed a predominance of
low-molecular weight and apoptotic (150–200 bp) appearance,
whereas after recovery, such cf-DNA pattern was not observed in
any of the patients. It is thus likely that the detected low-molecular
weight cf-DNA originated from apoptotic cells in the course of the
acute phase of the disease. In fact, results from a recent study in
PUUV infected patients suggest that acute hantavirus infection is
associated with immune reaction-induced renal tissue damage
[26]. Moreover, the observed correlation between maximum total
plasma cf-DNA concentration and the low-molecular weight cf-
DNA band intensity supports the hypothesis that the increase in
plasma cf-DNA is due to apoptosis. Notably, NE is a general
infection and thus the low-molecular weight DNA fragments could
be derived from a variety of affected tissues. Similar results in
qualitative cf-DNA pattern have recently been observed in
bacteremia patients [34]. However, in the current study, the
plasma cf-DNA band intensity was not associated with the level of
renal function or clinical picture of the disease. We did not detect
any qualitative patterns in urine cf-DNA that could be attributed
to the disease severity, either. Nevertheless, two patients with renal
insufficiency had a clear low-molecular weight cf-DNA band in the
urine during the acute phase of the disease, potentially indicating
increased apoptosis in the renal system.
The observation that the correlates for maximal total urinary cf-
DNA excretion were different from those of the maximum plasma
cf-DNA concentration suggest that the amount of cf-DNA in urine
may not be clinically relevant and the excretion of cf-DNA does
not reflect the degree of inflammation in the kidneys in acute NE.
Our findings are corroborated by previous results which have
demonstrated that in hematopoietic stem cell transplant patients,
the quantity of donor-derived cf-DNA in urine does not correlate
with that of plasma and that the predominant cf-DNA fragment
size differs between plasma and urine [44–45]. A similar
phenomenon regarding the DNA fragment size discrepancy
between plasma and urine cf-DNA has also been observed in
pregnant women [46]. In fact, urinary cf-DNA is likely to consist
of a heterogeneous mixture of cf-DNA fragments originating from
dying cells in the renal system and from the pool of plasma
circulating cf-DNA. The former is supported by the observation
that patients with urinary tract infection have elevated urine cf-
DNA levels [44], whereas the latter has been demonstrated in
colorectal cancer patients who displayed tumor-derived mutated
K-ras sequences in the transrenal urine cf-DNA [47–48]. Likewise,
Y-chromosomal DNA sequences have been detected in the urine
of pregnant women carrying male fetuses [44]. Based on animal
studies, however, it has been estimated that only 0.5–2% of the
circulating DNA passes through the kidneys and is excreted into
the urine in a polymeric form [44,49]. The exact mechanism by
which cf-DNA crosses the glomerular basement membrane is
currently unknown, yet the maximum urinary excretion of cf-
DNA is anticipated to be influenced by renal function although
our current results do not seem to support this hypothesis.
Previously cf-DNA has been investigated in a variety of clinical
conditions. However, studies concerning infections other than
sepsis are scarce. In septic patients, there are studies showing
elevated cf-DNA levels that also predict outcome [32,34,50–51].
In trauma patients, cf-DNA predicted inflammatory second hit
and sepsis [52]. In febrile patients, cf-DNA showed prognostic
value in assessing the probability and severity of infection and
sepsis [53]. In viral infections, elevated levels of cf-DNA have been
found in patients with occult hepatitis B [54].
In conclusion, the plasma levels of cf-DNA are elevated during
acute PUUV infection and correlate with the apoptotic band
intensity. The total plasma cf-DNA concentration correlates with
some variables reflecting the severity of the disease. The urinary
excretion of cf-DNA does not reflect the degree of inflammation in
the kidney.
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